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ABSTRACT 
Streptococcus pyogenes is a Gram-positive, human-specific bacterial pathogen with the 
ability to cause a wide range of diseases from strep throat to necrotizing fasciitis and toxic 
shock syndrome.  In addition, S. pyogenes may also induce post-streptococcal sequelae 
including rheumatic fever, acute glomerulonephritis, and reactive arthritis.  Although 
primarily recognized as a pathogen, S. pyogenes also colonizes the skin and throat often 
without causing disease, and while numerous surface adhesions are important to attach to 
these surfaces, additional factors important for colonization and persistence by S. 
pyogenes are poorly understood. In addition to host defence mechanisms, the upper 
respiratory tract also contains other endogenous microorganisms that compete for the 
same niche. In order to gain a more complete understanding as to how S. pyogenes is able 
to adapt within the nasopharyngeal environment, a recombinase-based in vivo expression 
technology (RIVET) system was developed to identify genes activated in the 
nasopharyngeal niche using a humanized murine model.  Using RIVET, 82 unique clones 
were recovered revealing 22 ‘cryptic’, 9 ‘typical’, and 30 ‘antisense’ in vivo induced 
promoters with single inserts.  One ‘typical’ promoter (Pblp) that controlled a putative 
class IIb bacteriocin operon was further characterized.  Testing this promoter as a single 
clone in the RIVET system confirmed its activation in vivo.  However, in vitro testing 
failed to activate this bacteriocin, despite continued addition of the characterized 
pheromone, SilCR.  A blp operon deletion was out-competed by the wild-type S. 
pyogenes in vivo, but not in vitro. Activation of the bacteriocin in vivo provides a further 
explanation for the ability of S. pyogenes to occupy the nasopharyngeal niche and begin 
the process of colonization.  This work provides a new molecular tool for the in vivo 
analysis of S. pyogenes, and demonstrates a novel bacteriocin system important for niche 
adaptation by S. pyogenes. 
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1.1 Streptococcus pyogenes 
Streptococcus pyogenes (also commonly referred to as Group A Streptococcus) is a 
Gram-positive, human-specific bacterial pathogen. S. pyogenes is an aerotolerant 
anaerobic coccus that forms long chains of cells when actively dividing.  A characteristic 
of S. pyogenes is the formation of zones of β-haemolysis around colonies when grown on 
blood agar plates (1).  The genome of S. pyogenes is a single circular chromosome of 
~1.9 Mbp with a low G+C content of ~39% and is well known for the abundance of 
exogenous genetic elements including prophage and prophage-like elements, and 
integrated conjugative elements.  These elements occupy ~10% of the chromosome and 
provide the greatest amount of genetic difference between strains (2).  Virulence factors 
are commonly found on these elements including the well-known superantigens (SAgs).  
Using the Lancefield classification of serologic typing that is based on surface 
carbohydrate production, S. pyogenes is the only member of the Group A streptococci.  
Serotyping is based on the surface expressed M protein, of which more than 100 
serotypes exist (1, 3).  More recently, this serotyping system has been replaced with the 
nucleotide sequence of the 5´ end of the emm gene, producing over 223 serotypes to date 
(4). 
1.2 Global burden of disease caused by S. pyogenes 
S. pyogenes has the ability to cause a wide spectrum of diseases and contributes to an 
immense burden of human illness on a global scale (5).  These diseases can range from 
mild, non-invasive pharyngitis (strep throat) and impetigo, to far more severe invasive 
diseases such as necrotizing fasciitis and toxic shock syndrome.  Further post-infection 
complications can also result from non-invasive diseases in the development of acute 
post-streptococcal glomerulonephritis (APSGN) and acute rheumatic fever (ARF), which 
may lead to rheumatic heart disease (RHD) and reactive arthritis (1). 
Mild diseases by S. pyogenes cause the most number of cases, with pharyngitis 
contributing to more than 616 million cases per year and impetigo estimated to be at an 
incidence of 111 million people.  Furthermore, approximately 1.78 million new severe 
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cases per year have been estimated at 663 000 invasive infections, 472 000 cases of 
APSGN, and 282 000 of RHD.  The remaining 366 000 include stroke, endocarditis, or 
requiring prophylaxis due to RHD.  Combined diseases lead to over 517 000 deaths per 
year world-wide.  When broken down, APSGN causes the fewest number of deaths at 
5000 per year, followed by invasive disease at 163 000.  It is RHD that causes the most 
deaths at 233 000 per year, with the remaining 116 000 due to complications arising from 
diseases caused by RHD.  There are an estimated 15.6 million current cases of RHD and 
this continues to be the greatest cause of death caused by S. pyogenes in the world (5). 
Antibiotics have been routinely used to treat S. pyogenes infections for decades and, to 
date, there have been no documented strains of S. pyogenes that have developed 
resistance to β-lactam antibiotics (6).  Unfortunately, resistance to second line antibiotics, 
such as macrolides, tetracyclines, and fluoroquinolones, seems to be on the rise, creating 
difficulties treating patients with allergies to penicillin and other β-lactams (6, 7).  To 
combat this, development of an effective vaccine is ongoing, and as humans remain the 
only reservoir for S. pyogenes, it creates the possibility of severely reducing S. pyogenes 
disease (8). 
1.3 Dissemination of S. pyogenes throughout the globe 
Disease caused by S. pyogenes is not evenly distributed around the world.  In developing 
countries, due to the lack of sanitary conditions and access to appropriate treatment, the 
rate of invasive disease and RHD is much higher than in developed countries (5).  The 
dissemination of different strains also likely contributes to this imbalance.  Different emm 
types are more prevalent in contrasting geographical areas, and specific emm serotypes 
are often more commonly associated with different types of disease (9).  Accumulating 
over 100 data sets (38 081 S. pyogenes isolates), Steer et al. demonstrated the varying 
emm types occurring in Africa, Asia, Latin America, Middle East, Pacific Island 
countries/Indigenous Australians, and Established Market Economy countries (such as 
Canada, US, most of Europe, Japan, Australia, New Zealand) (9). 
The top three emm types for each region divided by pharyngeal, skin, invasive, and 
combined diseases are shown in Table 1.1.  These data, where available, demonstrate the
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diverse emm types between regions and disease, as well as the common strains that are 
important worldwide.  Overall diversity of S. pyogenes can be demonstrated by the 
number of emm types that account for the first 50% of the total population.  From the data 
accumulated by Steer et al., Africa and the Pacific Island counties/Indigenous Australians 
showed the greatest variability with the top 50% represented by 18 and 19 emm types 
isolated, respectively.  On the other hand, Asia, Latin America, Middle East, and 
Established Economy Market Countries have a similar but much lower diversity with the 
top 50% representing only 3, 6, 5, and 5 emm types, respectively (Table 1.1) (9).  The 
smaller proportions and therefore greater number of isolates represented, gives Africa and 
the Pacific Island counties/Indigenous Australians a far greater diversity compared to the 
other regions. 
When looking at a global scale, emm1 and emm12 play an important role in causing 
disease world-wide.  However, outbreaks of disease caused by emm types that are not 
typical to the area can also occur.  For example, isolates from patients during an acute 
APSGN outbreak in the south province of Guizhou, China demonstrated that emm60 and 
emm63 predominated at 43.5% and 30.4%, respectively, with four other emm types 
present, all under 9% (10).  ARF outbreaks have also occurred in Salt Lake City, Utah, 
United States in 1985 and 1998.  In 1985, emm18 dominated while in 1998 the most 
prominent were emm4 and emm12 (11).  Thus, individual emm serotypes may dominate 
across large geographical regions, yet specific disease states and outbreaks can be linked 
to different serotypes. 
1.4 Clinical diseases 
1.4.1 Pharyngitis  
Pharyngitis is an inflammatory response due to infection of the pharynx.  S. pyogenes is 
the most common cause of bacterial pharyngitis and primarily affects school-age children 
ranging from 5-15 years of age (12, 13).  Inflammation specifically involves the pharynx 
and the tonsils, often with the presence of pus, and includes symptoms such as fever, 
headache, nausea, and other flu-like symptoms.  While normally associated with school-
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age children, it can also be linked to all ages in crowded areas such as military facilities 
(1, 14).  In addition to this, episodes become recurrent in a small percentage of people 
(15).  Several theories exist to explain this phenomenon including antibiotic failure due to 
poor patience compliance, antibiotic degradation from nearby β-lactamase producing 
bacteria, tolerance, invasion of cells, and reinfection by S. pyogenes from repeated 
exposure or as a consequence from the eradication of competing bacteria (7, 16, 17).  
Tonsillectomy has shown to decrease infections caused by S. pyogenes with those 
suffering from recurrent pharyngitis (18, 19).  Although pharyngitis caused by S. 
pyogenes is usually acute, uncomplicated, and self-limiting, if untreated it may lead to 
other consequences as described below (20).   
1.4.2 Impetigo 
Impetigo, or pyoderma, is a localized purulent infection of the skin that can occur in the 
bullous and nonbullous forms.  While both forms can be caused by Staphylococcus 
aureus, only the more common nonbullous form can be caused by S. pyogenes.  
Nonbullous impetigo is most prevalent in warm, humid climates among children below 
school-age in economically disadvantaged families (21).  Starting as a single red macule, 
nonbullous impetigo can rapidly become vesicles that rupture and dry, forming honey-
coloured crusts.  Although often spread by autoinoculation, it is self-limiting after several 
weeks if left untreated (22).  While both S. aureus and S. pyogenes are sometimes found 
within the same skin lesions, typically S. aureus dominates the moderate climate cases 
and S. pyogenes predominates humid and warmer climates (23, 24).  Interestingly, S. 
pyogenes strains that cause impetigo are not known to cause pharyngitis or ARF, but can 
be nephritic (these last two discussed below) (21).  This implies a varying disease tropism 
for different strains of S. pyogenes, which is discussed in more detail in subsequent 
sections.  
1.4.3 Scarlet fever 
Typically occurring in children between the ages 4 and 7, scarlet fever is associated with 
pharyngitis, fever, a bright tongue with a strawberry appearance, and a sandpaper-like 
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rash starting on the face and neck and spreading to the trunk and other parts of the body 
(25).  Scarlet fever used to be a major cause of child morbidity and mortality in the 19th 
and early 20th centuries.  However, due to improved living conditions in industrialized 
nations and the discovery of antibiotics, incidents decreased and it became more of a mild 
disease (26, 27). 
1.4.4 Necrotizing fasciitis 
Necrotizing fasciitis, previously called Streptococcus gangrene, is a rare deep bacterial 
infection of the subcutaneous tissue, resulting in the destruction of the surrounding fascia 
and fat (28).  This deep penetration can occur following a break in the epithelial layer 
caused by some form of trauma such as cuts, burns or even surgical procedures, but many 
incidences occur in the absence any known portal of entry (29, 30).  Within the first day, 
flu-like symptoms appear as well as pain that is disproportionate to the injury.  At a more 
advanced stage, swelling and dark patches will appear, eventually filling with fluid.  The 
area will ultimately become necrotic, with separation of the dead tissue.  It is also 
possible for patients to development streptococcal toxic shock syndrome, described below 
(29).  Treatment of necrotizing fasciitis involves immediate surgical debridement of the 
affected tissues as well as antibiotic treatment and supportive therapy.  Surgical 
debridement is performed until all dead tissue is removed, potentially leading to 
amputation (30). 
1.4.5 Streptococcal toxic shock syndrome 
Streptococcal toxic shock syndrome (STSS) is caused by a hyperactive immune system 
triggered by potent immunostimulatory toxins called superantigens (SAgs), leading to a 
massive cytokine response.  In contrast to toxic shock syndrome caused by S. aureus 
where the infecting organism often remains localized, STSS typically occurs during the 
context of an invasive infection by S. pyogenes (31).  Early symptoms may be flu-like and 
include fever, sore throat, swollen glands, rash, diarrhea, and vomiting.  After 3-4 days, 
the fever remains persistent and hypotension and shock develop, which can lead to 
tachycardia and multi-organ failure.  Coagulation can also occur leading to gangrene or 
also the development of necrotizing fasciitis from the invasive infection (32).  Treatment 
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includes the use of antibiotics and fluids to maintain blood pressure, and may include 
additional developmental therapies such as the administration of intravenous 
immunoglobulin (IVIG) and activated protein C.  IVIG would potentially contain anti-
SAg antibodies, effectively neutralizing the SAgs, while activated protein C can help 
prevent coagulation from occurring (33-35). 
1.4.6 Acute post-streptococcal glomerulonephritis 
APSGN is a renal disorder first reported by von Plenciz over 200 years ago, and was a 
feared consequence following scarlet fever (36).  Caused only by certain ‘nephritogenic’ 
S. pyogenes strains, APSGN typically affects children between the age of 2 and 12 
following pharyngitis or a skin infection (37).  Depending on the original infection, the 
latent period for APSGN is 1 to 4 weeks from a skin infection and 1 to 2 weeks for 
pharyngitis (1).  Symptoms include edema, hypertension, and dark coloured urine from 
blood due to the impaired filtering properties of the glomerulus (1, 38).  APSGN patients 
show spontaneous recovery over 95% of the time and generally only supportive therapy 
maintaining blood pressure and fluids is required.  Very rarely are any long term effects 
seen after recovery in children; however, adults seem more likely to develop chronic 
symptoms afterward (1, 39). 
1.4.7 Acute rheumatic fever and rheumatic heart disease 
ARF is an autoimmune disease caused by the cross reaction of antibodies directed against 
S. pyogenes with human tissues (40).  ARF most commonly involves inflammation of the 
joints, central nervous system, or the heart, typically arising 2 to 5 weeks after non-treated 
pharyngitis.  Along with one of the major areas of swelling, additional symptoms include 
fever, malaise, tachycardia, and anemia (6, 41).  Inflammation of the joints (arthritis) is 
the most common symptom and occurs in 75% of ARF patients.  Affecting the large 
joints, painful episodes can last from a number of days to weeks, and treatment includes 
pain medication and anti-inflammatory drugs (41, 42).  Occurring in approximately 10% 
of patients is a neurological manifestation of ARF known as Sydenham’s chorea.  The 
characteristic of the disease is the presence of involuntary, purposeless, and jerky 
movements of the face and extremities that disappear while sleeping, typically lasting 8 to 
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15 weeks (41, 42).  Lastly, while not the most common, inflammation of the heart tissue 
is the most serious as permanent, long-term damage to the heart can occur.  This damage 
is given the term rheumatic heart disease (RDH) and occurs most frequently to the mitral 
valve (41, 42).  Healing of the valves results in scarring and fibrosis preventing proper 
function.  Damaged valves show narrower openings and allow blood to leak back, which 
can lead to congestive heart failure. Treatment of RHD involves the use of anti-
inflammatory and diuretic drugs with valve replacement in severe cases (42, 43). 
1.5 Molecular mechanisms of colonization and disease 
1.5.1 Barriers of the human host 
The major recognized sites of colonization by S. pyogenes on the human host include the 
skin and the nasopharynx (44, 45).  In order to attach and colonize, group A streptococci 
have to bypass or subvert a number of mechanical, chemical, and biological barriers.  
Healthy skin creates an intact barrier that microorganisms cannot penetrate, as well as the 
process of desquamation that must be overcome (46, 47).  Along with this, skin has a low 
moisture content, low pH, and produces antimicrobial compounds such as fatty acids, 
lysozymes, and defensins (48, 49).  Finally, S. pyogenes must compete with other bacteria 
for the same space, with Staphylococcus epidermidis a prime example, as it creates 
peptides toxic to S. pyogenes (47). 
The oral cavity maintains the same physical barriers as the skin, and bacterial 
competition, but also contains saliva (50).  Saliva has many different functions involved 
with eating, maintaining healthy teeth, and also has many antimicrobial properties (51).  
Saliva contains many components, including those of the innate and acquired immune 
system, that interact with the oral microbiota, controlling the composition of the 
microorganisms within the oral cavity (51).  These include immunoglobulins, defensins, 
lysozyme, as well as cysteine and serine proteinase inhibitors (51, 52).  For example, 
immunoglobulin A (IgA) from human saliva showed both interference with binding and 
opsonisation of S. pyogenes in vitro (53-55).  Agglutinins have shown to cause co-
aggregation with some strains, and subsequently these strains would be swallowed (56, 
57).  Additionally, the commensal bacteria S. salivarius produces a bacteriocin that is 
  
10 
known to be toxic to S. pyogenes (58). 
The innate immune system also provides a significant barrier that S. pyogenes must 
overcome in order to colonize the host.  Innate immunity utilizes a pattern recognition 
strategy based on a set of conserved molecular patterns, referred to as pathogen-
associated molecular patterns (PAMPs) (59). Unique to microbes, PAMPs are recognized 
by pattern recognition receptors (PRRs), such as Toll-like receptors (TLR), on immune 
cells (60).  These targets are generally indispensable to the organism and therefore rarely 
become modified due to mutation (61).  With varying numbers between species, TLRs 
can detect multiple PAMPs with TLRs 1, 2, 4, 5, and 6 recognizing bacterial products 
exclusively (62).  After recognition, PRRs signal to the host via signalling cascades, 
which ultimately results in the activation of gene expression and the production of a wide 
range of molecules such as cytokines, chemokines, cell adhesion molecules, and 
immunoreceptors (60). 
TLRs are present on numerous innate cell types such as macrophages, neutrophils, and 
dendritic cells (DC).  Distributed throughout the body in morphologically diverse forms, 
macrophages are capable of engulfing invading microbes, causing the release of 
cytokines.  This in turn diverts blood flow to the affected tissue in order to attract cells 
capable of killing microbes including more macrophages as well as neutrophils and DCs 
(60-62).  DCs, like macrophages, are also found in most parts of the body and kill 
microbes via phagocytosis.  Coming into contact with pathogens causes these cells to 
activate, starting the production of cytokines (63).  One important feature of both DCs 
and macrophages is the ability to present foreign antigen to naïve T cells, creating the 
bridge between the innate to the adaptive immune systems (61, 64).  Neutrophils likewise 
combat invading microbes using phagocytosis, but also possess granules made up of 
proteolytic enzymes and antimicrobial proteins that combine with phagosomes in a 
process called degranulation (65, 66).  Activated neutrophils also create neutrophil 
extracellular traps, generated by the release of DNA and granule components, to trap and 
destroy invading microbes (66).  
The last major component of the innate immune system discussed here is the complement 
system, which can recognize invading pathogens through the classical, alternate, or lectin 
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pathway (67).  Activated in different manners, the complement pathways begin a highly 
regulated cascade of enzymatic reactions that generate effector compounds able to 
intercept invading pathogens and induce a pro-inflammatory response (68, 69).  Classical 
and lectin pathways are activated via bound antibodies and microbial carbohydrates, 
respectively.  The alternate pathway, on the other hand, is autoactivated, with the 
hydrolyzation that begins the cascade always occurring at a slow rate (68, 70).  These 
effector compounds bind to self and non-self carbohydrates, lipids, and proteins 
indiscriminately.  Self-cells block further activation through the presence of specific 
regulatory proteins.  Pathogens, lacking these proteins, further activate the complement 
system (68, 70).  This leads to the production of C3b, an opsonin that coats the cell, 
inducing phagocytosis, and the assembly of the membrane attack complex, which causes 
pore formation and lysis (68). 
1.5.2 Mechanisms of adhesion 
Once the initial barriers have been crossed, S. pyogenes must adhere to host cells to begin 
colonization.  To accomplish this, S. pyogenes utilize surface components called adhesins, 
which bind in a stereochemical manner to complementary molecules on the tissue surface 
called ligands or receptors (71).  The process of adhesion and colonization has been 
studied for decades, but it still has not been completely characterized at the molecular 
level due to its complexity.  S. pyogenes uses a multi-adhesin approach, which 
complicates research since removing a single adhesin may have little to no effect (50).  
While many different adhesins have been discovered, not all are present on each strain, 
and different adhesins have been found to be important depending on the tissue.  Some of 
the best-characterized adhesins are described below. 
1.5.2.1 Fibronectin binding proteins 
Fibronectin (Fn) was first shown as a ligand by Simpson et al. with the adherence of S. 
pyogenes to polymorphonuclear leukocytes and oral epithelial cells (72, 73).  Fn is a large 
glycoprotein dimer of two ~250 kDa fragments, each covalently linked near the C-
terminus.  Each monomer is made of 12 type I repeats, two type II repeats, and 15 to 17 
type III repeats (74).  Found as two forms, the soluble form occurs in various body fluids 
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such as plasma and the insoluble form occurs on cell surfaces and interstitial connective 
tissues (50, 75).  Numerous adhesins have been found to bind Fn and have been grouped 
together as the Fn binding proteins. 
First, the Fn binding protein F1 (PrtF1, also called SfbI) was found separately by Talay et 
al. and Hanski et al. (76, 77).  Not present in all strains of S. pyogenes, complementation 
of PrtF1/SfbI to strains without it, and unable to adhere to Fn, were then able to bind Fn 
(76-78).  Interestingly, Hanski et al. also showed that while adherence to epithelial cells 
was affected by the loss of PrtF1/SfbI, the loss of M protein had no effect (77).  
PrtF1/SfbI binds to Fn from two distinct regions; the upstream Fn-binding domain 
(UFBD) immediately followed by a region of 2 to 6 repeats of repeat domain 2 (RD2) 
(79-81).  UFBD attaches to the N-terminal region of Fn composing of both the fibrin and 
collagen binding domains (70 kDa), while just the fibrin domain (30 kDa) binds most 
efficiently to RD2 and does not interact with the collagen domain (45 kDa) (79, 81). 
Serum opacity factor (SOF, also called SfbII) was discovered based on its ability to turn 
human serum opaque.  It was not until much later that it was found that SOF had Fn 
binding domain repeats located at the C-terminus.  SOF was found on ~50% of S. 
pyogenes isolates, with 30% to 60% homology between serotypes (82-84).  Unlike 
PrtF1/SbfI, SOF binds to the 30 kDa portion of Fn, utilizing the C-terminus repeats, with 
adherence maintained by as little as one repeat (85, 86).  Knockout studies of the SOF 
gene showed that strains retained ~10% of the wild-type ability to bind Fn, and pre-
treatment with anti-SOF antibodies reduced adherence to human epithelial HEp-2 cells by 
50% (86, 87).  SOF has also been shown to bind fibulin-1, a secreted glycoprotein 
associated with the extracellular matrix, through a domain different then that of Fn.  It is 
hypothesized that SOF binds to Fn, fibulin-1, and gelatin forming a quaternary complex, 
but further research is required for confirmation (88). 
Protein F2 (PrtF2) is a Fn-binding protein comprised of two distinct variants; S. pyogenes 
Fn-binding protein (PFBP) and Fn-binding protein of group A streptococci type B 
(FbaB).  PFBP consists of a UFBD followed by three different repeat domains.  Whole 
Fn, as well as the 70 kDa and 30 kDa N-terminal fragments, can bind to the PFBD 
domain (89-92).  FbaB is shorter than PFBP due to a shortened central region, causing the 
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first half of the UFBD to be missing, followed by two to four different repeat domains 
(89, 92, 93).  It remains unknown if the shorter UFBD domain affects Fn binding, 
however, a knockout of both variants showed a significant decrease in the ability to 
adhere to epithelial cells (91, 93).  In addition, using an intraperitoneal mouse model, it 
was shown that FbaB is an important virulence factor, as a FbaB knockout showed a 50% 
reduction in lethality compared to the wild-type strain (93). 
1.5.2.2 M protein  
The best known surface structure of S. pyogenes is the M protein, encoded by the emm 
gene (94).  The M protein is an α-helical coiled-coil, extending by ~50 nm from the 
surface of the cell, and ending with a short non-helical N-terminus (95, 96).  Combined of 
many different sections, the common M protein framework is comprised of a signal 
sequence, a hypervariable terminus (A repeats), a less variable central domain (B 
repeats), and a highly conserved C-terminus (C repeats) (97-100).  Known to be involved 
in virulence, it was first shown to be important with adherence in 1972 by Ellen et al. 
when an M protein deficient S. pyogenes adhered to human buccal epithelial cells in 
fewer numbers that the wild-type (101).  This decrease could be repeated when the wild-
type was pre-treated with anti-M protein antibodies, and this phenotype was shown 
numerous times by other groups (71, 101-104).  Nevertheless, finding the M protein 
ligand has been complicated due to the multiple adhesins present, as well as the many 
different ligands to which the M protein binds.   
One M protein ligand was found to be the soluble and insoluble forms of Fn (100, 105-
107).  This was best demonstrated when L. lactis, unable to bind Fn or epithelial cells, 
was given this ability when expressing M protein (100).  While shown to bind to the B 
repeat region of the M protein, Fn has failed to bind to some M protein types, with M1, 
M3, and M5 showing definite binding (100, 106, 108, 109).   
Another M protein ligand is the complement regulatory protein (CD46), a membrane 
protein that prevents autologous complement activation (110).  Specifically, the C repeat 
of M protein was found to bind to the short consensus repeat regions 3 and 4 of CD46 
(111).  Once again, variability within M proteins was demonstrated when two of three S. 
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pyogenes strains attached to human CD46 expressed via mouse cells (104).  Feito et al. 
also showed CD46 binding even with emm deleted, indicating the presence of other 
adhesins (112).   
The M protein has also been shown to bind cell surface glycosaminoglycans (GAGs).  
Composed of repeating, unbranched disaccharide units, there are several different classes 
based on this composition.  Binding to M protein were the dermatan sulphate and heparan 
sulphate classes (113, 114).  Binding occurred predominantly via the C repeat region 
towards the C-terminus end (114). 
Finally, there has also been contradictory evidence indicating that sialic acid and fucose 
glycoproteins, contained within mucin, both do and do not act as a ligand for M protein.  
Further evidence is required in order to determine whether or not either of these are 
potential ligands (115-117). 
1.5.2.3 Pili 
Another surface structure shown to be important for adhesion by S. pyogenes has been 
pili.  While long known to be present on Gram-negative bacteria, it has only been in the 
last 11 years that pili have been found on Gram-positive bacteria, in particular S. 
pyogenes (118).  Genes encoding S. pyogenes pili are located in the highly variable 
fibronectin-binding, collagen-binding T antigen (FTC) region of the genome, and there 
are nine different types (118, 119).  These types are created through variations in gene 
sequence and overall operon structure.  Regardless of these variations, the basic pili 
structure of S. pyogenes is composed of a single backbone protein polymerized to form 
long strands with an ancillary protein cap (118, 120-126).  Many in vitro experiments 
demonstrated that the central region of the ancillary protein cap was used by S. pyogenes 
to adhere to host cells, although the corresponding ligand has never been discovered (120, 
121, 124, 126, 127).  Becherelli et al. also recovered fewer numbers of a cap protein 
knockout compared to wild-type using an intraperitoneal mouse model (126).  On the 
other hand, Crotty Alexander et al. observed increased lethality of a mutant containing a 
knockout of the backbone protein compared to wild-type in three mouse models 
(subcutaneous, pneumonia, and sepsis).  An explanation for this outcome is that pili does 
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indeed provide adhesion for colonization, but when single bacteria break away to invade 
the blood or deeper tissue, the presence of pili provides a pattern easily identified by 
phagocytes (127).  Therefore, further work is required to determine the precise function 
of pili in S. pyogenes. 
1.5.2.4 Hyaluronic acid capsule 
The capsule of S. pyogenes is composed of hyaluronic acid, a high molecular weight 
disaccharide comprised of repeating units of glucuronic acid linked to N-
acetylglucosamine (GlcNAc), and is a molecular mimic to the hyaluronic acid produced 
by humans (128, 129).  Although produced at various levels by different strains, it 
provides protection from phagocytosis, demonstrated by the inability of the mutant 
lacking the capsule to survive in blood compared to the wild-type (13, 130-133).  Further 
in vitro work demonstrated that hyaluronic acid utilizes CD44 as a ligand to bind to cells.  
Strangely, hyaluronic acid mutants were actually able to bind better than wild-type 
counterparts in vitro, presumably because hyaluronic acid masks other potential adhesins 
(128, 134).  While this may appear as a disadvantage, the hyaluronic acid capsule may 
still provide a benefit against the human host.  Utilizing intraperitoneal injection, 
pneumonia, and throat colonization models with mice, as well as baboon throat 
colonization model, the hyaluronic acid capsule mutant was cleared significantly faster or 
failed to cause disease when compared to the wild-type strain.  The theory is that the 
hyaluronic acid capsule does indeed help with adhesion, and also provides a significant 
protection against phagocytosis to allow colonization (13, 128, 130-132). 
1.5.2.5 Lipoteichoic acid 
Lipoteichoic acid (LTA) is a cell wall polymer composed of an unbranched 1,3-linked 
glycerolphosphate backbone, linked to the bacterial membrane via a lipid anchor.  The 
hydroxyl group of C2 is also modified with D-alanyl or glycosyl groups to varying 
degrees (135).  LTA from S. pyogenes was found to stick to various cells (PMNs, buccal 
epithelial cells, HEp-2), and pre-treatment of host cells with LTA prevented adherence by 
S. pyogenes, thus demonstrating LTA as an adhesin (71, 136-141).  Furthermore, utilizing 
an intranasal mouse model, treatment with LTA prior to S. pyogenes challenge 
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demonstrated a drastic reduction in colonization and the survival of all mice (141).  The 
receptor for LTA on these various cells was determined to be Fn as S. pyogenes could no 
longer bind to Fn or Fn coated beads when pre-treated with LTA (73, 106).  Specifically, 
it has been suggested that ester-linking fatty acids of LTA recognize a fatty acid binding 
site on Fn (142, 143). 
1.5.2.6 Adhesin expression and tissue tropism 
S. pyogenes possess a large number of adhesins that creates a complex system that is also 
difficult to study due to the many overlapping functions.  It is also thought that 
differential distribution and regulation of these genes would allow S. pyogenes to produce 
an adhesin profile to allow for tissue-specific tropism (44).  In support of this concept, 
research has shown that S. pyogenes strains do not all adhere to the same cells in vitro, 
indicating that they are expressing different genes. 
Numerous groups showed no difference in adherence to buccal cells when the M protein 
was removed (108, 115, 144, 145).  Conversely, Courtney et al. found differences when 
using HEp-2 epithelial cells and Wadstrom et al. found differences with human 
pharyngeal epithelial cells (115, 144, 145).  Okada et al. was able to show that loss of 
PrtF1 only had an effect on the adherence to Langerhans cells, and the loss of M protein 
only showed an effect with keratinocytes (146).  Similarly, Hanski et al. showed the 
importance of PrtF1 but not M protein with hamster trachea cells (77).  Fibronectin 
binding protein 54, on the other hand, has been shown to be necessary for adhering to 
human buccal cells, but unnecessary for HEp-2 cells (147).  Lastly, extracellular factor 
protein showed no change with Detroit 562, Ca9-22, and HEp-2 cells, however, did show 
a significant decrease in adherence to HaCaT cells (all epithelial cells) (148).  
Based on data such as this, the theory of a two-step adhesion process arose.  The first step 
involves a hydrophobic interaction between a lipid moiety of LTA and the fibronectin 
sector of the host cell.  While this reaction is weak and reversible, it allows the repulsion 
between negatively charged S. pyogenes and host cell membranes to be overcome.  The 
second step is then the attachment of an adhesin creating a tissue specific interaction that 
is almost irreversible with its receptor (50, 149, 150).  Adhesins other than M protein 
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potentially included in the model include PrtF1, SOF, and PrtF2.  Understanding the in 
vivo regulation of these adhesins and how the adhesion process occurs could greatly 
increase our knowledge of S. pyogenes and how it is able to colonize and potentially 
cause disease. 
1.5.3 Secreted proteins 
Along with surface structures, S. pyogenes secretes many proteins that aid in colonization 
and survival.  A wide range of functions include degradation of DNA from neutrophil 
extracellular traps by the DNAse Sda1, inhibition of the complement system by 
streptococcal inhibitor of complement (SIC) and C5a peptidase, and inhibition of 
opsonophagocytosis via Mac protein (6, 151).  S. pyogenes also secretes multiple 
proteases, a major one being SpyCEP, which degrades chemokines (152).   
Streptococcal pyrogenic exotoxin B (SpeB) is a cysteine protease that has garnered 
considerable attention due to its predominant secretion and indiscriminate specificity 
(153).  Some of its targets include immunoglobulins, C3b, chemokines, and fibronectin of 
the host, as well as self proteins such as M protein, C5a peptidase, Sda1, and 
streptokinase (153, 154).  Contradictory evidence has hindered the exact role of SpeB in 
virulence, nevertheless, the ability to vaccinate against S. pyogenes infection utilizing 
anti-SpeB antibodies suggests an important role (155-157). 
Also secreted are the pore forming toxins streptolysin S (SLS) and streptolysin O (SLO).  
SLS is a 2.8 kDa peptide that inserts into the membrane of targets such as erythrocytes, 
leukocytes, and platelets.  A carrier molecule such as albumin, LTA, or RNA is also 
required to function (158).  Targeting the same cells is SLO, an oxygen labile, 61 kDa 
protein that oligomerizes binding to target membrane cholesterol (159, 160).  Conflicting 
results have made identifying their function in virulence uncertain, but it appears that they 
contribute to tissue destruction and the inhibition of neutrophil recruitment (159-163). 
Finally are SAgs, potent immunostimulatory toxins that bind to the MHC class II of 
antigen presenting cells and the TCR of T cells, in a way that activates the T cell 
independent of the antigenic peptide (164).  This results in an enormous activation of T 
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cells and an immense cytokine response, secreting predominantly IL-2, IFN-γ, TNF-α, 
IL-1β, and IL-6, with the ability to cause widespread tissue damage and organ 
dysfunction (165).  Their purpose has been widely speculated since they cause the 
activation of the immune system, and possibly the death of the host, seemingly decreasing 
their own chances for survival.  However, their importance was recently shown in a 
humanized mouse model of colonization when S. pyogenes failed to colonize efficiently 
once certain SAgs were knocked out.  Restoration of the SAgs re-established the 
colonisation phenotype demonstrating their role in colonization (166). 
1.5.4 Invasion 
Another characteristic of S. pyogenes is the ability to invade different types of eukaryotic 
cells (167-169).  S. pyogenes is able to invade host cells without causing any overt 
damage, yet can still be shed in the saliva, and can persist within cells in the absence of 
clinical disease (170).  Internalization occurs through the interaction of integrins on the 
surface of epithelial cells with receptors on S. pyogenes via a bridge such as Fn, causing a 
remodelling of the cytoskeleton structure (171).  Integrins are protein heterodimers made 
up of transmembrane α and β subunits with various combinations.  This defines adhesion 
specificity, allowing for the interaction with extracellular matrix ligands such as Fn, 
vitronectin, laminin, and collagen (172).  The best characterized receptors are PrtF1/SfbI 
and the M protein which interact with integrin α5β1 via whole Fn (173-176).  Many 
interactions can induce clustering which leads to cellular signalling with different 
signalling cascades shown to be created between M protein and PrtF1/SfbI (171, 177).  
The M protein causes actin polymerization which leads to a cytoskeleton rearrangement 
leading to surrounding and engulfment by microvilli using a “zipper-like” method (177-
179).  Strains expressing PrtF1/SfbI, on the other hand, cause the formation of large 
invaginations using caveolae-mediated endocytosis without actin polymerization (180-
182).  The biological significance for S. pyogenes to enter cells has yet to be fully 
elucidated (16, 169). 
1.5.5 Molecular basis of tissue tropism 
S. pyogenes strains can be further subdivided according to the disease they cause, and 
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therefore the niche in which they prefer, based on a specific genetic profile, with some 
exceptions known to exist (44).  As sequencing of many emm genes became available, 
specific profiles first began to form based on emm strains and the diseases caused.  Based 
on the combination of four different subfamily regions encoding part of the peptidoglycan 
domain of the emm protein, S. pyogenes strains were divided into five patterns from A to 
E (183-185).  Patterns A, B, and C are comprised of strains that cause pharyngitis, pattern 
D is comprised of strains that cause impetigo, and pattern E included strains that seem to 
have no preference and can cause both pharyngitis and impetigo (185).  Pattern E strains 
may be particularly important as these isolates may allow for the transfer of genetic 
material, including mobile genetic elements, between pharyngeal and skin strains.  A 
world wide sampling over six continents showed an overall distribution of 21% pattern 
A-C, 38% pattern D, and 37% pattern E (4% unidentifiable) (4).  Continued sequencing 
has identified numerous other genes specific to each pattern. 
An important genetic component of tissue tropism includes mga, formerly referred to as 
mry or virA, located upstream of emm.  mga [multiple gene regulator of group A 
Streptococcus (186)] is a positive transcriptional regulator of the emm family genes along 
with speB, scpA, and sof, among others.  Continual sequencing showed the divergence 
pattern of mga matching the pattern of the emm cluster downstream.  When looking for 
genetic links to niche specialization, Bessen et al. found that mga could be divided into 
two alleles based on its sequences.  First, mga-1 alleles were found in A-C strains, while 
mga-2 alleles were found in D and E (183, 185, 187).  Comparison of mga within the 
same allele showed minimal nucleotide diversity with differences of only 3.3% and 2.5% 
within mga-1 and mga-2, respectively.  Comparison between alleles, on the other hand, 
showed a nucleotide diversity of 24.5%.  Comparing amino acid diversity showed similar 
results of 2.9% and 1.5% within mga-1 and mga-2, respectively, and 20.7% between the 
two alleles (187). 
Another gene combination important with tissue tropism is that of plasminogen (Plg)-
binding group A streptococcal M protein (PAM), one of the emm-like genes, and 
streptokinase (Ska).  Host Plg binds to PAM, which interacts with Ska, yielding bacterial 
bound plasmin (188).  Ska, a broad spectrum proteinase involved with dissolving blood 
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clots, is made up of three domains: alpha, beta, and gamma.  When comparing sequences, 
beta showed the most divergence, causing ska to be divided into two major groups, with 
one sub group (ska-1, -2a, and -2b).  Pattern A-C is represented mostly by ska-1; 
however, those that did have ska-2 were all ska-2a.  The vast majority of pattern E strains 
possessed ska-1 and all A-C and E pattern strains lacked PAM.  When looking at D 
pattern strains, the majority possessed ska-2b and also possessed PAM.  The D strains 
that did possess ska-1 lacked PAM.  Since emm and ska are separated by 33-38 kb on the 
chromosome, it is less likely that they are associated due to tight linkage and is more 
likely due to epistasis from essential function for each other (188).  
sof is another gene linked with tissue tropism, and while SOF is distinct from the M 
protein, it parallels the M protein by serological specificity.  Located 10-16 kb upstream 
of the emm and emm-like genes, sof is regulated by mga (189, 190).  Once thought to be a 
lipoproteinase, SOF has now shown to bind high density lipoprotein in human blood 
causing the release of lipid cargo, which in turn leads to serum opacity (191, 192).  When 
comparing this to emm chromosomal patterns, sof is found in 100% of pattern E strains 
and very few other strains (44). 
Also shown to be involved in tissue tropism is the FCT region, a section of the 
chromosome 300 kb downstream from mga.  This region is highly recombinatorial and 
contains Fn- and collagen-binding proteins as well as T antigen loci (119).  Observed 
under linkage disequilibrium with mga are the regulators of FCT; rofA, a positive 
transcriptional regulator, or nra, a negative transcriptional regulator.  Strains of S. 
pyogenes contain only one or the other in most cases with rofA or nra occupying the same 
locus of the FCT region between strains (44, 187).  Along with either nra or rofA includes 
many microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) that bind to human fibronectin or collagen (prtF1 and prtF2).  This 
feature makes the proteins produced in the FCT region important for host tissue 
adherence (189).  The majority of A-C pattern strains contain rofA along with mga-1, 
while D pattern strains harbour nra with mga-2.  The E pattern strains contain rofA, 
similar to A-C strains, but possess mga-2 similar to D pattern strains (44, 187).  Along 
with this, the collagen binding protein encoded by cpa is present in the majority of pattern 
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D strains, but only about half of pattern E strains, and few pattern A-C strains.  For prtF1, 
the distribution is the opposite being present in the majority of A-C and E strains and 
being present in few D strains.  Finally, prtF2 is distributed similar to that of cpa (189). 
Another protein, S. pyogenes nicotinamide adenine dinucleotide (NAD) glycohydrolase 
(SPN), has also been implicated in playing a role in tropism.  This enzyme cleaves the 
glycosidic bond of β–NAD+, producing nicotinamide and adenosine diphosphate ribose 
(ADP-ribose) (193).  Activity of SPN can partially predict the emm pattern type; an active 
SPN shows an E pattern 85.5% of the time, D pattern 10.9% of the time, and A-C only 
3.6% of the time.  When SPN is inactive, the D patterns predominates at 63.8%, the A-C 
pattern at 31%, and the E pattern at 5.2% (194). 
Lastly, SAgs also have a molecular connection to particular emm pattern types.  It had 
been assumed that SAgs would be spread equally between strains since they are contained 
on mobile genetic elements. However, when looking at the alleles of streptococcal 
pyrogenic exotoxin A or C (speA, speC) from sequenced S. pyogenes strains, non-random 
association was found.  Patterns A-C contained speC2 while pattern E contained speC1, 
despite both patterns being well represented of the nasopharyngeal reservoir.  Pattern D 
also matched E containing speC1.  speA consists of numerous alleles but was found to 
have arose from only two lineages termed I and II.  This data showed speA to be the 
opposite of speC with E and A-C, with being of lineage I while D contained speA of 
lineage II (195). 
Through the increasing ease at which genomes can be sequenced and the data accessed, 
the complex issue of tissue tropism with S. pyogenes is becoming more clear.  While first 
grouped based solely on the emm gene sequence, an entire genomic sequence can now be 
associated with the disease causing phenotype, allowing for a more complete picture.  
Continually investigating the genome in order to understand how it functions will allow 
for a more complete phenotype associated with every genome. 
1.5.6 emm types, diseases, and the associated non-suppurative sequelae 
While each emm type pattern based on molecular evidence is associated with non-
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invasive pharyngitis and/or impetigo, patterns have also been associated with post-
streptococcal sequelae such as APSGN and ARF.  Accepted dogma of S. pyogenes 
disease philosophy has been that ARF occurs following S. pyogenes pharyngitis (196).  In 
early documented cases of ARF published in the 1880s, not a single patient was reported 
to have a skin disease before, during, or after an ARF attack (197).  In the 20th century, 
ARF continued to be seen as a consequence of pharyngitis in the general population, but 
with increased occurrences to students at boarding schools and cadets in military 
academy.  The first clear evidence of pharyngitis causing ARF was the use of randomized 
penicillin treatment for pharyngitis in military barracks in the 1950s.  The risk of ARF 
within the penicillin treated group was 70% lower (197).  It was also shown that not all 
pharyngitis strains cause ARF, with those causing ARF being termed rheumatogenic (42).  
Looking at specific molecular characteristics of the rheumatogenic strains, they fall under 
the A-C pattern and also lack the ability to produce lipoprotein lipase and SOF (42, 198).  
Based on these factors, rheumatogenic strains contain the M types 1, 3, 5, 6, 14, 18, 19, 
24, 27, and 29.  Falling under the A-C pattern further demonstrates the idea that ARF is 
preceded by pharyngitis (1, 4, 42).  However, some differences do occur, such as in 
Polynesian populations of Hawaii, where ARF was caused by S. pyogenes with M types 
71, 93, and 98 (D pattern) and M types 92, 103, and 112 (E pattern).  Despite the decline 
of ARF in the industrial developed world, this disease remains endemic in the developing 
countries, and particularly among indigenous peoples (5).   
Driven by the epidemiological evidence from the northern Australian indigenous people 
is the idea that impetigo could also be a driving force behind ARF in impetigo endemic 
regions (199).  The Australian indigenous people have the highest ARF rate in the world 
at ~550 per 100 000, yet rates of pharyngitis are low (200-202).  Impetigo, on the other 
hand, is very common with frequencies of 50-70% every year (199, 201, 202).  In 
addition, the classic rheumatic emm types are barely present, representing only 2% of the 
strains in one report (203), 6% of another (204), or were not present at all (201).  This 
lead McDonald et al. to conclude that common and recurring skin infections may lead to 
an immune response against throat infections, and that ARF, at least in this area, may 
follow impetigo infection (202).  The link between impetigo and ARF is interesting, but 
as Kaplan and Bisno described, the lack of antibodies fails to provide tangible proof of 
  
23 
active immunity, and has pointed out that other studies have shown the ability of 
rheumatogenic strains to persist within communities giving rise to the disease, despite 
being sometimes notoriously hard to isolate from ARF patients (196).  Further work is 
required to be able to completely confirm or deny this theory. 
Another question is the reason for the increased rate of ARF for the Australian indigenous 
people compared to the general population.  Interestingly, other native populations also 
possess an increase incidence of ARF within their populations.  The Māori and Pacific 
Islanders of New Zealand show a rate of ARF 10 to 20 times above the general New 
Zealand population, respectively (205).  Looking at just the 5-14 year age group, those 
most likely to get the disease, the rate is a staggering 20 to 40 times the normal 
population.  For the general population of all three groups, this leads to death rates per 
100 000 people at 7.3 and 7.0 for the Māori and Pacific Islanders, respectively, and 3.7 
for the general New Zealand population (206).  A Hawaiian study comparing Caucasian 
to Hawaiian and other Polynesian residents of the rate of ARF showed rates ranging from 
19.2 to 120.7 times greater than Caucasian people based on information from patients of 
21 years and younger (207).  Further research including all age groups demonstrated that 
the ethnic population still has a greater risk to ARF by 4.8 times.  Most importantly, this 
was not due to socioeconomic status, therefore, showing a potential genetic link for an 
increased risk of ARF for certain populations (208). 
APSGN, on the other hand, has followed infection of both the throat and skin (196).  The 
most common strains that cause APSGN from skin infections include M types 2, 49, 60, 
and 61 of the E pattern, along with M59 of pattern D and M57 of pattern A-C.  Those 
known to cause APSGN from throat infections are M1 and M12 from the A-C pattern and 
M4 and M25 of the E pattern (1, 4).  Strains of pattern E seem to be the most common 
cause of APSGN from a molecular level.  In Guizhou, China, an outbreak occurred with 
pattern E making up 73.9% of the strains, with the remaining patterns making up less than 
9% each (10).  Even in some instances when the rare M types were the ones causing 
disease, such as M types 48 and 73 in Trinidad and M type 63 in China, they were all still 
pattern E (10, 209). 
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1.5.7 Molecular mimicry 
Autoimmune diseases, such as ARF and RHD, are caused when the immune system 
recognizes self antigens as foreign, which can then lead to inflammation and possibly 
even the destruction of specific tissues (210).  This self-recognition can be induced due to 
what is known as molecular mimicry, defined as the sharing of epitopes between antigens 
on both the host and a pathogen (211).  Occurring between disparate proteins or 
molecules, epitopes must be close enough in homology to share amino acids determinants 
or conformational shapes, but still distant enough in order to be recognized as foreign by 
the immune system (212).  There have been defined antigens for mimicry such as 
identical amino acid sequences, homologous but non-identical amino acid sequences, and 
lastly, mimicry occurring on two dissimilar epitopes such as peptides and carbohydrates 
(211).  Although it is rare to identify a single pathogen that initiates a specific 
autoimmune disease, ARF has been known to be caused by S. pyogenes for many decades 
(210).  This has lead to considerable research involving molecular mimicry with S. 
pyogenes and host tissues. 
Cavelti first discovered the presence of anti-cardiac antibodies in ARF patients in 1945, 
and was able to produce them in rats using dead streptococci, showing that damage could 
still occur to the heart without the need for active dividing bacteria (43).  While present in 
those with non-supportive sequelae such as ARF and RHD, these antibodies can also be 
found in some patients with uncomplicated diseases such as pharyngitis, but at 
significantly lower titers (43, 213, 214).  Most commonly affected is the mitral valve, 
which separates the left atrium, receiving oxygenated blood from the lungs, from the left 
ventricle, which pumps oxygenated blood through the aorta.  The aortic, tricuspid, and 
pulmonary valves are less commonly affected, roughly in that order, with the pulmonary 
valve being rarely affected (41, 42). 
It is thought that monoclonal antibodies created against the α-helical coiled-coil shape of 
M protein and GlcNAc of the group A carbohydrate are the cause of this disease.  These 
antibodies are also able to bind to smooth muscle cells, cardiac myocytes, endothelial 
cells, valvular interstitial cells, basement membrane, and elastic regions (215, 216).  
Structures identified to contain the α-helical coiled-coil structures to which antibodies 
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bind to include laminin, keratin, and the intracellular proteins myosin, tropomyosin, and 
vimentin.  Various experiments were able to show cross-reactivity by deriving antibodies 
from GlcNAc, M protein, laminin, myosin, and others that could bind to all reciprocal 
antigens (215-220).  
The theory of ARF is that antibodies bind to elements on the mitral valve, causing 
damage through complement.  This causes a disruption in the endothelial layer, exposing 
more antigenic sites.  Endothelial cells, as a result, also express more vascular cell 
adhesion molecule-1 (VCAM-1).  This leads to inflammation and the attraction of 
lymphocytes that are able to extravasate under the endothelial layer forming nodules, 
leading to a Th1 response with the cytokines IL-1, TNF-α, and IFN-γ expressed.  
Repeated bouts of ARF can leave scarring on the heart valve tissue, preventing proper 
function (211, 216).  Surgery may also be required to correct severely damaged valves 
and, depending on the circumstances, can involve repair or complete replacement of the 
valve.  It has been shown that valve repair should be utilized when possible due to better 
overall outcomes compared to valve replacement (221). 
Other theories also exist to explain the cause of ARF and RHD.  Root-Bernstein proposed 
that while the overall cause is still via molecular mimicry, due to the rarity of cases in 
relation to the number of S. pyogenes infections it must occur only when a dual infection 
happens along with the coxsackie virus, which can cause myocarditis (222).  Dual 
infections of the cardiomyocytes allows an inflammatory response with binding of 
antibodies to laminin, collagen, and other exterior antigens, causing damage to expose 
myosin and other internal antigens (222).  Tandon et al., on the other hand, suggested that 
the interaction between the N-terminus of the M protein and the CB3 region in collagen 
type IV creates an antibody response against collagen, as well as an inflammatory 
response, thus no specific molecular mimicry was involved (223). 
APSGN, as previously described, is also associated with non-invasive diseases.  As far 
back as the 18th century, APSGN following scarlet fever was well known and potentially 
dangerous.  It was first postulated in 1903 by Clemens von Pirquet that APSGN was 
caused by antibody-driven immune reactions that harmed the body rather than being 
beneficial (37).  Schick first demonstrated this idea around 1908 by comparing the 
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difference in time between the response to injections of a heterologous protein to the 
onset of APSGN after scarlet fever (224).  Later in the 20th century it was realized that not 
only was scarlet fever caused by S. pyogenes, but also APSGN (37).  Sera from patients 
with APSGN were shown to contain antibodies against type IV collagen, laminin, heparin 
sulfate proteoglycan, and galactosamine-containing proteoglycan of the basement 
membrane (225, 226).  Along with these antibodies, complement protein 3 (C3) and other 
immunoglobulins were also found deposited on the glomeruli in APSGN patients (224).  
Since Schick’s work, it has been generally accepted that APSGN is an immune-mediated 
disease along with the idea that like rheumatogenic S. pyogenes, there are also 
nephritogenic strains.  Despite this, the responsible antigen(s) from S. pyogenes still 
remains debatable (227).  One of the most popular candidates is nephritis-associated 
plasmin receptor (NAPlr) (228).  NAPlr is a glycolytic enzyme with plasmin binding 
activity, and shows adhesion to fibronectin, myosin, and actin (228, 229).  In patients 
with ASPGN, anti-NAPlr antibodies were found in the sera and in glomerular biopsies 
with antibodies bound to glomerular endocapillary neutrophils, mesangial cells, 
endothelial cells and the glomerular basement membrane (228-232).  There have been 
some discrepancies, however, as Batsford et al. was unable to find these same antibodies 
within ASPGN patients in either sera or biopsies and hypothesized that these differences 
could be do to dissimilarities in genetics and demographics of the groups used between 
researchers (227, 231).  Despite this, some still believe the importance of NAPlr in the 
cause of the disease with the following theory.  In the initial stages, before antibody 
production, NAPlr accumulates in the renal glomeruli on the mesangial matrix and 
glomerular basement membrane, entering in circulation from a throat or skin infection.  
Here it traps plasmin, in its active form, causing damage by degrading the glomerular 
basement membrane through its own action or through the further activation of promatrix 
metalloproteases.  This also leads to inflammation due to the recruitment of neutrophils 
and macrophages (230, 232).  Once antibodies are formed, immune complexes have the 
ability to pass through the damaged glomerular basement membrane where they 
accumulate in the subepithelial space creating “humps”, a distinguishing characteristic of 
the disease.  Finally, the activation of complement is the last step leading to the overt 
disease stage (232). 
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The other common antigen associated with APSGN is SpeB.  Poon-King et al. isolated a 
plasmin-binding protein, that also bound with antibodies in APSGN sera, and N-terminal 
sequencing showed that it was SpeB (233). ASPGN patients showed high anti-SpeB 
(zymogen or protease form) titers compared against controls without the disease (227).  
Biopsies showed staining of anti-SpeB antibodies to mesangial areas and regions of 
peripheral capillary walls.  Double staining showed some co-localization with NAPlr and 
localization with both C3 and IgG within the humps (227, 232).  SpeB is also known for 
its plasmin binding activity, which like NAPlr, may cause inflammation leading to the 
penetration of leukocytes and antigen-antibody complexes (234). 
Most interesting is the finding of Luo et al., using a mouse model of APSGB.  Injecting 
mice with a protease negative SpeB strain of S. pyogenes resulted in IgG deposits in the 
glomeruli, along the glomerular capillary walls, and in the mesangium of the kidney.  
Along with this, leukocyte infiltration and C3 deposition was found, along with 
proteinuria.  When passively immunizing with a monoclonal anti-SpeB antibody, it was 
found to bind heat shock protein 70 and thioredoxin on mouse kidney endothelial cells.  
Antibody deposits and complement activation were also evident in the glomeruli along 
with proteinuria, showing glomerular damage.  This provided not only evidence of 
molecular mimicry and associated auto antigens, but also the potential non-importance of 
protease activity from SpeB (235). 
1.6 Identification of genes important for in vivo survival and pathogenesis 
In order to fully understand the multifaceted process of S. pyogenes colonization at the 
molecular level, an approach is required that can identify numerous components 
simultaneously.  More specifically is the identification of genes activated only by the 
environment created by the in vivo model.  There are many different techniques that have 
been developed in order to identify genes in this way.  Each has its own strengths and 
weaknesses, and sometimes are more suitable depending on the model and pathogen 
being used.  Some strategies include signature-tagged mutagenesis (STM), microarray, 
RNA sequencing (RNA-seq), differential fluorescence induction (DFI), in vivo induced 
antigen technology (IVIAT), in vivo expression technology (IVET), and recombinase-
based in vivo expression technology (RIVET), and each will be discussed below. 
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1.6.1 Signature-tagged mutagenesis 
STM is a negative selection method that uses random integration of a transposon.  First 
used in Salmonella enterica serovar Typhimurium (S. typhimurium), this method 
successfully identified known virulence genes, therefore, validating the method, as well 
as many new virulence genes (236).  In STM, a transposon is flagged with a specific 
DNA tag to allow for specific PCR identification from a mix of multiple clones.  In 
practice, a number of transposons, each with a different tag, are used to generate multiple 
transposon libraries, created from the organism of interest.  These clones are separated, 
via plating, and individual clones are picked and maintained using microtiter plates.  A 
portion of the library of clones is assembled as a pool containing one clone from each of 
the differently tagged transposon libraries.  They are grown in vitro, and from here a 
portion is removed and pooled (the input pool), and DNA is extracted.  The remaining 
pool is then exposed to the in vivo environment.  The group of clones is recovered (the 
output pool), and DNA is extracted.  PCR is then used do identify the clones present in 
both the input and output pools using primers specific for each transposon tag.  The 
presence of a clone within the input pool but absent in the output pool identifies it as a 
gene dispensable in vitro but required in vivo.  The clone can then be identified from the 
plates where it is stored for further analysis.  This must then be repeated for the remaining 
clones (236-239). 
This method has been successfully used in many different Gram-negative and positive 
bacteria including Listeria monocytogenes (240), Neisseria meningitides (241), 
Burkholderia cenocepacia (242), S. aureus (243), Streptococcus agalactiae (244), and 
also, importantly, S. pyogenes (239).  While transposon libraries can be created with 
relative ease, it does require the storage of thousands of individual clones for the 
screening process, which can be labourious since STM is a negative selection screening 
system. 
1.6.2 Microarray   
One common technique used currently to evaluate global gene expression is the 
microarray (245).  Along with gene expression profiling, microarrays can also be used for 
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(but not limited to) pathogen detection, genome comparison, single nucleotide 
polymorphism (SNP) detection, and alternate exon splicing.  For a basic microarray, an 
array of known probes is bound to a solid support and an unknown target is then 
hybridized to the array where it can be analyzed and quantified (246).  Many different 
microarray technologies exist varying in how the probe support is constructed and 
analyzed, but the most basic, and probably the most common, are the printed and the in 
situ microarrays (247). 
Printed microarrays have probes created either by PCR or using oligonucleotide 
synthesis. Based on the different production methods, PCR probes typically range from 
200 bp to 800 bp, while oligonucleotides probes typically range from 25 bp to 150 bp.  
The probes are then printed onto supports, such as glass, with the PCR probes first being 
denatured.  To increase the accuracy of measurements, each gene has multiple probes 
associated with different regions of the gene (248).  This leads to printed microarrays 
containing approximately 10 000 to 30 000 probes, but are considered low density (247).  
Next, the RNA target is extracted and converted to cDNA from two sources; the organism 
of interest obtained from the model system and the organism grown in vitro in laboratory 
conditions.  The cDNA is also labelled with fluorescent dyes; the two different sources 
each represented by a different colour.  From here equal amounts of cDNA from each 
condition are added to the slide to allow hybridization to the immobilized probes in a 
competitive manner.  The chip is scanned to determine the expression of the genes by 
measuring the intensity of the fluorescent signal.  The range of colour intensity represents 
the change of gene expression between the two samples (245, 249, 250).   
In situ-synthesized microarrays use oligonucleotide probes that are printed directly onto 
quartz wafer chips used as supports.  Similar to printed arrays, probes range from 25 bp to 
150 bp but in situ arrays typically carry more that 106 probes and therefore are considered 
high density.  These microarrays have high specificity due to the increased number of 
probes per gene, classically using 11 probes for every 600 bp.  In addition, probes with 
mismatches are also included to ensure no mispairings are occurring.  The RNA is 
extracted, converted, and labelled in the same manner, however, in situ microarrays do 
not use competitive hybridization, and instead, compare the two samples on two separate 
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identical microarrays (247, 250). 
Microarrays have many associated benefits.  They allow gene expression of an entire 
organism to be measured at once from a single RNA sample, eliminating the requirement 
of clone libraries (251).  Also, the microarray can be performed with a relatively small 
amount of RNA obtained from the source.  However, microarrays can only be constructed 
for organisms for which the genome sequence is known.  Microarrays are also currently 
not cost effective, requiring specialized equipment for operation (251). Also important to 
consider is that the upregulation of mRNA still does not necessarily indicate the 
expression of protein, as other mechanisms may yet control translation of the gene 
product.  Finally, microarrays only provide a snapshot time point from which the RNA 
was extracted.  Therefore, an accurate depiction of the organism might not be shown, as 
certain genes may not be captured during their change in regulation. 
1.6.3 RNA sequencing 
RNA-seq uses deep sequencing in order to both map and sequence the transcriptome in 
question.  Instead of capturing transcripts of interest via hybridization like microarrays, 
the transcripts are sequenced and mapped, without reference transcripts, creating a map of 
structure and expression level (249, 252).  While different sequencing technologies are 
used, RNA-seq sample preparation is relatively the same.  Briefly, RNA is converted to 
cDNA using random hexamers or poly-A primers.  Followed by RNA degradation, the 
cDNA is made double stranded.  The addition of adapters to both ends creates known 
sequences for PCR primers.  The sample is then amplified via PCR and sequenced.  The 
number of reads each gene receives allows the level of expression to be determined (252, 
253).  To date, the major RNA-seq systems include SOLiD sequencer, 454 FLX 
Pyrosequencer, and Illumina Genome Analyzer, each with their own technology for the 
PCR process. 
RNA-seq provides many benefits despite being at an early stage.  Most importantly, 
unlike hybridization technology, it can be used without a reference genome or transcript. 
Since it works at the level of the nucleotide by sequencing small fragments, RNA-seq can 
find anomalies such as SNPs, discern transcription boundaries, and identify where exons 
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splice.  Finally, RNA-seq has much greater sensitivity for genes at both low and high 
expression, creating a more accurate overall readout (252).  However, RNA-seq still 
remains very costly to use, with numerous sample reads required to ensure coverage of 
the genome and accuracy (249, 254).  Challenges also currently exist within the 
bioinformatics programs used as long stretches of single nucleotides or repeats can be 
difficult to interpret accurately.  Sample preparation can also bias the fragments towards 
either the 5’ or 3’ end, at the RNA or cDNA stage, respectively (252).  Finally, the large 
amount of sequencing data requires appropriate bioinformatics resources and expertise. 
While user friendly software is being developed, using command line languages is still 
necessary to make use of these large data files (249). 
1.6.4 Differential fluorescence induction 
Another method used to identify genes induced in specific environments is DFI.  This 
promoter trap approach utilizes green fluorescent protein (GFP) as a selectable marker 
and exploits fluorescence-activated cell sorting (FACS) to allow high-throughput 
screening of gene expression (255).  A genomic library of fragments cloned upstream of a 
promoterless gfp is created and transformed into the organism of interest.  If the fragment 
is an active promoter, gfp will be expressed, identifying the clone.  The pool of clones is 
first grown under standard in vitro conditions allowing the activation of all constitutive 
promoters.  Using FACS, these clones can be eliminated.  The remaining pool of clones 
can then be grown under the condition of interest.  Promoters specific for this condition 
will cause GFP expression, allowing these clones to be separated using FACS.  This pool 
of clones can then be plated to identify single clones that can be sequenced to determine 
the active promoter (255).  Other groups have utilized a method where the pool of clones 
is grown under the condition of interest first, identifying all active promoters, followed by 
growth under standard conditions to identify the promoters specific to the condition of 
interest (256-259).  
DFI has shown versatility due to its ability to work for both Gram-positive and Gram-
negative bacteria including Streptococcus pneumoniae (257), S. aureus (258), S. 
typhimurium (255), and L. monocytogenes (259).  DFI is able to use a positive selection 
technology to screen a large number of clones rapidly by using the semi-automated 
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approach of flow cytometry.  To date, DFI has never been used with S. pyogenes, 
however, successful creation of the system would require some modification.  S. 
pyogenes seems to possess a high background rate when viewing with green fluorescence 
under a microscope (unpublished results).  This may require the use of a red fluorescent 
gene, which is currently an active area of research in our laboratory. 
1.6.5 in vivo-induced antigen technology  
In vivo-induced antigen technology (IVIAT) is a technique that identifies the 
immunogenic antigens of a pathogen as opposed to genes or their promoters.  Briefly, 
sera from infected individuals are pooled and incubated with the organism of interest 
grown in laboratory conditions.  This allows for the absorption of the antibodies 
associated with in vitro growth from the collected sera.  Next, a genomic library from the 
organism of interest is created in protein expression vectors that are expressed in 
Escherichia coli, followed by colony hybridization with the pool of remaining antibodies 
that has not been absorbed.  Any antibodies that bind are interpreted as in vivo induced 
antigenic determinants.  Following this, colonies that bind the in vivo enriched sera have 
plasmids extracted and sequenced to determine the gene upregulated in vivo.  
Confirmation can then be determined by repeating the system using individual clones and 
qRT-PCR utilizing model systems (238).  IVIAT has been used successfully on a number 
of bacterial pathogens including Mycobacterium tuberculosis, Vibrio cholerae (260), and 
S. pyogenes (261). 
IVIAT demonstrates the ability to identify in vivo induced genes utilizing a system that 
can probe the organism of interest using material obtained from the organisms intended 
site of infection, and not a model system.  This has tremendous advantages as the 
organism is behaving in its natural state and therefore the results are more easily 
interpreted.  Along with this, IVIAT allows the screening of many clones at once.  
However, the screening process tends to be laborious and the serum must be properly 
absorbed against the organism of interest in order to ensure that all antibodies against in 
vitro proteins are removed.  Despite these efforts, there always seems to be a fair number 
of false positives as demonstrated by the groups utilizing this technique (261, 262).  
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1.7 Genes important for in vivo survival and pathogenesis of S. pyogenes 
Most of these technologies have been utilized to identify in vivo induced genes required 
by S. pyogenes to grow under various conditions.  These have helped to further improve 
knowledge about how S. pyogenes reacts with the human host from both pharyngitis and 
deep tissue infections.  Below represents a summary of the important findings learned 
about this human pathogen utilizing these technologies. 
The STM method has recovered a total of 29 genes shown to be required for S. pyogenes 
in vivo growth (239).  Six of the genes identified have also been previously identified 
including hasA, mga, smeZ, amrA, and two sil genes, lending support to the validity of the 
other genes.  Genes identified covered a range of categories including transport, 
regulators, cellular processes, and secreted proteins.  Some of the interesting genes 
involved in virulence included transport.  The first was a putative macrolide efflux pump 
(mefE) that was shown to be involved in biofilm formation but did not provide any 
antibiotic resistance (239, 263).  Another was an ABC transporter, salT, which is part of 
the salivaricin bacteriocin locus.  Interestingly, S. pyogenes does not produce the 
bacteriocin and so the function of the transporter remains unknown.  Other putative 
transporters and cytosolic proteins of unknown function were also identified showing 
there are still many genes for which we have yet to learn the function (239, 263). 
RNA-seq has been performed on S. pyogenes twice, both involved in the identification of 
small RNA (sRNA).  Tesorero et al. was able to find a small RNA with a link to acid 
stress during growth and infection by identifying the mRNA involved (264).  Another 
group, Deltcheva et al., identified a novel sRNA that forms part of the complex involved 
in the processing of pre-crRNA (CRISPR RNA; clustered, regularly interspaced short 
palindromic repeats), short RNA elements that interfere with exogenous DNA elements 
(265). 
Microarrays have probably given the most information and have been used in many 
models spanning ex vivo [human blood (266) and saliva (267)], in vitro (a range of 
temperatures) (268), and in vivo [mouse soft tissue infection models (269, 270) and a 
cynomolgus macaque model of pharyngitis (271)].  The first microarray chip for S. 
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pyogenes was created incorporating 92% of the known ORFs in strain SF370 and used to 
determine how temperature regulated gene expression.  It was shown that 9% of the 
represented genes expressed a change when grown at 29°C, with a large number of those 
genes from the extracellular proteome (268).  When using ex vivo experimentation, the 
strain and the technology changed.  The microarray utilized shorter oligonucleotides of a 
higher density, creating much greater coverage of the genome, and was designed to cover 
six different S. pyogenes strains.  Using this microarray technology, the two component 
system sptR/S was found to play a key role for persistence in saliva and was controlling 
genes involved with nutrient acquisition, response to oxidative stress, and evasion of 
innate and acquired immune responses (267, 272).  When S. pyogenes was exposed to 
blood, the greatest change in gene expression was seen at the 30 minutes (min) period 
with 76% of the genome demonstrating a difference in expression.  The streptokinase 
gene, ska, was upregulated along with adhesins such as emm1, collagen-binding proteins, 
and capsule; all of this indicating that mga was an important factor.  S. pyogenes also 
changed the expression of many genes involved with metabolic functions, through the 
covR/S two-component system, in order to adapt to its new environment (266).   
Numerous in vivo studies have also been performed to analyze gene expression at the 
genome level.  From the mouse model of soft tissue infection, it was proposed that S. 
pyogenes goes through a three-step process in order to establish itself in a host: 
establishment, adaptation, and dissemination.  These steps involve the orchestration of a 
number of genes at each stage.  Establishment implicated the activation of genes involved 
in adherence and evasion of the immune system.  Adaptation involved continued immune 
evasion as well as aggregate formation and rapid replication.  Finally, the dissemination 
stage included nutrient acquisition along with tissue breakdown and shedding (269).  
Experimental pharyngitis using cynomolgus macaques also identified three separated 
phases of disease including colonization, acute, and asymptomatic.  Colonization and 
inflammation was associated with the expression of SAgs and the different phases of 
diseases were associated with the regulators from two two-component systems (covR/S 
and spy0680/spy0681).  covR/S was not expressed during the colonization phase, but was 
turned on during the acute phase, and repressed during the asymptomatic phase.  
spy0680/spy0681 was turned on during the colonization and asymptomatic phases (271).  
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Realizing that two-component systems were important for the survival of the organism, 
the mouse abscess model was used with two-component system knockout mutants.  The 
spy0680/M5005_spy0681 knockout showed significantly larger abscess sizes compared to 
the wild-type, while the other strains showed no difference.  This was not surprising as it 
is a known repressor and has been shown to be active during the asymptomatic phase of 
experimental pharyngitis in cynomolgus macaques (270).   
Utilizing microarray data from nine strains isolated from patients before 1987, clusters 
were created composed of three invasive strains and six pharyngeal strains.  Based on 
genome expression differences of ~10% they were divided into the pharyngeal 
transcriptome profile (PTP) and the invasive transcriptome profile (ITP).  The distinction 
between the two genomes was found to be a seven bp insertion creating a truncated covS, 
the histidine kinase of the covR/S two-component system (273).  Later work showed that 
SpyCEP, a protease that increases expression in the covR/S truncation, was able to cleave 
chemokines associated with neutrophil activation, explaining their absence from sites of 
infection (274).  Important work also asked how S. pyogenes was changing from a 
metabolic perspective, and how this changed pathogenicity.  It was found that catabolite 
control protein A (CcpA) controlled virulence factors as well as carbohydrate utilization 
genes, having a severe affect on mouse oropharynx colonization (275).  Further work was 
done to examine the maltose repressor (MalR), a surface carbohydrate binding protein.  A 
malR knockout showed a significant reduction in colonization, but no lack of invasive 
disease, demonstrating how carbon sources can determine pathogenesis (276).  Future 
work continues to use the same type of gene chip covering research in many different 
areas with to increase our overall knowledge of S. pyogenes. 
Finally, utilizing the IVIAT method, 16 genes were initially identified in S. pyogenes, 
after which three were identified to be truly upregulated in vivo, as determined by qRT-
PCR analysis.  These genes included coaA, a putative pantothenate kinase, pbp1A, a 
putative penicillin binding protein, and tdcF, a hypothetical protein (261).  coaA catalyzes 
the first step in the biosynthetic pathway leading to coenzyme A, essential in the 
metabolism of fatty acids, carbohydrates, and amino acids (261).  Penicillin-binding 
proteins are essential for cell morphology and are typically involved in peptidoglycan 
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synthesis, but pbp1A was also found to be important for the resistance of phagocytosis in 
S. agalactiae (261).  tdcF encodes a hypothetical protein with 60% homology to a protein 
in Vibrio vulnificus that was found to have a translation initiation inhibitor function.  
These two genes may have a similar function found in S. pyogenes (261). 
1.8 Rationale and Hypothesis 
Each of the systems discussed have both strengths and weaknesses, and have been able to 
provide valuable information about S. pyogenes from different models and systems, 
including from the in vivo environment.  One of the major drawbacks of the techniques 
mentioned is the limitation of the extracted data to a single time point.  Utilizing RNA-
seq, microarray, or DFI, data analysis shows gene expression only at the time of 
extraction, and therefore is unable to catch genes where expression might have increased 
and then fallen back to normal levels.  STM allows the ability to identify genes necessary 
at different time points since once the gene is needed the clone will be removed from the 
pool.  However, using this method requires the storage of a massive number of individual 
clones and in vivo studies also require large numbers of animals, making the method cost 
inhibitory.  Finally, the limiting characteristic of IVIAT is due to the use of E. coli as a 
protein expression vector.  Should expression of the protein be toxic, difficult to express, 
or expressed in low quantity, the protein would not be detected by the antiserum.  
Another in vivo-induced potential model that is able to overcome some of the weaknesses 
of these systems is recombinase-based in vivo expression technology (RIVET).  RIVET 
uses a method where a permanent change is inherited when a promoter is activated, which 
can then be screened for, and potentially allows all activated clones throughout the in vivo 
growth period to be identified.  This strategy has never previously been used with S. 
pyogenes before, but has been performed on many Gram-positive organisms to date 
including S. aureus (277), M. tuberculosis (278), Lactobacillus plantarum (279), 
Enterococcus faecalis (280, 281), and Streptococcus thermophilus (282).  In order to 
learn more about S. pyogenes, RIVET will be used for the first time in this organism. 
It is hypothesized that RIVET will provide a novel tool that will be able to identify S. 
pyogenes genes that are important for colonization of the nasopharynx.   
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1.9 Major Objectives 
In order to test this hypothesis there are two major objectives.   
Objective 1: To construct and evaluate a functional RIVET system using S. pyogenes 
strain MGAS8232, utilizing a potential counter-selective gene.   
Objective 2: To use the system within our established nasopharyngeal model to allow for 
the identification of in vivo-induced genes that are required for the colonization and 
adaptation of the nasopharyngeal niche, furthering our knowledge of the organism S. 
pyogenes. 
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2.1 Introduction 
2.1.1 In vivo expression technology 
IVET was developed as a method to identify bacterial genes that are required in order to 
circumvent the immune system of the host and cause disease.  The presumption was that 
environmental cues, differently represented in various host tissues, control the expression 
of specific genes (1).  The first type of IVET system was developed utilizing a purA 
auxotrophic strain of S. typhimurium, which has greatly attenuated growth in minimal 
media and in vivo.  Therefore, in order to survive in vivo, purA would have to be 
expressed.  By cloning genome fragments prior to purA, in vivo induced promoters could 
be identified from clones that survived growth in vivo.  Briefly, S. typhimurium genomic 
DNA was partially digested into various sizes and cloned into a suicide vector, creating a 
transcriptional fusion with both purA and lacZY, potentially controlling both genes.  After 
transformation, the vectors were incorporated into the chromosome.  The pool of clones 
was then passed through the chosen mouse model, recovered, and plated on rich media in 
order to separate constitutive promoters from those that were induced in vivo.  Clones 
with constitutive promoters still expressed lacZY and were identifiable by a colourimetric 
assay. Those showing no colour, and therefore had no lacZY expression, were only active 
in vivo. These clones were also verified by lack of growth in minimal media, showing that 
purA was not expressed. In order to confirm in vivo activity, in vitro versus in vivo lacZ 
expression was measured by inoculating single clones into mice (1).  This was later 
developed to be used by Pseudomonas aeruginosa utilizing a purine deficient strain.  
Clones were identified post-in vivo growth by finding smaller sized colonizes on media 
with a minimal amount of the required purine.  This system was used to identify in vivo-
induced genes in a mouse, and in human cystic fibrosis mucus (2, 3). 
While this initial technology was successful, it was limited to the complementation of a 
purine auxotrophic strain.  To expand the system, the purA gene was replaced with a 
chloramphenicol resistance marker.  As before, a pool of plasmids containing random 
chromosomal fragments was created and cloned prior to the promoterless 
chloramphenicol gene.  The pool of plasmids was then amplified and transferred into S. 
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typhimurium via conjugal transfer utilizing E. coli.  Since the plasmid cannot replicate in 
S. typhimurium, only cells with chromosomal integrations could survive.  The cells were 
then injected into mice, after which chloramphenicol was injected twice daily and added 
to drinking water.  Once colonies were recovered, in vivo active promoters were those 
that grew in vitro showing no colour, and therefore did not express lacZ and could no 
longer resist chloramphenicol, due to the silencing of the in vivo-induced promoters.  One 
noticeable problem was the cloning of multiple fragments into some plasmids.  Therefore, 
potential clones were all verified via sequencing to ensure that only the fragment 
immediately to the 5’ end of the cat-lac fusion was used for integration into the 
chromosome.  In addition to a mouse model, a macrophage model was also used 
successfully as the in vivo system (4).  Both of these IVET systems were used to identify 
S. typhimurium genes in various in vivo models (5), along with Yersinia enterocolitica (6, 
7), demonstrating the versatility of the IVET model. 
2.1.2 Recombinase-based in vivo expression technology 
Over the years, IVET technology has been continually improved.  A major limitation of 
the assay was sensitivity, as the system required continual expression of a gene to allow 
the survival of the clone, and therefore any promoters demonstrating any short bursts of 
expression would not be detected.  In order to overcome this, a reporter system utilizing a 
heritable change was used to replace purine autotrophy (8, 9).  The chromosomal library 
was cloned in front of a promoterless resolvase gene (tnpR), which recognizes res sites on 
DNA.  TnpR mediates strand exchange between two res sites causing excision of the 
DNA in a non-reversible reaction, termed resolution. In order to make use of this system, 
a tetracycline marker was placed between two res sites, termed a cassette, and inserted 
into the chromosome of V. cholera.  The chromosomal library was then cloned upstream 
of tnpR in plasmids that were then also integrated into the chromosome.  Clones were first 
grown in vitro, followed by plating on tetracycline to eliminate those that contained 
constitutive promoters.  Therefore, all colonies that were able to grow contained inactive 
promoters (or fragments not containing promoters) and were picked, pooled, and used to 
challenge mice.  After recovery, patch plating was performed to recover tetracycline 
sensitive clones, and therefore those with in vivo active promoters (8, 9).  This method 
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was a vast improvement over other IVET models due to the fact that it eliminated the in 
vitro promoters before the in vivo selection.  This also showed the first discovery of 
antisense RNA transcripts utilizing IVET (9).  
Lowe at al. performed the first IVET in a Gram-positive species, S. aureus, several years 
later (10).  The chromosomal library was cloned in front of a promoterless tnpR and 
transformed into a strain containing an integrated kanamycin marker flanked by res sites.  
Without making use of a colourimetric assay, in vitro promoters were first eliminated by 
growth in the presence of kanamycin.  Following a murine abscess model, bacteria were 
recovered and in vivo induced promoters were identified by kanamycin sensitivity via 
colony patching (10).  Continual use and evolution of IVET beyond this point started to 
cause a change in the name of the system.  IVET only referred to the earlier scheme in 
which the library fragments were cloned in front of a purine or antibiotic gene, while the 
system utilizing library fragments to express tnpR to excise a chromosomal fragment 
between res sites was now referred to as recombinase-based in vivo expression 
technology or RIVET (11-15). 
There has been one additional major development in the RIVET system, which is now 
called second generation RIVET, that enhances post-in vivo screening.  First performed in 
M. tuberculosis, a counter-selectable gene was included within the cassette (16).  
Counter-selection works by converting a non-toxic pro-drug into a toxic form, causing 
death.  Meanwhile, the absence of the gene means the non-toxic pro-drug remains in its 
native form, and has no effect.  In this case, the sacB gene causes sensitivity to sucrose, 
presumably due to the accumulation of levans (17).  In order to identify promoters, a M. 
tuberculosis chromosomal library was cloned upstream of tnpR, and this was transformed 
into Mycobacterium smegmantis containing a res-kan-sacB-res cassette within the 
chromosome.  Growth in vitro in the presence of kanamycin eliminated all in vitro 
expressing promoters and the remaining clones were then grown in vivo, recovered, and 
then grown on sucrose.  All clones that contained in vivo induced promoters expressed 
tnpR, resolved the cassette, and were not affected by sucrose due to the loss of sacB (16).  
Second generation RIVET has been used with numerous Gram-positive species with sacB 
and uracil phosphoribosyl-transferase (upp) as popular counter-selection methods (16, 18-
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20). 
2.1.3 Utilization of the RIVET method in S. pyogenes 
Based on the second generation RIVET system as described, a cassette was to be 
constructed for S. pyogenes consisting of two selection markers for pre- and post-in vivo 
selection (Figure 2.1).  However, the Cre recombination system was applied in this work 
due to its immediate availability and its previous successful use with Streptococcus 
gordonii in our laboratory.  The Cre recombinase recognizes loxP sites to cause the 
permanent resolution event.  The cre gene comes from the E. coli P1 bacteriophage and, 
together with the loxP site, is important in the viral life cycle. The P1 DNA must be 
circularized before being packaged, and so loxP sites at either end of the linear DNA 
strand are recombined via Cre to form a circular DNA strand (21).  Therefore, similar to 
the tnpR-res system, loxP sites flanking selectable markers in the chromosome can be 
removed, or resolved, with the expression of cre within the cell.  A single loxP site 
contains two 13-nucleotide inverted repeats separated by an 8-bp spacer (bold and 
underlined) making a 34 bp site 
(ATAACTTCGTATAATGTATGCTATACGAAGTTAT) (21, 22).  Two Cre molecules 
bind to each loxP site to perform the reaction, and if the loxP sites are oriented in the 
same direction, the DNA between the sites becomes excised via recombination.  
However, when the loxP sites are oriented in opposite directions, the DNA between the 
sites is simply inverted, and would remain within the chromosome.  To perform the 
reaction it has been found that no energy co-factors are required, only buffers and simple 
salts (21). 
In order to gain further understanding by how S. pyogenes is able to both colonize and 
compete within the nasopharynx, it is important to understand how S. pyogenes adapts 
and alters gene expression in this in vivo environment.  Herein, a RIVET system was 
engineered and constructed, tested, and used for the first time with S. pyogenes in an 
established mouse pharyngeal model to provide clues as to how this important bacterial 
pathogen survives within this limited biological niche. 
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Figure 2.1: Overview of the RIVET design 
A) A genetic RIVET cassette was inserted into the genome of S. pyogenes.  The cassette 
contained an antibiotic resistance (tetracycline, tetR) marker and a counter-selection gene 
(thymidine kinase, tk).  B) Random genomic fragments from S. pyogenes were cloned 
upstream of a promoterless cre gene, and the plasmids (erythromycin resistant, ermR) 
were transformed into S. pyogenes containing the cassette.  C) The S. pyogenes promoter 
library was incubated in vitro under erythromycin and tetracycline selection.  
Erythromycin retains the plasmids and tetracycline eliminates any in vitro active 
promoters, as any active promoters will express cre, cause excision of the cassette, and 
the loss of tetracycline resistance.  The pool of remaining clones was used in an in vivo 
model of colonization.  Clones containing in vivo active promoters express cre and 
resolve the cassette.  Clones were then recovered via patching for loss of tetR.  Initially, 
counter-selection, the conversion of a non-toxic pro-drug to a toxic form, was attempted, 
however it proved to be unreliable.  Sequencing and bioinformatics were subsequently 
used to identify the in vivo induced fragments and the associated gene(s).  False positives 
were ruled out by transforming single plasmids back into cassette-containing S. pyogenes 
and grown in vitro and in vivo. 
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2.2 Materials and Methods 
2.2.1 Bacteria and growth conditions 
Bacterial strains used in this study are listed in (Table 2.1).  All cloning was carried out 
using E. coli XL1-Blue grown on Brain Heart Infusion (BHI) media (BD Biosciences, 
Franklin Lakes, NJ, USA) media supplemented with 1.5% agar (BD Biosciences, 
Franklin Lakes, NJ, USA) or Luria Burtani (LB) broth (BD Biosciences, Franklin Lakes, 
NJ, USA) broth shaking at 250 rpm.  Erythromycin (erm) was supplemented at 150 µg 
mL-1 as required.  S. pyogenes MGAS8232 is an M18 serotype isolated from a rheumatic 
fever patient in Utah in 1987 with a genome of 1.985 Mbp (NC_003485.1) (Smoot et al., 
2002).  This strain was grown statically in Todd Hewitt broth (BD Biosciences, Franklin 
Lakes, NJ, USA) with the addition of 1% yeast extract (THY) (EMD Millipore, Billerica, 
MA, USA) at 37°C.  As appropriate, 1.5% agar (Invitrogen Life Sciences, Burlington, 
Ontario, Canada) and/or erm (1 µg mL-1) and/or tetracycline (tet) (0.5 µg mL-1) was 
added.  Bacillus subtilis was grown statically overnight in BHI media at 37°C.  All 
antibiotics were purchased from Acros Organics (Thermo Fischer Scientific, New Jersey, 
NJ, USA).   
2.2.2 S. pyogenes total DNA extraction 
Briefly, for total DNA extractions two mL of overnight culture was washed twice with 
one mL of 0.2 mM sodium acetate.  The pellet was resuspended in 500 µL Tris EDTA 
Glucose buffer (10 mM Tris, 2 mM EDTA, 25% glucose), adding 5 µL 200 mg mL-1 
lysozyme and 5 µL 10 U µL-1 mutanolysin.  Cells were incubated for 1 hour (h) at 37°C.  
After centrifugation (21 000 × g), the pellet was resuspended in 500 µL lysis buffer (50 
mM EDTA, 0.2% SDS) with 5 µL 20 mg mL-1 proteinase K, 5 µL 20 mg mL-1 RNase and 
incubated at 65°C for 2 h.  Next, 50 µL 5 M potassium acetate was added, thoroughly 
mixed to precipitate proteins and centrifuged at 21 000 × g for 10 min.  The supernatant 
was put into a new tube and mixed with 500 µL ice cold 95% ethanol to precipitate DNA.  
After one wash with 70% ethanol, DNA was dried and resuspended in 100 µL Qiagen 
Elution Buffer (Qiagen, Toronto, Ontario, Canada). 
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Table 2.1: Bacterial strains used in this study 
Name Genotype Reference 
E. coli Xl1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F ́ proAB lacIqZ∆M15 Tn10 (tetR)] 
Stratagene, USA 
S. pyogenes 
MGAS8232 
Isolated 1987, M18 serotype, 1.895 Mb, 
NC_003485.1 
(23) 
B. subtilis 168 4.216 Mb, NC_000964 (24) 
S. pyogenes 
MGAS8232 Δupp 
MGAS8232 with upp removed from the chromosome This study 
S. pyogenes 
MGAS8232 Cas2 
MGAS8232 containing the loxP-tetR-tk-loxP cassette 
within the chromosome 
This study 
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2.2.3 Polymerase chain reaction 
All primers were designed using Primer3Plus (http://primer3plus.com/cgi-
bin/dev/primer3plus.cgi) and are shown in (Table 2.2).  The provided melting 
temperature (Tm), calculated with sequences without the added restriction enzymes or 
other additional sequences, was used as the annealing temperature.  Primers were ordered 
from Sigma-Aldrich (Oakville, Ontario, Canada) and resuspended in Milli’Q water at a 
100 mM stock.  All PCR was performed using the following cycle: 5 min at 95°C, [30 
seconds (sec) 95°C denature, 1 min Tm°C anneal, 1 min per 0.8 kb of length 74°C 
extension] × 36 cycles, followed by 5 min at 74°C.  All reactions utilized Pfu polymerase 
and Pfu buffer (20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH4)SO4, 5 mM 
MgSO4, 0.1 mg mL-1 bovine serum albumin, 0.1% Triton X-100) produced in house.  
Primers were used at a final concentration of 1 µM each and both Pfu and the DNA 
template were added at 1 µL per 100 µL of total reaction volume.  All reactions were 
performed in a Peltier Thermocycler PTC-200 or a MJ Mini Gradient Thermal Cycler 
(Bio-Rad Laboratories Inc, Hercules, CA, USA). 
2.2.4 DNA visualization 
DNA was visualized on 0.8% w/v agarose (Invitrogen Life Sciences, Burlington, Ontario, 
Canada) gels.  DNA was loaded using dye made in lab (5% w/v glycerol, 0.04% w/v 
bromophenol blue, 0.04% xylene cyanol) and electrophoresed for 1 h at 100 V.  All gels 
were run with the 1 kb Plus DNA Ladder as a size standard (Invitrogen Life Sciences, 
Burlington, Ontario, Canada). Gels were stained utilizing ethidium bromide (0.1%) for 15 
min and visualized under ultraviolet light. 
2.2.5 Plasmid isolation, DNA digestion, and ligation 
Plasmids were isolated from E. coli using the Qiagen Miniprep Kit (Qiagen, Toronto, 
Ontario, Canada) following the manufacturer’s instructions.  All plasmids used are listed 
in (Table 2.3).  Digestions were carried out utilizing restriction enzymes from New 
England Biolabs (Ipswich, Massachusetts, USA) or Roche (Mississauga, Ontario, 
Canada) following the manufacturer’s instructions.  All DNA was measured using a.  
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Table 2.2: Primers used in this study 
Name Sequence 5' to 3'ab Restriction Site 
upp Up For CCCTCTAGAGTGGTGCCGATTTATTTGATG XbaI 
upp Up Rev CCCGGATCCGCGAAATAACTTGACATTTTCC BamHI 
upp Down For CCCCTGCAGCTGGTGATCGTTTATTTGGGAC PstI 
upp Down Rev CCCCTCGAGCGGCCTTGATAAAGTTCATGG XhoI 
snPgyra for CGCGGATCCGCAAAAGCTCATACGGTCTT BamHI 
snPgyra rev GCGAAGCTTCCATGGGATCTTGCATTTAAGGAATGCTC NcoI 
sacB For CCCGTCGACAGGAGGATGAAAGAAACGAACCAAAAGC
CATA 
SalI 
sacB Rev CCCCTGCAGTTATTTGTTAACTGTTAATTGTCCTTGTTCA
AGGATGC 
PstI 
sacB RT for GCGGATCAAAAATGACGATT n/a 
sacB RT rev CCTTTCGCTTGAGGTACAGC n/a 
0442 RT for ACTAGCGACGACGATTGCTT n/a 
0442 RT rev ATAGCCAGTTGGCCACAAAC n/a 
upp RT for CGGAGTGGTTCCTATCCTCA n/a 
upp RT rev TTCACGCTCTTCCACATCAG n/a 
clpP RT for CGTCGTCAAACCACATCAAC n/a 
clpP RT rev ATCCCAATACCAGCACGAAG n/a 
tsf for CGCCTCGAGACTTGCTCAATTGAACCACG XhoI 
tsf rev loxp GCGATCGATATAACTTCGTATAGCATACATTATACGA
AGTTATCCGTTTTGACACAACAAAAAGA 
ClaI 
tet for CGCGGATCCAGATAAAAAGTTGATCTTTGTGAAAAC BamHI 
tet rev CGCAAGCTTTTAGAAATCCCTTTGAGAATGTTT HindIII 
tk pET for GCGCCATGGCTTCATACCCATGTCA NcoI 
tk rev CCCTCTAGATTAGTTAGCTTCACCCATTTCACG XbaI 
pepO for loxp GCGTCTAGAATAACTTCGTATAATGTATGCTATACGA
AGTTATACACCAATAAGGAAGCAAAAA 
XbaI 
pepO rev GCGCCGCGGAGCCTAAATGATTGGTGGA SacII 
tk RT for GCTCCACCACCAGCTCTTAC n/a 
tk RT rev GGTCGATGTGACGGTCTTCT n/a 
pepO RT for ATTCTGAGCCTTCCTCACGA n/a 
pepO RT rev CGAAGAAGGCAACGAAAAAG n/a 
tsf RT for GGCGTTATGGACGCTAAAAA n/a 
tsf RT rev TGCGTTTACCAATTCAACGA n/a 
cre F pTRK GCGCCTGCAGAAGGAGGCACTCAAAATGTCCAATTTAC
TGACCGTA 
PstI 
cre R pTRK GCGCCCCGGGCTAATCGCCATCTTCCAGCAG XmaI 
cre F FOR pMSP  GCGCTCTAGAAAGGAGGCACTCAAAATCTCCAATTTAC
TGACCGTA 
XbaI 
cre F REV pMSP  GCGCTCTAGAAAGGAGGCACTCAAAATCTCCAATTTAC
TGACCGTA 
XbaI 
cre R REV pMSP GCGCCTGCAGCTAATCGCCATCTTCCAGCAG PstI 
cre R FOR pMSP GCGCCTGCAGCTAATCGCCATCTTCCAGCAG PstI 
M13 For GTAAAACGACGGCCAGT n/a 
M13 Rev CAGGAAACAGCTATGAC n/a 
a-restriction sites underlined; b-loxP sites bolded 
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Table 2.3: Plasmids used in this study 
Name Notes Source/Reference 
pTRKL2 ermR low copy shuttle vector (25) 
pG+host5 ermR temperature sensitive shuttle vector (26) 
pMSP3535 ermR shuttle vector with nisin inducible promoter 
(Pnis) 
(27) 
pMSP3535::cre 
reverse 
cre cloned in reverse orientation of Pnis as control This study 
pMSP3535::cre 
forward 
cre cloned in proper orientation to Pnis This study 
pTRKL2::cre cre cloned without a promoter to accept library 
fragments 
This study 
pG+host5::Δupp pG+host5 containing the construct used to remove 
upp from the S. pyogenes MGAS8232 genome 
This study 
pCAS4tet pG+host5 containing the loxP-tetR-tk-loxP cassette 
for insertion into the genome of S. pyogenes 
MGAS8232 
This study 
pDG1515 tetR vector designated for homologous 
recombination in B. subtilis 
(28) 
pUC57::tk Codon optimized tk GenScript, Corp. 
pTRKL2::PgyrA::sacB pTRKL2 containing sacB under control of the 
MGAS8232 gyrase A promoter 
This study 
pTRKL2::PgyrA::upp pTRKL2 containing upp under control of the 
MGAS8232 gyrase A promoter 
This study 
pTRKL2::PgyrA::tk pTRKL2 containing tk under control of the 
MGAS8232 gyrase A promoter 
This study 
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NanoDrop spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA).  
Ligations were performed utilizing 0.5 µg or 1 µg of plasmid.  Sticky end inserts were 
ligated in an insert:plasmid ratio of 1:1 and incubated for 1 h at 16°C.  Blunt end ligations 
were incubated overnight at 4°C in a 5:1 ratio.  Total reaction volumes were kept at 20 µL 
and used T4 DNA Ligase (New England Biolabs, Ipswich, Massachusetts, USA). 
2.2.6 E. coli competent cells 
To prepare competent E. coli, a 1% inoculation from an overnight E. coli culture was 
made into PSI broth (2% w/v Tryptone, 0.5% w/v yeast extract, 0.5% w/v magnesium 
sulphate, pH 7.6) and grown at 37°C with aeration until an OD600 of 0.5 was reached.  
Bacteria were cooled on ice for 15 min then centrifuged at 5000 × g.  The pellet was 
resuspended 0.4× the original volume in TfbI buffer (100 mM rubidium chloride, 50 mM 
manganese chloride, 30 mM potassium acetate, 10mM calcium chloride, 15% v/v 
glycerol, pH 5.8) and chilled for 15 min.  The bacteria were centrifuged and resuspended 
in 0.04× the original volume in TfbII buffer (75 mM calcium chloride, 10 mM rubidium 
chloride, 10 mM 3-[N-morpholino]propanesulfonic acid, 15% v/v glycerol, pH 6.5), 
aliquoted (200 µL) and placed immediately at -80°C. 
2.2.7 E. coli transformation  
For transformation, competent E. coli cells were thawed on ice, 10 µL of the ligation 
reaction was added, and cells were incubated on ice for 30 min.  After heat shocking at 
42°C for 45 sec, cells were left on ice for another 2 min, 900 µL of LB media was added, 
and cells are incubated at 37°C for 1 h with shaking at 250 rpm.  Cells were plated onto 
BHI agar containing 150 µg mL-1 erm and incubated at 37°C until colonies formed.  
2.2.8 Colony PCR to identify clones 
In order to identify clones, individual colonies were numbered, picked using a sterile 
toothpick, and touched to the bottom of a PCR tube.  A PCR master mix containing M13 
primers (flanking the multiple cloning site of plasmids used) was added to each tube (20 
µL) to identify clones containing inserts.  Products were amplified and visualized on an 
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agarose gel to identify clones.  All clones were verified with sequencing at London 
Regional Genomins Centre, London, Ontario, Canada. 
2.2.9 S. pyogenes competent cells 
To prepare competent S. pyogenes cells, THY broth containing 0.6% glycine was 
inoculated 1:50 with an overnight culture.  After 2 h, hyaluronidase was added to a 
concentration of 1 mg mL-1.  Once the OD600 was between 0.25 to 0.3, bacteria were 
centrifuged at 7000 × g for 5 min. Bacteria were resuspended in 0.4× of the original 
volume in 15% glycerol.  The bacteria were centrifuged and resuspended in 0.04× the 
original volume in 15% glycerol, aliquoted (200 µL) and placed immediately at -80°C. 
2.2.10 S. pyogenes electroporation 
To transform S. pyogenes, tubes of competent S. pyogenes cells were allowed to come to 
room temperature and 2 µg DNA was added to each tube of cells, mixed, and transferred 
to a 2mm electroporation cuvette.  Using the BioRad GenePulser (Mississauga, Ontario, 
Canada), cuvettes were pulsed using 2100 V and a pulse length of 1.1 ms.  Bacteria were 
then transferred to 10 mL THY and recovered at 37°C.  After 6 h, bacteria were 
concentrated 10×, plated on THY containing the appropriate antibiotics, and incubated at 
the required temperature. 
2.2.11 Construction of S. pyogenes MGAS8232 Δupp via homologous recombination 
Using the PCR primers listed in Table 2.2, two 500 bp portions of the chromosome 
immediately flanking upp were PCR amplified and purified using the QIAquick PCR 
Purification Kit (Qiagen, Toronto, Ontario, Canada) as per the manufactuer’s instructions. 
The upstream PCR product, along with pG+host5, was digested with XbaI and BamHI, 
ligated, transformed into competent E. coli, and screened for positive clones.  Once 
verified via sequencing, this intermediate clone was digested with PstI and XhoI along 
with the downstream PCR product.  These were then ligated and transformed into 
competent E. coli, to generate pG+host5::Δupp.  The final clone was verified with 
sequencing.   
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Following electroporation of the temperature sensitive integration construct, 
pG+host5::Δupp, cells were grown at 30°C in THY erm  for 4 days, replacing media every 
24 h. Next, cells were shifted to 40°C and grown for an additional 4 days in THY erm, 
changing media every 24 h.  At this temperature, the plasmid no longer replicates, and 
cells that have integrated the plasmid will remain resistant to erm.  The culture was then 
plated for single colonies.  Clones were grown individually in THY erm, genomic DNA 
was extracted, and PCR was used to ensure integration of pG+host5::Δupp into the 
chromosome. Once confirmed, clones were grown in liquid culture at 30°C for 4 days in 
THY, replacing media every 24 h.  Two functioning origins of replication create an 
undesirable situation within the cell, forcing a recombination event to occur.  The culture 
was then plated to obtain single colonies that are patched onto plates with and without 
antibiotics to isolate colonies that have lost the plasmid, all at 40°C. Individual clones 
were then screened by PCR for the correct deletion/insertion.  Clones were then verified 
with sequencing. 
2.2.12 Verification of S. pyogenes MGAS8232 Δupp 
In order to test for sensitivity to 5-fluorouracil (5-FU), MGAS8232 Δupp and MGAS8232 
wild-type were grown overnight in THY, serially diluted 10-fold, and plated on M9T1 
(M9 salts, 1% Tryptone, 0.1% glucose, 1.5% agar) with and with out 30 µM 5-FU (EMD 
Millipore, Billerica, MA, USA) and grown overnight at 37°C.  A sample from both 
MGAS8232 Δupp and MGAS8232 wild-type overnight THY cultures were also taken for 
qRT-PCR analysis.  For growth curve analysis MGAS8232 Δupp and MGAS8232 wild-
type was grown in triplicate overnight in THY.  All samples were normalized to an OD600 
0.01 and plated in triplicate using 200 µL per well.  Following this, 50 µL of mineral oil 
was placed in the top of each well and the plate was analyzed using a Bioscreen C 
Automated Microbiology Growth Curve Analysis System  (Growth Curves USA, 
Piscataway, NJ, USA) at 37°C with constant ‘medium’ shaking, reading every 0.5 h over 
a 24 h period. 
2.2.13 Construction of counter-selection plasmids 
The sacB gene was PCR amplified from the genomic DNA of B. subtilis subs. subtilis str. 
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168, purified using the QIAquick PCR Purification Kit (Qiagen, Toronto, Ontario, 
Canada), and digested with SalI and PstI.  pTRKL2::PgyrA::sacB was created in a two step 
ligation process first cloning sacB into SalI and PstI digested pTRKL2.  PgyrA was then 
PCR amplified from S. pyogenes MGAS8232, digested with BamHI and XhoI, and ligated 
into the BamHI and SalI digested intermediate plasmid.  Clones were verified with 
sequencing at each stage.  The human herpes simplex virus-1 thymidine kinase gene was 
codon optimized for S. pyogenes and synthesized by GenScript Corp (Piscataway, NJ, 
USA).  PgyrA was amplified from MGAS8232 DNA and digested with BamHI and NcoI 
and tk was amplified from pUC57::tk (GenScript Corp) and digested with NcoI and XbaI.  
pTRKL2 was digested with XbaI and BamHI, and in one ligation reaction, the promoter 
was fused to tk to create pTRKL2::PgyrA::tk.  The construct was verified with sequencing. 
2.2.14 Testing counter-selection plasmids 
To test the different counter-selection genes, each was first transformed into S. pyogenes 
MGAS8232 as described in (2.2.10).  S. pyogenes containing each plasmid construct, as 
well as pTRKL2 as a control, was grown overnight in THY erm, serially diluted 10 fold, 
plated on the respective media, and grown overnight at 37°C.  S. pyogenes containing 
pTRKL2::PgyrA::sacB was plated on THY erm with and with out 15% sucrose.  Overnight 
growth from THY erm liquid culture was also used for qRT-PCR analysis.  S. pyogenes 
containing pTRKL2::PgyrA::tk was plated on BMEM (DMEM/F12, 1x vitamin solution, 
sodium bicarbonate, 1.5% agar) erm with and with out ganciclovir (Cedarlane Labs, 
Burlington, Ontario, Canada) at 1000 µg mL-1.  Media components were purchased as 
follows: M9 salts, Tryptone, and agar from BD Biosciences (Franklin Lakes, NJ, USA), 
glucose and sodium bicarbonate from Sigma-Aldrich (Oakville, Ontario, Canada), and 
DMEM/F12 and vitamin solution from Gibco Life Sciences (Burlington, Ontario, 
Canada) 
2.2.15 S. pyogenes RNA extraction 
S. pyogenes cells, from frozen or grown overnight in liquid media, were incubated with 
RNAprotect Cell Reagent (Qiagen, Toronto, Ontario, Canada) according to the 
manufacturers instructions.  The cells were pelleted and resuspended in 500 µL Tris 
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EDTA Glucose buffer (10 mM Tris, 2 mM EDTA, 25% glucose), adding 5 µL 200 mg 
mL-1 lysozyme and 5 µL 10 U µL-1 mutanolysin.  Cells were incubated for 1 h at 37°C.  
After centrifugation (21 000 × g), the pellet was resuspended in 500 µL lysis buffer (50 
mM EDTA, 0.2% SDS) with 5 µL 20 mg mL-1 proteinase K and incubated at 65°C for 2 
h.  The RNeasy Kit (Qiagen, Toronto, Ontario, Canada) was used according to the 
manufacturers instructions with the lysed cells. 
2.2.16 Quantitative reverse transcriptase polymerase chain reaction 
cDNA was generated from the processed RNA with SuperScript II Reverse Transcriptase 
and Random Primers (both from Invitrogen, Burlington, Ontario, Canada) according to 
the manufacturers instructions.  Primers were designed to maintain an amplicon length of 
~200 bp and Tm of ~60°C.  Along with the proS control, all genes to be measured were 
first amplified from wild-type DNA and the samples were purified using a Qiagen 
QIAquick PCR Purification Kit (Qiagen, Toronto, Ontario, Canada), quantified using a 
NanoDrop spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA), and 
serially diluted using Qiagen Elution Buffer to 10-10.  The qRT-PCR reactions were 
performed in triplicate using iQ SYBR Green Supermix (Bio-Rad, Mississauga, Ontario, 
Canada) with the appropriate primers and template.  The primer set for each gene was 
added to reactions with the following: no template, DNA gradient of the gene being 
measured from 10-3 to 10-10, and the cDNA from the sample being measured.  Samples 
were run on a Rotor-Gene 6000 (Corbett Life Science, Kirkland, Quebec, Canada) and 
analyzed with the provided software.  All cycles used an initial 95°C at 5 min followed by 
40 cycles of 10 sec 95°C denature, 10 sec 60°C anneal, and 15 sec 72°C extension. 
2.2.17 Construction of the loxP-tetR-tk-loxP cassette (pCAS4tet) 
Based on previous bioinformatic analysis of Rho-independent terminators (de Hoon et al., 
2005), a chromosomal location downstream of two opposing genes (pepO and tsf) with 
their own Rho-independent terminators was used to insert the cassette.  Two regions of 
~500 bp were designed, flanking the insertion site, to allow for homologous 
recombination of the cassette into the genome. The downstream recombination site was 
PCR amplified from the MGAS8232 genome and ligated into the XbaI and SacII sites of 
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pG+host5. Next, the upstream recombination amplicon was inserted into the XhoI and 
ClaI sites of the intermediate clone.  In order to incorporate the loxP sites, these 
sequences were included in the recombination site primers proximal to the cassette.  Next, 
PgyrA::tk was PCR amplified and cloned between the loxP sites utilizing BamHI and XbaI.  
Lastly, tetR was amplified from pDG1515, digested with HindIII and BamHI, and cloned 
into the intermediate digested with ClaI and BamHI to create the final cassette.  Clones 
were verified with sequencing at each stage and for the final construct designated 
pCAS4tet.  Each insert was also verified by individual excision from pCAS4tet and 
visualized by gel electrophoresis.  The pCAS4tet was further tested for proper excision ex 
vivo using Cre recombinase (New England Biolabs, Ipswich, Massachusetts, USA) with 
supplied positive control and empty vector (negative control) according to the 
manufacturer’s instructions.  DNA was then visualized on an agarose gel.   
2.2.18 Construction and verification of S. pyogenes MGAS8232 Cas2 
Using the recombination sites, the cassette within pCAS4tet was inserted into the 
chromosome of MGAS8232 via homologous recombination using the same method 
outlined in 2.2.11.  Successful integration of the cassette was verified via sequencing.  To 
test for spontaneous excision of the RIVET cassette, S. pyogenes MGAS8232 Cas2 
(Cas2) was grown overnight in THY tet and subcultured (1%) into THY without any 
antibiotics.  From here, daily subcultures would continue into THY without antibiotics.  A 
sample was taken daily, serially diluted 10-fold, and plated onto THY agar with or 
without tet.  Colony forming units (CFUs) were counted and compared for analysis.   
To test excision of the RIVET cassette via Cre, pMSP3535, pMSP3535::cre reverse, and 
pMSP3535::cre (Table 2.3) were transformed into MGAS8232 Cas2 and grown 
overnight in THY erm/tet.  Two samples were taken of each and resuspended in fresh 
THY erm with or without nisin at 100 ng mL-1.  After overnight growth, cells were 
serially diluted 10-fold, plated on THY agar containing erm or tet, and grown overnight. 
CFUs were counted and compared for analysis 
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2.2.19 Creation of the S. pyogenes promoter library and removal of in vitro activated 
promoters 
Total genomic DNA (gDNA) from wild-type MGAS8232 was digested with various 
amounts of Sau3AI (0, 0.25, 0.5, 1, 2, 4 Units of enzyme) for 1 h.  Digestions were used 
in 1:2 ratio ligations with pTRKL2::cre digested with BamHI.  Ligations were 
transformed into E. coli, and all colonies were scraped off plates, concentrated, and mixed 
plasmids were isolated using the Qiagen Miniprep Kit (Qiagen, Toronto, Ontario, 
Canada).  These plasmids were then transformed into Cas2. Instead of plating, cells were 
grown in liquid in the presence of erm and tet for 24 h to remove in vitro active promoters.  
A small sample was taken, serially diluted 10-fold, and plated to determine CFUs, while 
the remaining cells were frozen at -80°C for further in vivo experiments. 
2.2.20 Identification of in vivo induced promoters 
Animal experiments were conducted in accordance with guidelines established by the 
Canadian Council on Animal Care and approved by the Animal Use Subcommittee at the 
University of Western Ontario (Appendix 1). Using ~108 Cas2 CFUs from batches in 
which in vitro promoters were removed, the cells were warmed to room temperature for 
30 min, and subsequently inoculated through the nasal route into C57BL/6 mice that 
expressed both human HLA-DR4 and HLA-DQ8 mice (29) according to the method of 
Kasper et al. (30). After 48 h, mice were sacrificed and the complete nasal passages were 
removed, homogenized, and plated as described (30).  Colonies were enumerated on THY 
erm plates and the remaining cells were maintained at -80°C.  From this frozen stock, 
~150 CFU was plated onto THY agar plates and grown overnight.  Colonies were patched 
onto THY agar plates with and without tet to screen for the loss of the cassette.  Tet 
sensitive clones were subsequently grown, DNA was extracted, transformed into E. coli 
to purify plasmids, and inserts were sequenced.  Homology searches of potential promoter 
regions were performed using the Basic Local Alignment Search Tool nucleotide 
(BLASTn) tool at the website of the National Center for Biotechnology Information 
(http://www-ncbi-nlm-nih-gov). Further analysis was conducted using the Comprehensive 
Microbial Resource at the J. Craig Venter Institute (http://cmr.jcvi.org/tigr-
scripts/CMR/CmrHomePage.cgi).  
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2.3 Results 
2.3.1 Selection of a suitable counter-selection method 
In order to enhance the screening method of the RIVET system, a counter-selection 
strategy was first investigated.  Counter-selection has been used in S. pyogenes 
successfully before as a method to screen for double cross over clones when creating 
mutants (31).  Based on a strain with natural resistance to streptomycin from a mutated 
rpsL gene, the plasmid containing the genetic crossover contains a wild-type rpsL that 
would provide no protection against streptomycin.  Since the wild-type sensitive allele is 
dominant over the mutant resistant allele, when both are present the strain is sensitive to 
streptomycin.  When the sensitive gene is removed, the clone becomes resistant (32, 33).  
However, due to the lack of natural streptomycin resistance in MGAS8232, an alternative 
counter-selection was necessary.  Three potential counter-selection methods were tested 
for their potential use: sacB (levansucrase), uracil phosphoribosyltransferase (upp 
[UPRTase]), and Herpes simplex virus 1 thymidine kinase (HSV1-tk). 
The first potential counter-selection method attempted was sacB.  The sacB gene encodes 
levansucrase, which catalyzes the hydrolysis of sucrose to glucose and fructose as well as 
the polymerization of fructosyl groups to form levan (34).  It was shown previously that B. 
subtilis could be made sensitive to sucrose when expressing sacB with a mutation within 
the signal peptide.  It was hypothesized that the lethality of a mutated levansucrase is 
caused by the detrimental accumulation of levans (34).  Thought it could be made more 
efficient, the entire signal peptide was removed.  Therefore, sacB was cloned from the B. 
subtilis 168 genome, without the signal peptide, and cloned into the pTRKL2 plasmid 
under the control of the S. pyogenes gyrA promoter (PgyrA).  After the clone was verified 
with sequencing, the clone pTRKL2::PgyrA::sacB was transformed into S. pyogenes 
MGAS8232.  Along with an empty vector control, pTRKL2::PgyrA::sacB was tested on 
media containing up to 15% sucrose.  The transcription of sacB was confirmed via qRT-
PCR; however, even when grown on the highest concentration of sucrose, 
pTRKL2::PgyrA::sacB did not cause any lethality (Figure 2.2). 
The second attempt to generate a counter-selection system in S. pyogenes was the use of 
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Figure 2.2: Evaluation of sacB as a counter-selection gene in S. pyogenes 
A) Serial 10-fold dilutions of S. pyogenes MGAS8232 containing pTRKL2 (vector) or 
pTRKL2::PgyrA::sacB grown on THY agar or THY agar including 15% sucrose.  B) qRT-
PCR analysis of sacB transcription from S. pyogenes containing pTRKL2 or 
pTRKL2::PgyrA::sacB after overnight growth in THY.  Expression is relative to the 
housekeeping gene proS.  N=3, unpaired t-test, *** p<0.0001. 
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the upp gene.  In the cell, UPRTase normally converts uracil to UMP, allowing the cell to 
use exogenous uracil.  However, UPRTase can also convert 5-FU, a toxic pyrimidine, 
into 5-fluoro-UMP.  This is then metabolized into 5-fluoro-deoxyuracil monophosphate 
which inhibits thymidylate synthetase, an enzyme required for growth (35).  Since upp is 
endogenous to S. pyogenes, a knockout first had to be created.  Utilizing molecular 
recombination techniques outlined in the Materials and Methods, MGAS8232 Δupp was 
generated.  Following this, growth on media with or without 5-FU, along with 
MGAS8232 wild-type as a control, demonstrated that 5-FU was no longer toxic to 
MGAS8232 Δupp (Figure 2.3A). 
Further testing against MGAS8232 Δupp was carried out to ensure that the mutation had 
no obvious detrimental effects.  First evaluated was a growth curve against MGAS8232 
wild-type to ensure that growth was not affected.  Curiously, MGAS8232 Δupp grew at a 
faster rate to a higher overall OD than MGAS8232 wild-type (Figure 2.3B).  Next, RNA 
was extracted from both MGAS8232 wild-type and MGAS8232 Δupp, and the expression 
of the genes immediately upstream and downstream to upp were compared.  While there 
was no difference in the expression of the upstream gene, spyM18_0442, the downstream 
gene, clpP, showed increased expression with MGAS8232 Δupp (Figure 2.3C).  
Therefore, MGAS8232 Δupp contained differences that could have undesirable effects on 
in vivo growth, and for this reason, upp was not chosen for a counter-selectable marker. 
The last counter-selection method evaluated was the thymidine kinase (tk) gene from the 
Human Herpes Simplex Virus-1 (HSV).  The HSV-tk has relaxed specificity and can 
phosphorylate substrates other than thymidine.  This allows for the addition of pro-drugs 
(e.g. ganciclovir) that can be phosphorylated by HSV-tk, but are not phosphorylated by 
native tk.  Once the pro-drug is phosphorylated by HSV-tk to the mono state, it can be 
then recognized by cellular kinases and converted to the di- and tri-phosphorylated state, 
where it can be incorporated into replicating DNA, causing cessation of DNA replication, 
leading to cell death (Figure 2.4A). 
In order to engineer this human viral gene to be expressed in a prokaryote, the cDNA was 
codon optimized for S. pyogenes and synthesized.  Once produced, tk was cloned under 
the control of PgyrA in pTRKL2, transformed into MGAS8232 and tested with the pro- 
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Figure 2.3: Evaluation of upp as a counter-selection gene in S. pyogenes and 
MGAS8232 Δupp fitness 
Serial 10-fold dilutions of S pyogenes MGAS8232 wild-type (top dilutions) or 
MGAS8232 Δupp (bottom dilutions) were grown on A) M9 tryptose agar or M9 tryptose 
agar containing 30 µM 5-FU.  B) Growth curves comparing MGAS8232 wild-type and 
Δupp.  Overnight cultures were subcultured to OD600 0.01, and grown for 24 h, with OD 
measured every 0.5 h.  N=3.  C) qRT-PCR transcriptional analysis of spyM18_0442, upp, 
and clpP from MGAS8232 wild-type and Δupp after overnight growth in THY.  N=3, 
unpaired t-test, ns=0.8490 (spyM18_0442), *** p=0.0004 (upp), * p=0.0464 (clpP). 
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Figure 2.4: Ganciclovir method of counter-selection and initial test in MGAS8232 
A) Ganciclovir (GCV) and incorporation via HSV1-tk.  Due to its lack of specificity, 
HSV1-tk is able to mono-phosphorylate GCV (inset) to GCV-MP.  The kinases of S. 
pyogenes then have the ability to di- and tri-phosphorylate GCV-MP.  GVC-TP can then 
be incorporated into DNA, preventing further incorporation of nucleotides, stopping DNA 
replication, and leading to cell death.  B) Evaluation of HSV-tk and GCV as a counter-
selection pair in S. pyogenes.  Serial 10-fold dilutions of S. pyogenes MGAS8232 
containing pTRKL2 (vector) or pTRKL2::PgyrA::tk grown on BMEM agar and BMEM 
agar containing 1000 µg/ml GCV. 
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drug ganciclovir.  At the highest concentration tested, a counter-selection phenotype was 
demonstrated in which ~2 logs of growth were lost (Figure 2.4B).  This then provided a 
potential counter-selection method that could be built into the RIVET design for S. 
pyogenes.  
2.3.2 Construction of pCAS4tet  
To engineer a RIVET system, a suitable location for the cassette to be inserted into the S. 
pyogenes MGAS8232 genome had to be found prior to construction could begin.  An 
appropriate location would not compromise growth or the expression of nearby genes.  It 
was decided to identify two genes that terminated facing each other to avoid disrupting 
any promoters.  Additionally, two genes were selected each with predicted transcriptional 
terminators so that the cassette could be placed between, and therefore not disrupt any 
transcriptional units.  Using the work of Hoon et al., it was possible to find many 
promising sites, and ultimately the region between pepO and tsf was selected as an 
appropriate location (36).  Using 500 bp of chromosomal DNA to allow for 
recombination, the cassette could be inserted between the transcriptional terminators.  
These two chromosomal fragments were PCR amplified, each containing the necessary 
loxP site on one PCR primer, and each fragment was cloned into pG+host5.  Between the 
loxP sites tet and PgyA::tk, were then cloned, forming the cassette (Figure 2.5A).  Once 
completed, pCAS4tet, was verified via sequencing and restriction digestion analysis 
(Figure 2.5B).  Finally, pCAS4tet was tested for its ability to excise the cassette using the 
Cre protein.  Using empty pG+host5, a positive control (linear stranded DNA with loxP 
sites), and pCAS4tet, all were incubated with and without Cre protein and analyzed by 
agarose gel electrophoresis (Figure 2.5C).  The negative control, pG+host5, showed no 
changes with the presence of Cre, however the positive control showed the addition of 
bands, indicating that Cre had caused recombination of the loxP sites contained within the 
DNA.  Lastly, in pCAS4tet, when incubated with Cre the top band of DNA seems to have 
been split into two (arrows), as well as the addition two faint bands of approximately 3.5 
kb and 5.5 kb (arrows) (Figure 2.5C).  This indicated recombination of the loxP sites by 
Cre, and therefore, potential resolution of the cassette. 
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Figure 2.5: Visual verification of pCAS4tet construction and excision of the cassette 
via Cre 
A) Plasmid map showing the completed pCAS4tet indicating restriction enzymes used.  
The loxP sites are enlarged to show their position.  B) pCAS4tet was verified via 
restriction enzyme analysis. Each component was removed from the construct as 
indicated by restriction enzyme digestion and ran on a 0.8% agarose gel. C) Verification 
of excision of the cassette from pCAS4tet ex vivo.  The negative control (pG+host5), the 
positive control (provided with Cre protein), and pCAS4tet were incubated with or 
without Cre and ran on a 0.8% agarose gel.  Arrows indicate recombination products of 
pCAS4tet. 
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2.3.3 Creation and verification of the cassette containing strain Cas2 
Next, pCAS4tet was transformed into MGAS8232 and the cassette was inserted into the 
chromosome, via recombination events similar to the construction of MGAS8232 Δupp, 
to create Cas2.  Using qRT-PCR, the expression of pepO and tsf was compared between 
Cas2 and MGAS8232 wild-type grown in vitro.  These results showed no significant 
difference in gene expression between the two strains (Figure 2.6A).  Secondly, Cas2 
was subcultured for 7 days in vitro without tet to determine if any spontaneous resolution 
of the cassette occurred.  There appeared to be little noticeable spontaneous loss of the 
cassette (Figure 2.6B). 
Further testing was also performed to ensure that the cassette could be excised from the 
chromosome properly.  In order to analyze this, a plasmid containing cre under the 
control of a nisin inducible promoter was transformed into Cas2.  Included were two 
controls: cre in the reverse orientation, and the empty vector.  Overnight cultures were 
given fresh media with erm, with or without nisin, and plated on THY erm, as a control, 
and THY tet, the next day (Figure 2.7).  As expected, all strains were able to grow on 
THY erm regardless of the presence or absence of nisin.  On the THY tet plate, the empty 
vector and cre in reverse controls both showed the similar amount of growth with or 
without nisin.  This indicated that no cassette excision was occurring.  With cre in the 
forward orientation, loss of growth was evident on the THY tet plate both in the presence 
and absence of nisin.  Excision of the cassette in the absence of nisin was most likely 
occurring because of small amounts of cre expression due to the leakiness of the nisin 
promoter.  In contrast, those grown overnight in nisin showed no growth on THY tet, 
indicating that the cassette was properly excised under the control of Cre.  
Cas2 was also tested for counter-selection, and gave an initial positive result, however 
with further testing, the method was unfortunately deemed unreliable in Cas2 (data not 
shown).  While qRT-PCR was able to verify HSV-tk transcription (Figure 2.6A), 
Western blot analysis failed to indicate the presence of protein from whole cell 
MGAS8232 and Cas2 extracts (data not shown).  A positive control confirmed that 
antibodies were functional. 
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Figure 2.6: Assessing Cas2 suitability 
A) Measuring transcription of genes flanking the cassette.  qRT-PCR analysis of pepO, tk, 
and tsf transcription after overnight growth comparing MGAS8232 wild-type and Cas2 
relative to proS housekeeping gene.  N=3, unpaired t-test, ns=0.1439 (pepO), 
***p<0.0001 (tk), ns=0.0838 (tsf). B) Cassette stability in Cas2.  Cas2 was grown 
overnight in THY containing tet, and subcultured daily in THY.  Each day 10-fold 
dilutions of the overnight culture were plated on THY agar and THY agar tet.  CFUs were 
counted the next day with the THY agar count set as 100%. 
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Figure 2.7: Evaluation of cassette resolution in S. pyogenes Cas2 
Using the nisin inducible vector pMSP3535, Cas2 was transformed with vector, cre 
reverse, or cre forward.  Two sets of overnight cultures were given fresh THY with erm, 
and half were also given nisin.  Following overnight growth, serial 10-fold dilutions were 
plated on A) THY agar with erm and B) THY agar with tet. 
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2.3.4 Creation of a genomic library and removal of in vitro active promoters 
In order to create a S. pyogenes promoter library, genomic DNA was extracted from 
MGAS8232 and digested with various amounts (0, 0.25, 0.5, 1, 2, 4 Units) of the 
restriction enzyme Sau3AI for 1 h.  Verified on an agarose gel, Figure 2.8A demonstrates 
successful digestion.  The DNA was then purified, pooled, ligated into the pTRKL2::cre 
plasmid in a 1:2 ratio (vector:insert) and transformed into E. coli.  In order to ensure 
fragment variability, random clones were selected and PCR amplified to determine the 
insert length, with one representative gel shown in Figure 2.8B.  All E. coli clones were 
then pooled and plasmids were extracted.  The plasmids, containing library fragments, 
were transformed into Cas2, and grown overnight in the presence of erm and tet in order 
to eliminate the clones expressing in vitro promoters.  The surviving clones were then 
concentrated and frozen. 
2.3.5 Identification of promoter regions induced in vivo using an acute 
nasopharyngeal infection model 
For the in vivo identification of promoters, 108 cells were taken from the frozen library 
stocks and inoculated into the nasal passages of each of four HLA-DR4/DQ8 mice.  The 
complete nasal turbinates (cNTs) were recovered, and after 48 h, counter-selection was 
attempted, but proved to be unreliable (data not shown).  Colonies were therefore patched 
to identify clones for which the cassette had been resolved.  In total, 171 plasmids were 
isolated and sequenced, leading to 82 unique sequences after duplicates were removed 
(Appendix 2).  Sequences were analyzed using BLASTn to determine which portion of 
the MGAS8232 genome was contained within the plasmid.  The inserts were divided into 
four different categories based on their position in the chromosome.  The first were 
‘typical’ promoters in which the fragment was upstream of the 5’ end of an annotated 
ORF.  Second were ‘cryptic’ promoters, where the fragment was contained completely 
within an ORF and facing the same direction.  Third were ‘antisense’ promoters, which 
were also contained completely within an ORF, but were facing the opposite direction.  
While not typical of obvious ORFs, these cryptic and antisense promoters could be 
involved in the regulation of the genome as sRNA molecules.  Lastly, some plasmids also 
contained multiple inserts, which likely arose from cloning artifacts.  
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Figure 2.8: Confirmation of S. pyogenes MGAS8232 gDNA digestion and cloned 
fragment size variability 
A) Digestion of S. pyogenes genomic DNA.  MGAS8232 gDNA was digested with 0, 
0.25, 0.5, 1, 2, and 4 Units of Sau3AI for 1 h and analyzed on a 0.8% agarose gel.  B) 
Verification of fragment variability in the genomic library.  Plasmids were extracted from 
a random number of transformed bacteria and fragment size was measured using PCR 
with flanking primers.  Included are no template as a negative control (-) and cre only 
positive control (+). Representative PCRs are shown on a 0.8% agarose gel. 
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Since it would be difficult to determine which insert acted as the promoter in each case, 
they were removed from further analysis.  
To further classify the identified promoters, they were divided by sense (including 
‘typical’ and ‘cryptic’) and antisense, and using the gene they were associated with, 
further divided based on function using the J. Craig Venter Institute Comprehensive 
Microbial Resource (Figure 2.9).  This allowed us to determine how the in vivo induced 
loci were distributed according to their potential function. The majority of processes 
associated with sense clones include amino acid biosynthesis, degradation of proteins, 
peptides, and glycopeptides, cell envelope, cell processes, and energy metabolism. While 
the highest category for antisense clones was hypothetical proteins, the highest categories 
with functions were cellular processes and DNA metabolism. Some interesting 
differences between the two categories are the presence of amino acid biosynthesis and 
regulatory functions, found only in the sense clones, while only the antisense clones 
contain the purines, pyrimidines, nucleosides, and nucleotides category. 
2.3.6 Analysis of ‘typical’ promoter 
From the total number of clones, nine ‘typical’ promoters were found (Table 2.4). 
Function was predicted using Basic Local Alignment Search Tool protein (BLASTp) 
analysis to similar known proteins.  Of particular interest were clones IVI100 and IVI156, 
representing a minor structural protein for ΦSpeC and a bacteriocin-like protein, 
respectively.  Previous work in our lab has shown ΦSpeC to spontaneously excise from 
the chromosome in vitro, however, this has never been further explored in vivo.  
Additionally, a role for bacteriocins in niche adaptation by S. pyogenes has not been 
previously studied.  These two genes possibly provide new areas of research related to 
colonization of the host.  In order to test the validity of these promoters, the promoter-
containing plasmids of IVI100 and IVI156 were transformed back into Cas2 and re-
evaluated both in vitro and in vivo, to establish if the promoters activated as previously 
determined. 
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Figure 2.9:  Separating RIVET clones based on function 
Potential in vivo-induced promoter elements were divided between sense and antisense, 
and using the J. Craig Venter Institute Comprehensive Microbial Resource. The 
sequences were further divided based on the predicted function of the associated gene. 
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Table 2.4: Potential ‘typical’ promoters identified 
Clone Corresponding 
Gene 
Description 
IVI49 spyM18_2257 chromosome segregation protein 
IVI53 spyM18_1223 amino acid ABC transporter, periplasmic 
amino-acid binding protein 
IVI60 spyM18_0197 hypothetical protein 
IVI72 spyM18_0784 tagatose-6-phosphate aldose/ketose isomerase 
IVI84 spyM18_2004 conserved hypothetical protein 
IVI87 spyM18_1912 pyruvate formate-lyase 
IVI100 spyM18_0771 hypothetical protein, phage associated 
IVI156 spyM18_0544 putative BlpM homologue 
IVI176 spyM18_0414 conserved hypothetical protein 
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2.3.7 Clone IVI156 contained an in vivo-induced promoter 
Cas2 containing either IVI100 or IVI156 was grown in vitro overnight in THY erm and 
then plated on THY erm agar and THY erm/tet agar.  For a control, Cas2 containing the 
promoterless pTRKL2::cre was used.  As with the initial RIVET screen, both IVI100 and 
IVI156 showed no promoter activity in vitro, as indicated by the maintenance of tet 
resistance in the Cas2 (Figure 2.10).  The promoterless control also maintained tet 
resistance.  Next, multiple cultures of each clone were grown overnight in vitro, 
combined, enumerated, and frozen.  From the frozen stock, 108 of the negative control, as 
well as IVI100 and IVI156 were each used to inoculate HLA-DR4/DQ8 mice.  The 
recovered clones were then plated and compared as they were for the in vitro portion 
(Figure 2.10).  As expected, the negative control showed no loss of the cassette.  Clone 
IVI100 appeared to show some loss of growth on THY tet, although this was not 
statistically different, potentially indicating partial loss of the cassette in vivo.  This may 
indicate activation of this promoter only occured in a portion of the cells in vivo.  Clone 
IVI156, on the other hand, showed complete loss of tet resistance, indicating full in vivo 
activation. 
2.4 Discussion 
S. pyogenes is a prominent human pathogen that is responsible for over 700 million 
global infections each year. In order to accomplish this, S. pyogenes must be able to 
colonize its host efficiently.  Since humans remain the only natural host, S. pyogenes has 
evolved ways in which to efficiently colonize via the skin or pharynx.  Colonization is a 
complicated process involving many facets from both the bacterium and the host.  In 
order to further understand this process, we took a broad approach and constructed a 
versatile RIVET system to identify genes in S. pyogenes that were induced specifically 
within the pharyngeal environment using a mouse model. 
Following the method for the second generation RIVET, a counter-selection method was 
initially included in order to make post-in vivo selection more efficient.  Three different 
methods were attempted with varying success.  The sacB gene provided no counter-
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Figure 2.10: Verification of promoter activity from clones IVI100 and IVI156 
The two clones, IVI100 and IVI156,along with pTRKL2::cre as a negative control, were 
transformed individually into Cas2, grown in vitro, and inoculated into HLA-DR4/DQ8 
mice (in vivo).  From each condition, serial 10-fold dilutions were plated on THY agar 
with or without tet and enumerated.  N=6 for cre and IVI157, N=7 for IVI100. 
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selection phenotype in the presence of sucrose (Figure 2.2A).  Although it was shown 
that the sacB gene was transcribed under our experimental conditions, we cannot rule out 
potential problems with translation or the protein product itself (Figure 2.2B).  This 
problem could have been related to the complete removal of the signal peptide.  While the 
upp/5-FU combination was quite robust as a counter-selection system, the polar effects 
caused by the knockout were undesirable for use in vivo (Figure 2.3).  Additionally, use 
of upp could not be used broadly in S. pyogenes, as each strain would require mutation of 
the endogenous upp gene.  One gene that did seem to have some initial success was that 
of HSV1-tk in conjunction with GCV (Figure 2.4B).  Unfortunately, continued use 
produced inconsistent results post-in vivo.  Similar to sacB, transcription of HSV-tk was 
shown (Figure 2.6A), however, the presence of the protein itself was not (unpublished 
data).  This could be due a weak antibody or poor translation of the gene.  There is also 
the possibility that S. pyogenes is able to break down GCV and metabolize it, hence the 
high concentration initially required.  Whatever the reason, should counter-selection be 
explored in the future with S. pyogenes, there are still several different methods that could 
be attempted. Although more laborious, patching colonies onto THY tet to identify clones 
that had resolved the cassette was successful, therefore this method was used in lieu of 
counter-selection.   
Once Cas2 had been created along with the library, in vitro promoters were removed and 
the remaining fragments were exposed to the in vivo model.  From this pool, 82 unique 
plasmids were recovered representing in vivo induced fragments (Appendix 2).  These 
potential promoters controlled genes that covered a broad range of categories with some 
noticeable differences between the sense and antisense groups (Figure 2.9).  In particular, 
the antisense fragments created an interesting group as these potential promoters would 
likely be involved in negative regulation of the corresponding gene product.  
Compared to eukaryotes, the bacterial chromosome is quite compact and was once 
thought to be relatively simple, with protein being the only regulatory mechanisms (37-
39).  It has only been in the past 12 years that regulatory RNAs are commonly being 
found and shown to contain important regulatory roles (40).  Regulatory RNAs generally 
fall into one of three categories: an element contained within the 5’ untranslated region 
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(UTR) of the mRNA, trans-encoded sRNA that target one or more genes that are located 
elsewhere on the chromosome, or cis-encoded sRNA that are encoded on the opposite 
strand of the gene they target (40, 41).  Multiple studies have recently found putative 
sRNAs within S. pyogenes, supporting the idea that they represent important regulatory 
mechanisms (42-46).  Three of these, fasX, pel, and rivX, have been studied extensively 
with fasX and rivX representing trans-encoded sRNAs and pel representing a cis-encoded 
sRNA.  Using microarray analysis, fasX (fibronectin/fibrinogen-binding/haemolytic-
activity/streptokinase-regulator-X) was shown to have many mRNA targets after 
exposure to human plasma (47).  By binding to the 5’UTR of the target mRNA, fasX was 
able to improve mRNA stability and translation for some targets and reduce it for others.  
It was best known for its ability to increase the expression of streptokinase and 
streptolysin S while it negatively affected the adhesion genes Fbp54, Mrp, and pili (47-
49).  The pleiotropic effect locus (pel) is a 459 bp transcript found to have a positive 
regulatory affect on the M protein, streptokinase, SpeB, and streptolysin S.  Once the 
region was sequenced it was discovered that sagA, the structural gene of streptolysin S, 
was within pel, while the remaining eight genes of the operon were further downstream.  
Contained within different reading frames from each other, the termination sequence for 
pel is contained within sagA and sagB (50-52).  While it is unknown how pel specifically 
regulates virulence factor expression, it has been demonstrated that it works at the RNA 
level by showing continual function even when translation has been prevented (52).  Also 
shown to function without translation, rivX is an sRNA that provides a link between the 
regulators CovRS and Mga.  The two-component system CovRS, along with some other 
unknown environmental factor(s), is able to suppress rivX, which is able to enhance Mga 
expression either directly, or though another regulator.  This then has an affect on 
numerous virulence factors such as speB and emm (53, 54).  This demonstrates the 
complicated systems used in order to control the expression of bacterial genes. 
The RIVET system seems to have uncovered some potentially interesting cis-encoded 
sRNAs.  Three of these sRNAs potentially control the virulence factors Mga, SpeA and 
MF3.  Mga is an important regulator controlling greater than 10% of the genome through 
both activation and repression (55).  At its core, Mga controls genes encoding adhesion, 
invasion, and immune evasion, and therefore is vital during the early stages of 
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colonization (56, 57).  Showing peak expression during exponential growth, Mga causes 
the self-autoinduction as well as the induction of M and M family proteins, SOF, C5a 
peptidase, and SIC, among others (56, 58, 59).  Virtaneva et al. demonstrated this 
expression pattern along with SpeA, SMEZ, and two different DNases (spd3 and sdaD2) 
using cynomolgus macaques in an in vivo model (60).  Continual growth then leads to 
early and late stationary phases representing a state of persistence, and potentially spread, 
and continual change of gene expression.  This further leads to the repression of mga and 
its associated genes as well as speA, spd3 and sdaD3 (59, 60).  Therefore, it is possible 
that S. pyogenes makes use of sRNA for quick repression of mga, speA, and mf3 along 
with others. 
From the group of sense clones, nine appeared to represent typical promoters, driving the 
expression of a gene(s) (Table 2.4).  The corresponding proteins were searched using 
BLASTp to identify a potential function and three appeared to be involved with 
metabolism.  This is not surprising since S. pyogenes is able to grow in multiple niches 
within the human body including the pharynx, the skin, and also within deeper tissues.  
Each environment represents its own set of challenges, one in particular being that of 
nutrient availability.  In order to survive, S. pyogenes must alter the expression of genes 
within its chromosome accordingly to make use of the nutrients available. 
Within the upper respiratory tract, S. pyogenes is most prevalent within the oropharynx, 
but can also be found within the nasopharynx and the nasal cavity (61).  The oropharynx 
represents the area immediately behind the oral cavity, starting with the soft palate and 
the base of the tongue, and ending at the posterior pharyngeal wall (62).  Running up the 
pharynx above and beyond the soft palate until reaching the nasal septum is the 
nasopharynx, past which is the nasal cavity (63, 64).  There are few sources from which 
S. pyogenes can obtain nutrients within the pharynx and nasal cavity with relatively the 
same provisions between niches.  Common nutrients include those obtained from the 
dead and dying cells of the host and other foreign cells, along with molecules from the 
interstitial fluid of the host.  Another major nutritional component in each niche is the 
fluid created for that area: nasal fluid is present in the nasal cavity, airway surface liquid 
(ASL) lines the nasopharynx and the posterior of the oropharynx, and saliva coats the oral 
  
105 
cavity and the anterior of the oropharynx (61, 65).  These fluids provide many functions 
including lubrication, protection, and pH balance.  The fluids are relatively similar with 
major differences including water content and the concentration of certain solutes.  Nasal 
cavity fluid and ASL consist of 90-95% water, while saliva consists roughly of 99% 
water.  Some of the major solutes contained within these fluids include proteins, mucin, 
DNA, urea, and various electrolytes.  In addition, saliva can also contain food debris that 
may provide several nutrients (61, 65-67).   
One of the typical promoters involved with metabolism, IVI87, controls the protein 
pyruvate formate-lyase, which is involved in carbohydrate utilization.  The preferred 
carbon course of S. pyogenes is glucose, and when it is found in excess a state of 
homofermentative glycolysis is maintained.  Through glycolysis, glucose is converted to 
pyruvate, which is then converted to lactate, and excreted (68).  However, within the 
upper respiratory tract there exists a very limited availability of free carbohydrates such 
as glucose (65).  S. pyogenes starts to compensate for this by changing to a process of 
mixed-acid fermentation, allowing for the continued production of adenosine triphosphate 
(ATP) via the recycling of NAD+.  Mixed-acid fermentation starts with the activation of 
pyruvate formate-lyase, demonstrated by clone IVI87, to begin converting pyruvate to 
Acetyl-CoA and formate (69-71).  Acetyl-CoA can then be used in two pathways: 
conversion to acetate creating ATP, or conversion to ethanol in the process of converting 
NADH back to NAD+ (72).  However, in order to sustain itself within the upper 
respiratory tract, S. pyogenes must also find an alternate carbon source (70, 73, 74).   
One important carbon source used by bacteria in the upper respiratory tract, including 
various types of streptococci, is that of mucin (75-78).  Mucin is a large repeating 
network of interconnecting molecules, reaching up to 1000 kDa, consisting of a protein 
backbone containing carbohydrate side chains linked via serine or threonine (65, 79).  
These carbohydrate side chains include fucose, galactose, N-acetylgalactosamine, N-
acetylglucosamine, and sialic acid (80).  S. pyogenes can utilize galactose through the lac 
operon and some strains, but not all, contain fucosidases, sialidases, and other genes that 
assist in the degradation of N-glycans (81).  S. pyogenes also possess the enzymes EndoS 
and hyaluronidase that release N-acetylglucosamine from the Fc region of IgG and 
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hyaluronate, respectively (65, 82).  RIVET also indicated the expression of 
spyM18_0784, via clone IVI72, a tagatose-6-phosphate aldose/ketose isomerase, involved 
in the pathway for the metabolism of N-acetylgalactosamine (83).  This could indicate the 
use of a N-acetylgalactosamine as a carbon source within the pharynx by S. pyogenes. 
The last identified activated gene that may be involved with metabolism was 
spyM18_1223, the binding protein for a polar amino acid ABC transporter.  The binding 
protein captures the substrate, delivering it to the membrane domains that transfer it 
across the cytoplasmic membrane (84, 85).  Detection of spyM18_1223 by other groups 
has also supported in vivo induction.  When grown in THY, spyM18_1223 was shown to 
be below antibody detection level (86).  However, when grown in blood antibody binding 
was detected and, more importantly, spyM18_1223 expression was found to have 
increased two-fold when analyzed from S. pyogenes positive pharyngitis patients (87, 88).  
This suggested that spyM18_1223 was only expressed under certain metabolic 
environments, including one that was replicated within the mouse nares. 
The next typical promoter activated in the mouse colonization model controlled 
spyM18_2257 or parB.  Binding to parS sites present at the oriC of the chromosome, 
ParB is thought to bind to other proteins and aid in chromosome segregation (89).  In 
other streptococcal strains ParB has shown to be expressed as both an operon with the 
upstream gene htrA, as well as an individual gene with its own promoter (90, 91).  In this 
case, Clone IVI49 identified the activation of parB individually in vivo.  Since 
chromosome segregation would be occurring in vitro, it is possible that parB was only 
being expressed in the operon form in vitro but switched to the individual form in vivo to 
be picked up by RIVET.  This change in expression could occur due to changes in the 
nutrients available and the appearance of other means of stress. 
For three promoters, spyM18_0197, spyM18_0414, and spyM18_2004, very little is 
known of the controlled gene(s) other than the domains present on the potential protein 
that is produced.  The protein product of spyM18_0414 contains a single cystathionine β-
synthase (CBS) pair (domain), which can be found in all three kingdoms of life.  CBS 
domains can be found in proteins of a wide range of functions including channels, 
kinases, and metabolic enzymes (92, 93).  The function of this particular protein remains 
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unknown.  The second protein, encoded by spyM18_0197, contains a transglutaminase 
domain.  Transglutaminases are enzymes responsible for a variety of post-translational 
modifications to proteins, principally introducing a cross-link between lysine and 
glutamine residues (94). Some pathogens highjack the transglutaminase, such as S. 
aureus, which uses the host transglutaminase of plasma factor XIIIa to cross-link itself to 
fibrin (95).  Other bacteria produce toxins that are transglutaminases that target host Rho 
proteins, modifying them post-translationally and impairing their GTPase activity (96).  
Finally, Francisella tularensis demonstrated attenuated growth in macrophages and mice 
when a protein with a transglutaminase domain was deleted (97).  How exactly S. 
pyogenes uses spyM18_0197 has yet to be determined, but it has been shown to be useful 
for the survival of other organisms.  The third protein was spyM18_2004, containing a 
PilT N-terminus (PIN) domain. PIN domains are found in all three kingdoms of life and 
function in signalling and riboexonuclease activity (40, 98, 99).  Once again, it is 
unknown how exactly this protein is used by S. pyogenes.  
Lastly, two of the typical promoters had been selected for further study, the first being 
spyM18_0771, a structural component of ΦSpeC.  The exact function of spyM18_0771 is 
unknown, however it is similar to Gp58, a minor structural protein from a Lactococcus 
delbrueckii bacteriophage. While there was no activation from this promoter in vitro, 
there only appeared to be a subpopulation of the in vivo group in which the promoter may 
have been activated (Figure 2.10).  Unpublished observations in our lab have shown the 
spontaneous excision of ΦSpeC in vitro at the genetic level using PCR, and this 
bacteriophage element can be induced using mitomycin C.  Other groups have also shown 
the production of active ΦSpeC upon co-culture with human pharyngeal cells (100).  We 
believe that during in vitro growth, the phage DNA may be recombining in and out of the 
chromosome, but not progressing any further in the lytic phase.  In vivo, an unidentified 
signal may induce the phage, including structural components, allowing for the detection 
of the spyM18_0771 promoter. Why only a certain number of cells seem to express the 
phage in vivo could be due to microenvironments within the mouse cNT. 
The second promoter selected for further testing was upstream of spyM18_0544, which 
showed full in vivo activation (Figure 2.10).  The spyM18_0544 gene encodes a putative 
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bacteriocin-like peptide with 50% similarity to the blpM bacteriocin gene of S. 
pneumoniae.  While bacteriocins, in particular lantibiotics, have been characterized from 
S. pyogenes, there are no reports to our knowledge of functional Class II bacteriocins 
from this organism. As a human pathogen, virulence factors involved with the interaction 
with the human body garner much more attention.  However, when interacting with the 
human host, S. pyogenes will encounter many other species of bacteria, some of which 
are vying for the same space.  The outcome of these interactions will also likely be 
critical because failure to compete with the natural microbiota will also prevent 
colonization from occurring.  Further work on this mechanism is required to determine 
how S. pyogenes might make use of this tool when colonizing. 
The development of the RIVET system for the first time in S. pyogenes was a successful 
endeavour that led to the identification of numerous in vivo-induced genes.  RIVET was 
able to identify not only just genes, but also potentially sRNA under the control of an 
inducible promoter.  Although further validation is necessary, these promoters help 
demonstrate the complex nature at which the chromosome and its elements are regulated 
and how multifaceted the colonization process is at the molecular level.  RIVET was able 
to identify promoters from several different categories with many including metabolism 
and virulence factors.  One very interesting promoter identified was IVI156, controlling a 
bacteriocin-like protein.  A bacteriocin would make an important niche adaptation tool for 
S. pyogenes as it may allow for the elimination of competing bacteria.  Further research 
will determine how S. pyogenes uses it as part of its colonization process. 
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3.1 Introduction 
3.1.1 Competition for the ideal niche 
In nature, almost all microbes are found growing and interacting in complex systems, 
however our knowledge of these networks still remains incomplete largely due to the 
inability to culture the majority of microbial species (1).  Living in symbiosis with the 
human body are bacteria, archaea, viruses, fungi, and protists.  These microbes growing 
within us can be mutual (beneficial to both), commensal (beneficial to one, the other is 
unaffected), or parasitic (one growing at the expense of the other) (2).  The adult human 
body is host to approximately 1014 cells within various niches, each home to multiple 
species of bacteria (1-4).  These microbes help maintain a healthy existence by promoting 
differentiation of host tissues, liberating nutrients from unusable dietary substances, 
stimulating the immune system, and importantly, protecting from invasion by pathogens 
(5).  Discussed earlier, the body defends against pathogens utilizing physical barriers, 
antimicrobial peptides, and the complement and immune systems.  In addition to this, the 
microbiota creates an unfavourable environment or competes directly with pathogens, a 
process referred to as “colonization resistance” (5, 6).  However, sometimes a disruption 
can occur within this homeostatic balance allowing an exogenous organism to colonize a 
particular niche, which can be detrimental when this invader is a pathogen (7, 8).   
Favourable niches on the human body where S. pyogenes is able to grow and survive are 
the skin and pharynx, each having a unique environment and microbiota.  In order to live 
within a favourable habitat, bacteria possess mechanisms, or tools, in order to provide a 
competitive advantage over other organisms.  These include secondary metabolites such 
as antibiotics, glycolipids, toxins, non-ribosomal antimicrobial peptides, and bacteriocins 
(9-11).  While S. pyogenes maintains an arsenal of virulence factors that target host 
defences, the microbiota provide a different challenge.  In Chapter 2, the use of the 
RIVET system showed the activation of the bacteriocin gene spyM18_0544 when S. 
pyogenes MGAS8232 was exposed to the nasopharynx of the mouse model.  Use of a 
bacteriocin may provide the ability for S. pyogenes to overcome colonization resistance 
presented by the microbiota of the host.  Further work shown here attempted to determine 
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the role of this bacteriocin as a necessary tool for colonization by S. pyogenes. 
3.1.1.1 The skin  
The human skin has a large microbiota consisting of bacteria, viruses, and eukaryotic 
organisms.  It can be an inhospitable environment for many microbes due to the low pH, 
lack of moisture, a temperature below that of 37°C, and the presence of antimicrobial 
compounds such as fatty acids, peptides, and enzymes.  In addition to this, the continual 
sloughing of dead skin cells on the surface can also prevent bacteria from colonizing (2, 
9, 12).  The main organisms making up the microbiota on the skin consist of the genera 
Corynebacterium, Staphylococcus, Propionibacterium, Micrococcus, Malassezia, 
Brevibacterium, Dermabacter, and Acinetobacter (2, 11).  These microbiota utilize many 
methods to prevent pathogens such as S. pyogenes from colonizing.  For example, S. 
epidermidis produces antimicrobial peptides and Propionibacterium acnes produces fatty 
acids, both that are harmful to S. pyogenes (13, 14).  S. pyogenes can be found on the 
skin, but it is often in a transient stage, and rarely part of the natural microbiota.  In the 
transient stage, S. pyogenes is unable to grow or multiply, therefore, leaving them unable 
to colonize asymptomatically.  However, in some instances S. pyogenes is able to 
disseminate in a local area to cause an infection (2, 8, 12, 15). 
3.1.1.2 The oral cavity 
The human oral cavity is a unique environment containing different areas such as the 
teeth, gums, cheeks, tongue, hard and soft palate, tonsils, pharynx, and esophagus, each 
having its own microbiota (9, 16).  It is a moist environment, kept at a relatively constant 
temperature between 34°C and 36°C, with most areas maintaining a pH close to neutral 
(7, 17).  The human mouth contains Archaea, amoeba, fungi, and bacteria with the most 
common phyla in the pharynx being Firmicutes, Bacteroidetes, Proteobacteria, 
Actinobacteria, and Fusobacteria (2, 3, 18, 19).  Within the mouth, S. pyogenes colonizes 
the tonsils within the nasopharynx and oropharynx and can be found asymptomatically 
ranging from 5% to 10% of healthy adults and ranging as high as 20% in school children 
during the winter months (20).  Within the oral cavity, S. pyogenes faces multiple 
mechanisms of colonization resistance.  Lactobacilli exist within the oral tract and the 
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lactic acid produced by these bacteria has been shown to degrade the LTA of S. pyogenes 
(7, 15).  In addition, lactobacilli work indirectly by decreasing production of IL-17 and 
IL-23 through the induction of TLR2/TLR4, preventing an inflammatory response and 
decreasing the cytotoxic response and growth of S. pyogenes (21).  Streptococcal species 
also play an important role as they make up a large proportion, if not the majority, of the 
oral microbiota (16-19).  Multiple strains of Streptococcus oralis and S. salivarius were 
able to show antagonistic properties against S. pyogenes.  Planktonic S. oralis and S. 
salivarius prevented the growth of S. pyogenes when grown together, possibly indicating 
nutrient competition, while pre-treatment with either individually also reduced S. 
pyogenes cell adhesion (8, 22).  Similar to lactobacilli, S. salivarius strains also caused 
immune modulation via a decrease in IL-6, TNF-α, and IL-1β, reducing the inflammatory 
response (22).  Finally, S. salivarius also possesses a bacteriocin with potent antibacterial 
activity against S. pyogenes (8, 22).  As demonstrated, the resident bacteria provide a 
difficult obstacle to overcome for successful colonization by S. pyogenes.  Therefore, the 
production of an antimicrobial directly affecting the host microbiota, such as a 
bacteriocin, could allow S. pyogenes to circumvent their defences and more easily 
colonize. 
3.1.2 Bacteriocins 
Bacteriocins are ribosomally synthesized polypeptides that possess antibacterial activity.  
Produced by both Gram-positive and Gram-negative bacteria, bacteriocins can be active 
against single species or across genera (15, 21, 23, 24).  Importantly, bacteria also possess 
mechanisms making them immune to their own bacteriocins.  Bacteriocins range in terms 
of size, target, mode of action, and mechanism of immunity, with activity between nano 
and picomolar concentrations (24-26).  It is estimated that upwards of 99% of the 
Bacteria and Archaea have at least one bacteriocin, but extensive genome analyses would 
be required to make this more accurate (24).  Research on this area, particularly with 
Gram-positives, has become more popular due to the realization that they are far more 
prevalent than previously thought, and because they are proving to have useful 
applications in several industries.   
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3.1.2.1 Potential Uses 
Since bacteriocins are potent antimicrobials they have potential commercial uses in 
various fields.  Bacteriocins with the broadest spectrum of activity, in most cases, are 
hampered for commercial productivity due to poor solubility (27, 28).  In the food 
industry, consumers demand products with minimal processing, lacking chemical 
preservatives, yet still maintain a long shelf life.  Food-safe bacteria can produce 
bacteriocins, typically lactic acid bacteria (LAB), which provide an alternative to 
undesirable chemicals.  These bacteriocins can potentially prevent the growth of both 
pathogens and spoilage organisms (24, 29, 30).  Bacteriocins can be introduced either 
through the addition of starter cultures within food products, the addition of purified 
bacteriocins, or using food products from the first method as an ingredient in another (30, 
31).  Bacteriocins have been approved in numerous countries for use in dairy foods, 
meats, fermented and non-fermented vegetables, juices, canned vegetables, and others 
(32). 
Bacteriocins may also have potential as alternatives to antibiotics in order to combat the 
growing problem of antibiotic resistant strains.  The potential advantages of bacteriocins 
includes 1) the current lack of widespread immunity, 2) the potential specificity prevents 
the widespread destruction of the bacterial communities within the body, and 3) 
bacteriocins possess a higher potency than antibiotics with little toxicity to human cells 
(28).  The bacteriocin nisin A has been demonstrated to be effective against methicillin 
resistant S. aureus, and importantly, shows effectiveness against biofilms, normally 
resistant to vancomycin (33).  E. faecalis resistant to vancomycin has also shown 
susceptibility to bacteriocins (34). Furthermore, with animals in the food industry, 
bacteriocins have been able to reduce the incidence of post weaning diarrhea in piglets, 
therefore, improving growth, in addition to vastly reducing the population of 
Campylobacter jejuni in chickens, and in another instance, increasing the overall growth 
rate of chickens while reducing the number of Bacteroides and Enterobacteriacae (32). 
Despite having little toxicity to normal eukaryotic cells, some bacteriocins have shown to 
have anti-neoplastic potential (32).  Numerous bacteriocins including microcins, pyocins, 
pediocins, and colicins have all shown activity against cancer cells derived from humans 
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and various animals (35).  Interestingly, bacteriocins still seem to have a specific cell 
target range they affect much like their bacterial target.  While their activity against 
bacterial targets is understood in some cases, how they are able to inhibit eukaryotic cells 
has not been established (8, 22, 35, 36). 
3.1.2.2 Bacteriocin Classification 
Gram-positive bacteriocins are divided into groups in a system first created by 
Klaenhammer (37).  Over the years this classification system has been changed and 
debated as the number of bacteriocins has increased, as well as the knowledge of their 
form and function.  Based on the beginning of Klaenhammer’s system, the most agreed 
upon division consists of three groups: (I) Lantibiotics are bacteriocins that derive their 
name from the addition of unusual amino acids such as lanthionine, β-methyllanthionine, 
and dehydrated residues.  Produced as prepropeptides, they undergo post-translational 
modification by specific enzymes to modify these residues.  A final enzyme cleaves the 
signal peptide during secretion of the mature peptide.  Smaller than 5 kDa, lantibiotics are 
peptides that are active against the target cell membrane.  Various groups have subdivided 
lantibiotics based on structure, enzymes used for modification, modified residues, and/or 
conserved sequences, however, there does not appear to be any sort of consensus.  The 
most well-known and researched lantibiotic is nisin, produced by L. lactis.  (II) Class II 
bacteriocins are small heat-stable, membrane active, non-lanthionine peptides that are less 
than 10 kDa.  The vast majority are produced in an immature form containing a signal 
sequence, which is cleaved at the double glycine (Gly-Gly) processing site upon 
secretion, producing the active form.  Class II bacteriocins are predicted to form a β-sheet 
structure, with amphiphilic helices containing differing amounts of hydrophobicity, and 
an overall moderate to high heat stability (100-121°C).  Class II bacteriocins can also be 
further subdivided based on structure.  Class IIa contain the pediocin-like bacteriocins, 
such as pediocin PA-1, that include a group of Listeria-active peptides that possess an N-
terminal consensus sequence of -Tyr-Gly-Asn-Gly-Val-Xaa-Cys-.  Class IIb bacteriocins 
are made up of two peptides for activity (labelled α and β), with lactococcin G (Lcn G) as 
the first found and best studied.  Class IIc bacteriocins are peptides that are made circular 
by the covalent linking of the N- and C- termini and Class IId bacteriocins consists of 
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single, linear, non-pediocin peptides including those that are leaderless, sec-dependent or 
otherwise, without an assigned class.  Further subdividing has been considered due to the 
different peptides involved. The Class III bacteriocins consist of large heat-labile 
proteins, greater that 30 kDa, and are divided into lytic proteins (Class IIIa) and non-lytic 
proteins (Class IIIb).  Examples include lysostaphin and helveticin J, respectively (25, 32, 
38-40).  Some groups have suggested the reclassification of class III bacteriocins to 
bacteriolysins since they are deemed lytic enzymes rather than peptides (24, 38).  There 
has also been some debate of the existence of peptides containing non-proteinaceous 
moieties and therefore the addition of a Class IV.  This includes antimicrobial peptides 
requiring post-translational cysteine S-glycosylation for function, but some groups argue 
that they are S-linked glycopeptides and not bacteriocins (41-43).  Further research is 
required in order to determine whether or not this could represent another class of 
bacteriocins.  While each class has a unique method of action, immunity, and control, 
specifically Class IIb will be specifically looked at further since the putative bacteriocin 
genes identified via RIVET were consistent with a Class IIb bacteriocin. 
3.1.2.3 Class IIb mechanism of action 
All known Gram-positive bacteriocins function by disrupting the membrane of their 
target (32, 44).  Class IIb bacteriocins are typically effective against a narrow range of 
targets, many staying within the same species (45-47).  This specificity seems to be 
determined predominately by residues within the N-terminus of the peptides, with the β-
peptide seeming especially important (48, 49).  The best-known Class IIb bacteriocin is 
Lcn G of L. lactis.  Lcn G is made up of two distinct amphiphilic helical peptides (Lcn-α 
and Lcn-β) that must be present in a ratio of approximately 1:1 for activity (28, 50-53).  
The presence of GxxxG motifs on both peptides allows the formation of a parallel 
transmembrane helical-helical structure with the residues 1 to 13 of Lcn-α aligning with 
the residues 14 to 24 of Lcn-β.  This structure is perpendicular to the membrane, creating 
a pore (32-34, 50, 53-56).  The pore allows the flux of potassium, sodium, and other 
monovalent cations, with the exception of protons.  This causes depletion in ATP pools as 
the cell attempts to maintain osmotic balance, eventually leading to the dissipation of 
membrane potential and cell death (51, 52).  Recently, a probable receptor for Lcn G on 
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L. lactis target cells was found as undecaprenyl pyrophosphate phosphatase (UppP).  
UppP is a membrane spanning protein that was expressed in cells sensitive to Lcn G.  
When UppP was no longer expressed, normally sensitive L. lactis cells become resistant.  
However, the exact involvement of UppP in Lcn G pore formation has yet to be 
elucidated (57). 
3.1.2.4 Class IIb immunity 
Self-immunity to Class IIb bacteriocins such as Lcn G is achieved using a single 
immunity gene (58).  These immunity proteins lack a signal sequence and have been 
shown to be present in the membrane and the cytoplasm (35, 59, 60).  Through the use of 
hybrid experiments it was shown that it is not the toxicity itself that triggers the 
immunity, but recognition of the bacteriocin.  Based on the knowledge of Class IIa 
bacteriocins, it is speculated that Lcn G binds to its receptor, presumably UppP, creating a 
conformational change and inducing membrane leakage.  The immunity protein is 
thought to recognize the bacteriocin-receptor complex where it can bind to prevent further 
leakage (37, 57, 61, 62). 
3.1.2.5 Class IIb expression and control 
Two-peptide bacteriocins can be found constitutively expressed by some strains while 
others are transcriptionally regulated by quorum-sensing systems.  Quorum sensing 
systems are composed of an induction peptide (IP), a histidine protein kinase (HPK), and 
a response regulator (RR), with the last two collectively known as a two-component 
system (24, 38, 43, 45).  The IPs, also known as pheromones, are small, unmodified 
peptides ranging from 19 to 24 amino acids containing an N-terminal secretion signal that 
is recognized by the same export machinery as the bacteriocin it controls (63).  
Pheromones allow the cell to measure its density within the environment and respond 
accordingly by triggering the expression of genes through the two-component system 
(64).  During initial growth, the pheromone, its required transporter, and two-component 
system are expressed at a low constitutive level.  When the pheromone reaches the 
threshold level, it triggers activity of the two-component system (autoinduction) through 
binding to the outer cell membrane bound HPK (45, 64, 65).  Inducing an 
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autophosphorylation event on a conserved histidine residue on the cytoplasmic side of the 
protein, this phosphate is then transferred to the cytoplasmic RR.  This changes the 
conformation of the RR allowing for a direct interaction with the binding sites of 
associated promoters, consisting of two repeated sequences separated by a spacer, leading 
to massive expression of the bacteriocin and associated genes, as well as more 
pheromone, two-component system, and transporter (45, 65).  Transcription occurs for a 
certain amount of time until, due to an unknown mechanism, the genes are down-
regulated causing expression to revert to basal levels (64). 
3.1.3 Bacteriocins of S. pyogenes 
Identified by creating a zone of inhibition of an agar plate, it was first discovered in 1949 
that a small number of S. pyogenes possessed antimicrobial activity (31, 66).  It was not 
until many decades later this inhibitory zone was identified as the lantibiotic streptococcin 
A-FF22 (SA-FF22) (41, 67, 68).  SA-FF22 showed no activity against Gram-negative 
strains, but was active against a wide range of Gram-positive strains including S. 
agalactiae, Streptococcus equi, Streptococcus cremoris, L. lactis, Bacillus cereus, and B. 
subtilis (69, 70).  Production of SA-FF22 requires the chromosomally encoded operon 
scnKRAA’MTFEG, which consists of a two-component system (scnKR), the lantibiotic 
(scnA), modification and transport enzymes (scnMT), and an immunity complex 
(scnFEG).  Presently there is no known function of scnA’.  Production of the lantibiotic 
begins as a prepropeptide of 51 amino acids and after modification and cleavage of the 
leader sequence, export results in a final 26 amino acid peptide.  A similar lantibiotic was 
also isolated from M49 strains of S. pyogenes showing only minor differences in amino 
acid sequences (27, 69, 71). 
S. pyogenes also produces another less well-characterized lantibiotic called streptin.  
Streptin is active against a wide range of Gram-positive species such as L. lactis, S. 
pneumoniae, S. salivarius, Streptococcus sanguis, Actinomyces species, and Clostridium 
species, among others.  Streptin showed no activity against a wide range of Gram-
negative species with Prevotella intermedia being the only exception (27, 51, 52, 57, 69, 
72, 73).  Production of streptin is required by the operon srtIRKATCBFEG located on the 
chromosome.  While the process is similar of SA-FF22, streptin utilizes three genes for 
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modification and secretion (srtTCB) and also possesses an additional gene involved in 
immunity (srtI) (7, 73).  While there has also been some thought that the streptin operon 
is also involved in streptolysin S formation, other groups have shown no link, indicating 
that more research in that area is required (7, 58, 73, 74). 
S. pyogenes can also produce a Class III bacteriocin termed streptococcin A-M57 (SA-
M57) that is encoded on the 3.3 kb plasmid pDN571.  Represented by the gene scnM57, 
the only other gene appearing on the plasmid is repA for replication, indicating that all 
other required genes must be chromosomally encoded.  It is believed that SA-M57 is 
produced as a prepeptide and secreted by a Sec-dependent transport system to yield a 
mature peptide of 16.9 kDa.  An immunity protein has not yet been identified.  While it 
has not been tested with a large number of organisms for activity, SA-M57 has shown 
activity against S. epidermidis, M. luteus, L. lactis, and Actinomyces species, to name a 
few.  There has been no activity against any Gram-negative species to date (9, 75-77). 
While bacteriocins are not highly characterized within the S. pyogenes species, they do 
seem to be actively present and could potentially provide an additional advantage when 
colonizing a niche.  In Chapter 2, spyM18_0544 was identified as being induced in S. 
pyogenes MGAS8232 by an unidentified signal while colonizing the upper respiratory 
tract of humanized mice.  This gene represents a putative bacteriocin, which is likely part 
of a larger operon including the necessary components.  Bacteriocins represent an 
interesting antimicrobial that is possessed by many bacteria and may help in colonization.  
We hypothesized that spyM18_0544 (herein referred to as blpM), and the downstream 
operon, represents a functional bacteriocin system that S. pyogenes uses for colonization 
of the nasopharynx. 
3.2 Materials and Methods 
3.2.1 Bacterial strains 
All strains used are shown in Table 3.1 and grown as previously described in 2.2.1.
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Table 3.1: Bacterial strains used in this study 
Name Genotype Reference 
E. coli XL1-
Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ́ 
proAB lacIqZ∆M15 Tn10 (tetR)] 
Stratagene, USA 
S. pyogenes 
MGAS8232 
isolated 1987, M18 serotype, 1.895 Mb, NC_003485.1 (81) 
S. pyogenes 
Δblp 
MGAS8232 with the blp operon deleted from the 
chromosome 
This study 
S. pyogenes 
Cas2 
MGAS8232 containing the loxP-tetR-tk-loxP cassette 
within the chromosome 
This study 
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3.2.2 Reagents 
The silCR (DIFKLVIDHISMKARKK) (78, 79) and control (FAKDIISKLVIRMHDKK) 
peptides were synthesized by Biomatik Corporation (Cambridge, Ontario, Canada) and 
resuspended in Milli’Q water to 10 mg mL-1.  The control peptide was created by 
scrambling the amino acids present in silCR 
(http://users.umassmed.edu/ian.york/Scramble.shtml).  Inhibitors N-[N-(L-3- 
transcarboxyirane-2-carbonyl)-L-Leucyl]-agmatine (E-64) and 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) (Sigma-Aldrich, Oakville, 
Ontario, Canada) and prepared in Milli’Q water at 1 mM and 1 M, respectively. 
3.2.3 Bioinformatics 
The genome of S. pyogenes MGAS8232 has been sequenced and annotated 
(NC_003485.1) (80, 81). ORFs were found in DNA sequences using ORF Finder 
(http://www.ncbi.nlm.nih.gov/projects/gorf/).  Both DNA and protein sequences were 
aligned using ClustalW Multiple Sequence Alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  Proteins were compared using BLASTp 
from NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  Promoter elements were found using 
SoftBerry prediction of bacterial promoters 
(http://linux1.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfin
db). 
3.2.4 in vitro activation of the blpM promoter 
MGAS8232 Cas2 containing IVI156 was grown overnight in THY media containing erm 
and tet as previously described.  Cells were subcultured into fresh THY erm along with 
the silCR peptide (10 µg mL-1) or the control peptide (10 µg mL-1), and with and without 
the protease inhibitor E-64 (10 µM) or AEBSF (1 mM).  After 24 h, 1 mL of culture was 
taken, serially diluted 10-fold, and plated on THY erm, with and without tet.  For qRT-
PCR, a sample was taken at 6 h and processed as described in 2.2.15 for RNA extraction 
and 2.2.16 for qRT-PCR 
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3.2.5 Creation of the Δblp mutant 
All PCR primers and plasmids used are listed in Table 3.2.  PCR was used to amplify a 
500 bp portion of the chromosome upstream of blpM, as well as a 500 bp portion of the 
chromosome downstream of spyM18_0547.  Products were purified utilizing a QIAquick 
PCR Purification Kit (Qiagen, Toronto, Ontario, Canada) according to the manufacturer’s 
instructions.  The upstream portion, along with pG+host5, was digested using PstI and 
SalI, purified, and ligated using the same method found in 2.2.5.  After confirming the 
intermediate clone via sequencing, it was then digested with SalI and BamHI, along with 
the downstream fragment.  The fragments were purified, ligated, and transformed as 
previously described.  The final clone, pG+host5::Δblp (Table 3.2) was confirmed via 
sequencing and transformed into MGAS8232 to undergo chromosomal recombination as 
described in 2.2.10. 
3.2.6 in vitro and in vivo competition experiments 
Wild-type MGAS8232 and MGAS8232 Δblp were grown overnight in THY, 
concentrated, and frozen at -80°C.  A small portion was serially diluted 10 fold and plated 
to calculate CFUs.  MGAS8232 and MGAS8232 Δblp were warmed to room temperature 
for 30 min and mixed 1:1 based on CFU counts. For in vitro experiments, a 1% 
inoculation was grown in 10 mL of THY broth and grown for 24 h, which was chosen to 
mimic the actual growth period in vivo. For in vivo experiments, 108 CFUs from the 1:1 
mixture were used to inoculate mice as described in 2.2.20.  Following harvesting of the 
nasal passages at 48h, a sample was serially diluted 10 fold and plated to calculate CFUs 
and the remainder was frozen at -80°C.  Fifty colonies from each in vivo inoculation were 
plated on THY, numbered, and 20 colonies were picked based on a random number 
generator (www.randomizer.org/form.htm).  Each colony was grown overnight in THY, 
total DNA was extracted, and PCR was used to determine if the colony was wild-type or 
Δblp based on the presence or absence of the blp operon using primers listed in Table 3.2. 
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Table 3.2: Primers and plasmids used in this study 
Primer Name Sequence 5' to 3'a Restriction Site 
blp up for GCGCTGCAGTCATCTTAGTGACTTTTACTGTC
GG 
PstI 
blp up rev GCGGTCGACAAGAACAGTATCCTGGTTTCAA
AA 
SalI 
blp down for GCGGTCGACCCTCACTAAATATATAAATGAC
TATCTATCACTG 
SalI 
blp down rev GCGGGATCCTAGAATCACTGCAGAAATAATA
ACAATACC 
BamHI 
 
Plasmid Name Notes Source/Reference 
pG+host5 ermR temerature sensitive shuttle vector (82) 
pG+host5:: Δblp pG+host5 containing the construct used to delete the 
bacteriocin and immunity protein from the S. 
pyogenes MGAS8232 genome 
This study 
a-restriction sites underlined 
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3.3 Results 
3.3.1 Bioinformatic analysis of the blp operon 
Following the sequencing of the in vivo-induced promoter within clone IVI156, 
downstream sequences in MGAS8232 were analyzed.  IVI156 contained a nucleotide 
sequence immediately upstream of the gene spyM18_0544.  Previously found in S. 
pyogenes JS95, this genes has been labelled as blpMH (9, 83) (Figure 3.1) due to its 
similarity to blpM, a gene encoding the first peptide of a Class IIb bacteriocin system in S. 
pneumonia (Figure 3.2).  The blpMH gene was 228 bp, and encoded a theoretical peptide 
of 75 amino acids (Figure 3.2).  As mentioned earlier, Class II bacteriocins utilize 
double-glycine type leader sequences for export (27, 84) and based on the location of the 
double glycine sequence in blpMH, a mature BlpMH peptide of 52 amino acids with a 
leader sequence of 23 amino acids was predicted (Figure 3.2). 
As a putative Class IIb bacteriocin, a second peptide would be required for activity (27, 
85, 86).  Immediately downstream of blpMH was spyM18_0545, also annotated as a 
bacteriocin peptide.  Utilizing the nomenclature derived from de Saiziew et al. and 
Hidalgo-Grass et al., this second gene was designated as blpNH (Figure 3.1) (9, 27).  
blpNH had a predicted ORF of 201 bp encoding a theoretical peptide of 66 amino acids 
with similarity to BlpN of S. pneumoniae.  Once again, based on the location of the 
double glycine sequence, BlpNH was predicted to consist of a mature peptide of 48 amino 
acids with a leader sequence of 18 amino acids (Figure 3.2).   
Also present on both BlpMH and BlpNH are four and five GxxxG motifs, respectively, 
which allow for helix-helix interactions between the two peptides to create a membrane 
penetrating structure (27, 55).  Since the Class IIb bacteriocins require both peptides for 
activity, this bacteriocin will herein be referred to as BlpMNH.  The use of BLASTp 
indicated that BlpMNH was widespread in virtually all fully sequenced strains of S. 
pyogenes, with similarities of 97% and above.  However, two notable exceptions were 
found in MGAS5005 and SF370.  While BlpNH was still 97% homologous or above for 
both strains, BlpMH was truncated in MGAS5005 and had less than 30% similarity in
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Figure 3.1: The blp operon and sil locus of S. pyogenes MGAS8232 
The sequence contained within clone IVI156 is indicated above the gene map.  The blp 
operon consisted of a Class IIb bacteriocin (blpMNH) along with the potential immunity 
genes spyM18_0546 and spyM18_0547. The sil locus is composed of a two-component 
system (silAB), the signaling peptides silC and silCR, and an ABC transport system 
(silDE).  silD is truncated due to a missing nucleotide and is split into two genes, the 
second being spyM18_0541 
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Figure 3.2: BlpMNH and BlpMN sequences 
Leader sequences are separated from mature peptides at the double glycine (indicated by 
arrow).  GxxxG highlights this motif found in Class IIb bacteriocins. 
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SF370.  Finally, further comparison of BlpMNH indicated that it was also present within 
several other streptococcal species including Streptococcus dysgalactiae, S. equi, and 
Streptococcus uberis. 
Bacteriocin systems also require an immunity gene, which is typically found downstream 
from the bacteriocin structural genes.  Downstream from blpNH was a potential ORF 
annotated as spyM18_0546, predicted to encode a 33 amino acid peptide (Figure 3.1).  
Using BLASTp, the peptide was found in some strains of S. pyogenes (e.g. 
SPYJRS4_0399) and S. dysgalactiae subsp. equisimilis, (SDE12394_02605), however, it 
was found to be of 69 amino acids in length.  Alignment was only found for the first 25 
amino acids of the N-terminus between spyM18_0546, SPYJRS4_0399, and 
SDE12394_02605 (Figure 3.3).  Comparison of the nucleotide sequence showed one less 
adenine nucleotide within the transcription region of spyM18_0546, alternating the 
reading frame, and potentially creating a premature stop codon (Figure 3.3).  This peptide 
could potentially be an immunity protein, although its function remains unknown. 
Further downstream was spyM18_0547, theoretically encoding a peptide of 42 amino 
acids that could also potentially function as a bacteriocin immunity protein (Figure 3.1).  
BLASTp analysis showed spyM18_0547 to be well conserved within 30 S. pyogenes 
strains, such as HSC5 (L897_02190).  However, spyM18_0547 may actually be truncated, 
as the most common predicted size is a 64 amino acid peptide found in over 130 strains, 
including common studied strains such as SF370 (spy_0486).  Comparison of the peptide 
and nucleotide sequences of spyM18_0547, L897_02190, and spy_0486 showed the loss 
of a single adenine base pair within the coding sequence of spy_0486, upstream from the 
start codon of spyM18_0547 and L897_02190 (Figure 3.4).  This peptide potentially 
produces an immunity protein as well, though the correct sequence and the corresponding 
sequence is once again unknown.  The predicted blp operon DNA sequence and matching 
peptides is represented in Figure 3.5.  
3.3.2 Bioinformatics of the regulation and transport of BlpMNH 
In addition to the bacteriocin structural and immunity genes, Class IIb bacteriocins also 
require dedicated transporters, and additionally, often encode proteins involved in
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Figure 3.3: Comparison of spyM18_0546 DNA and protein sequences from various 
strains 
spyM18_0546 is shown to have a premature stop codon (starting at base pair 100) due to 
the loss of a single adenine nucleotide (should be base pair 77) when compared to the 
same peptide from S. pyogenes JS94 (SPYJRS4_0399) and S. dysgalactiae subsp. 
equisimilis ATCC 12394 (SDE12394_02605).  Base pair numbers are indicated on the 
right. 
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spyM18_0546     ATGATCTATACGATTTTTATTATTATGAATGCGTCTATAATGTTTTTAATCATTGTTGAT  60 
                 M  I  Y  T  I  F  I  I  M  N  A  S  I  M  F  L  I  I  V  D 
SPYJRS4_0399    ATGATCTATACGATTTTTATTATTATGAATGCGTCTATAATGTTTTTAATCATTGTTGAT  60 
                 M  I  Y  T  I  F  I  I  M  N  A  S  I  M  F  L  I  I  V  D   
SDE12394_02605  ATGATCTATACGATTTTTATTATTATGCATGCGTCTATAATGTTTTTAATGATTGTTGAT  60 
                 M  I  Y  T  I  F  I  I  M  H  A  S  I  M  F  L  M  I  V  D 
 
 
spyM18_0546     GCCATTCATAAAAAAA-TGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 119 
                 A  I  H  K  K   M  L  I  N  L  Y  H  I  *  -  -  -  -  -  - 
SPYJRS4_0399    GCCATTCATAAAAAAAATGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 120 
                 A  I  H  K  K  N  V  D  K  S  I  P  Y  L  V  F  L  I  F  N   
SDE12394_02605  GCCATTCATAAAAAAAATGTTGATAAATCTATACCATATTTAGTGTTTTTAATTTTCAAT 120 
                 A  I  H  K  K  N  V  D  K  S  I  P  Y  L  V  F  L  I  F  N   
 
 
spyM18_0546     CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 179 
                  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
SPYJRS4_0399    CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 180 
                 Q  L  S  L  S  E  K  S  V  N  M  L  S  I  V  A  L  V  A  S 
SDE12394_02605  CAATTATCCCTTTCGGAAAAATCGGTAAACATGTTATCTATCGTAGCTTTGGTAGCGTCA 180 
                 Q  L  S  L  S  E  K  S  V  N  M  L  S  I  V  A  L  V  A  S 
 
 
spyM18_0546     TTATTTGTTTTTATCGATAAAAGAAAATAG 209 
                 -  -  -  -  -  -  -  -  -  - 
SPYJRS4_0399    TTATTTGTTTTTATCGATAAAAGAAAATAG 210 
                 L  F  V  F  I  D  K  R  K  * 
SDE12394_02605  TTATTTGTTTTTATCGATAAAAGAAAATAG 210 
                 L  F  V  F  I  D  K  R  K  * 
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Figure 3.4: Comparison of spyM18_0547 DNA and protein sequences from various S. 
pyogenes strains 
spyM18_0547 and L897_02190 are annotated with a start codon further downstream in 
comparison to others such as spy_0846.  In addition, spy_0846 is missing a single adenine 
nucleotide (base pair 18) within its coding region.  Base pair numbers are indicated on the 
right. 
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spyM18_0547     ATGGAAGTGCTAAAAAAATGGTCTGACTATCATAAATGGAGGCGGAAAAGACGGAGCAAA  60 
                 -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
L897_02190      ATGGAAGTGCTAAAAAAATGGTCTGGCTATCATAAATGGAGGCGGAAAAGACGGAGCAAA  60 
                 -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
spy_0486        ATGGAAGTGCTAAAAAA-TGGTCTGGCTATCATAAATGGAGGCGGAAAAGACGGAGCAAA  59 
                 M  E  V  L  K  N   G  L  A  I  I  N  G  G  G  K  D  G  A  N 
 
 
spyM18_0547     TATCTTTTTGACAGGGATGGCAGGTGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 120 
                  -  -  M  T  G  M  A  G  A  A  Q  G  V  T  V  C  A  Q  T  G   
L897_02190      TATCTTTTTGACAGGGATGGCAGGAGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 120 
                  -  -  M  T  G  M  A  G  A  A  Q  G  V  T  V  C  A  Q  T  G 
spy_0486        TATCTTTTTGACAGGGATGGCAGGTGCTGCGCAGGGAGTGACAGTTTGTGCTCAGACAGG 119 
                  I  F  L  T  G  M  A  G  A  A  Q  G  V  T  V  C  A  Q  T  G   
 
 
spyM18_0547     CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 180 
                  V  F  I  P  W  Q  G  Y  I  L  C  G  A  A  G  A  A  T  N  I 
L897_02190      CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 180 
                  V  F  I  P  W  Q  G  Y  I  L  C  G  A  A  G  A  A  T  N  I 
spy_0486        CGTATTTATCCCTTGGCAAGGTTATATTTTGTGTGGAGCAGCTGGTGCTGCTACAAATAT 179 
                  V  F  I  P  W  Q  G  Y  I  L  C  G  A  A  G  A  A  T  N  I 
 
 
spyM18_0547     TATCTGGCCTCACTAA 196 
                  I  W  P  H  * 
L897_02190      TATCTGGCCTCACTAA 196 
                  I  W  P  H  * 
spy_0486        TATCTGGCCTCACTAA 195 
                  I  W  P  H  * 
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Figure 3.5: The blp operon sequence in S. pyogenes MGAS8232 
The DNA and predicted amino acid sequences encoded within the blp operon of 
MGAS8232. The nucleotide and translation products for the blp locus are given below for 
the indicated region with corresponding nucleotide numbers as annotated in the S. 
pyogenes MGAS8232 genome sequence. Directions of the ORFs are indicated by arrows.  
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                     ←silE 
AACAAATGTTTTTCGATAGGATATCATTTGTAAAAGACCTTTCTATTAAATACTAAGCTA 434260 
 V  F  T  K  R  Y  S  I  M  
 
TTATGACATATATATAGGGAGTTTTTATCAAAAATCTTAAAAGGTATTTATAAAAGCATG 434320 
 
AATGGTATCATTTAAACTTCTTAATTAATTAACTATTGTCACAGCGTAAGTGTAGAGAGG 434380 
 
ATAAAAAGACATTTCATGATGAAAAATAGCCTTTTAAGATTTTGAAACCAGGATACTGTT 434440 
 
CTTTATGATATTCTGTACTAGCTCGAGGTTGCAACGAGACAAATTTAAGAATTATGAAAA 434500 
 
             spyM18_0544(blpMH)→ 
GAAGTTATTCGATATGGAGATAAAGAAACTGGAAACATTTCACCAAATGACTATAGAAAA 434560 
              M  E  I  K  K  L  E  T  F  H  Q  M  T  I  E  K  
 
GCTTGCCAAGGTTGAGGGTGGTAAGAATAATTGGCAGGCAAATGTCAGTGGGGTTATCGC 434620 
  L  A  K  V  E  G  G  K  N  N  W  Q  A  N  V  S  G  V  I  A 
 
TGCAGGTAGTGCTGGAGCTGCTATAGGTTTTCCAGTTTGCGGTGTAGCCTGTGGTTATAT 434680 
  A  G  S  A  G  A  A  I  G  F  P  V  C  G  V  A  C  G  Y  I  
 
TGGAGCTAAAACAGCTATTACTCTTTGGGCTGGTGTAACAGGAGCTACAGGCGGCTTCTA 434740 
  G  A  K  T  A  I  T  L  W  A  G  V  T  G  A  T  G  G  F  * 
             spyM18_0545(blpNH)→ 
GAGGAAAGAAAGGATGACAACAATGAAGGAATTAACAATTAATGACATGGCTAGTATAAG 434800 
              M  T  T  M  K  E  L  T  I  N  D  M  A  S  I  S 
    
TGGAGGAAACGCTCCAGGAGATGCTGTAATTGGTGGTCTTGGAGGCTTAGCTTCTGGATT 434860 
  G  G  N  A  P  G  D  A  V  I  G  G  L  G  G  L  A  S  G  L 
 
GAAATTTTGTAAACTGCCACATCCAGTATTGGCAGGTGGATGTGTTGTAGGATTTACAGT 434920 
  K  F  C  K  L  P  H  P  V  L  A  G  G  C  V  V  G  F  T  V 
                                  spyM18_0546→ 
TGGTGGAGCATATTTGGGATATACAGCAAATTAAATGATCTATACGATTTTTATTATTAT 434980 
  G  G  A  Y  L  G  Y  T  A  N  *  M  I  Y  T  I  F  I  I  M 
 
GAATGCGTCTATAATGTTTTTAATCATTGTTGATGCCATTCATAAAAAAATGTTGATAAA 435040 
  N  A  S  I  M  F  L  I  I  V  D  A  I  H  K  K  M  L  I  N 
 
TCTATACCATATTTAGTGTTTTTAATTTTCAATCAATTATCCCTTTCGGAAAAATCGGTA 435100 
  L  Y  H  I  * 
 
AACATGTTATCTATCGTAGCTTTGGTAGCGTCATTATTTGTTTTTATCGATAAAAGAAAA 435160 
 
TAGTGATTATGCCAATGAATTTAGATATCACTCTTAGCTTTTTAAAATACAAAAGAGTGA 435220 
 
AATTAAAATGAAAAAGACTTCAAAAATATGGAAGTGCTAAAAAAATGGTCTGACTATCAT 435280 
 
                                  spyM18_0547→ 
AAATGGAGGCGGAAAAGACGGAGCAAATATCTTTTTGACAGGGATGGCAGGTGCTGCGCA 435340 
                                   L  T  G  M  A  G  A  A  Q   
 
GGGAGTGACAGTTTGTGCTCAGACAGGCGTATTTATCCCTTGGCAAGGTTATATTTTGTG 435400 
  G  V  T  V  C  A  Q  T  G  V  F  I  P  W  Q  G  Y  I  L  C  
 
TGGAGCAGCTGGTGCTGCTACAAATATTATCTGGCCTCACTAAATATATAAATGACTATC 435460 
  G  A  A  G  A  A  T  N  I  I  W  P  H  * 
 
TATCACTGATATATAAGTAGTAGAGGAGTGGTATGAAAATTTTAGATATTATTTTTAACC 435520 
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regulation of the system.  Upstream of blpMH in MGAS8232 was a group of genes that 
correspond to the streptococcal invasion locus (sil) (9).  The sil locus is comprised of an 
ABC transporter (silDE), a pheromone (silCR), a peptide (silC), and a two-component 
system (silAB) (Figure 3.1).  While its exact purpose is unknown, the sil locus has been 
shown to be important for invasive infections (9, 63, 64, 76) and can regulate BlpMNH 
and its associated immunity protein (7). 
MGAS8232 encodes a full-length silE predicted to produce a 717 amino acid ATP-
binding cassette transporter according to BLASTp results.  However, silD and 
spyM18_0541 appear to be truncated portions of a complete 454 amino acid SilD, which 
works in conjunction with SilE to make a complete ABC-binding cassette transporter.  
Analysis of the nucleotide sequence revealed that a missing adenine caused early 
termination of MGAS8232 silD and spyM18_0541 appears to encode the C-terminus of 
silD (7, 9, 11) (Figure 3.6). 
In MGAS8232, further upstream of the putative bacteriocin transporters were silC and 
silCR, overlapping each other by 91 bp (7, 9), creating peptides of 39 and 41 amino acids, 
respectively (Figure 3.1).  SilCR contains pheromone characteristics such as a double-
glycine type secretion signal, creating a mature peptide of 17 amino acids, and an RKK 
motif at the C-terminus (9, 11).  On the other hand, the peptide SilC appears to lack any 
secretion signal or leader sequence indicating it may function in the cytoplasm.  BLASTp 
analysis of SilCR indicated 100% identity with other S. pyogenes strains encoding the sil 
locus, except JS95, which contains a single mutation changing the start codon from ATG 
to ATA (9, 78).  While silC was not annotated on the MGAS8232 genome, the correct 
DNA sequence was present and 100% identitcal to silC in S. pyogenes strains IB7 and 
JS95, and S. dysgalactiae subsp. equisimilis strains GGS1800 and N3. 
Finally, the two-component histidine kinase and response regulator, encoded by silB and 
silA, respectively, were encoded adjacent to the silCR/silC genes (Figure 3.1).  Once 
again, BLASTp analysis indicated nearly 100% identity between MGAS8232 and the S. 
pyogenes strains that encode the sil locus.  One exception was silB of JS95 that contains a 
short range of 11 different amino acids, seemingly unique to JS95. 
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Figure 3.6: The DNA and protein sequence of silD and spyM18_0541 
Comparison of silD and spyM18_0541 of MGAS8232 with silD of JS95.  The loss of an 
adenine nucleotide (base pair 479 in MGAS8232) creates a premature stop codon in 
MGAS8232 silD (starting at base pair 580).  ORF spyM18_0541 is the C-terminus of silD 
starting at base pair 747 and finishing at the proper stop codon of silD.  Large stretches of 
identical sequence were removed (indicated by ……).  Base pair number is indicated on 
the right. 
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8232 silD     ATGAATCCAAACCTTTTTAAAAGTGCGGAATTTTATCATCGACGTCATCATAACTTTGCA……  60 
               M  N  P  N  L  F  K  S  A  E  F  Y  H  R  R  H  H  N  F  A …… 
JS95 silD     ATGAATCCAAACCTTTTTAAAAGTGCGGAATTTTATCATCGACGTCATCATAACTTTGCA……  60 
               M  N  P  N  L  F  K  S  A  E  F  Y  H  R  R  H  H  N  F  A …… 
 
 
8232 silD   ……ACGTTTAATCATTTTCTCAAACAAACCCAAGATATAATCATTGGGTTTGCTAAAAAAA-T   479 
            ……T  F  N  H  F  L  K  Q  T  Q  D  I  I  I  G  F  A  K  K  M  
JS95 silD   ……ACGTTTAATCATTTTCTCAAACAAACCCAAGATATAATCATTGGGTTTGCTAAAAAAAAT   480 
            ……T  F  N  H  F  L  K  Q  T  Q  D  I  I  I  G  F  A  K  K  N  
 
 
8232 silD     GCTGAAGTCAATAATCAAGCAAGTCTTGCTAATCATGCCATTTCAGTTATTACTAGTCAG   539 
                L  K  S  I  I  K  Q  V  L  L  I  M  P  F  Q  L  L  L  V  S 
JS95 silD     GCTGAAGTCAATAATCAAGCAAGTCTTGCTAATCATGCCATTTCAGTTATTACTAGTCAG   540 
               A  E  V  N  N  Q  A  S  L  A  N  H  A  I  S  V  I  T  S  Q   
 
 
8232 silD     CTTGACGAACTTCATCAAAAAATTACAGATTATGAAGAGCTAAAGCGAGCTATTAATAAT…… 599 
                L  T  N  F  I  K  K  L  Q  I  M  K  S  *  -  -  -  -  -  -…… 
JS95 silD     CTTGACGAACTTCATCAAAAAATTACAGATTATGAAGAGCTAAAGCGAGCTATTAATAAT…… 600 
               L  D  E  L  H  Q  K  I  T  D  Y  E  E  L  K  R  A  I  N  N …… 
 
 
spyM18_0541 ……CAAAATATCTCAGAACTTGAATCTTCAATGGCAAACCTTAGTATCCAACGTGCTAGTACA   779 
            …… -  -  -  -  -  -  -  -  -  M  A  N  L  S  I  Q  R  A  S  T   
JS95 silD   ……CAAAATATCTCAGAACTTGAATCTTCAATGGCAAACCTTAGTATCCAACGTGCTAGTACA   780 
            …… Q  N  I  S  E  L  E  S  S  M  A  N  L  S  I  Q  R  A  S  T   
 
 
spyM18_0541   GGAAATTTATCTCTTCCAGACACTAGTCATAGGATCAAAATAGATATTTTAAAAACACAA…… 839 
               G  N  L  S  L  P  D  T  S  H  R  I  K  I  D  I  L  K  T  Q …… 
JS95 silD     GGAAATTTATCTCTTCCAGACACTAGTCATAGGATCAAAATAGATATTTTAAAAACACAA…… 840 
               G  N  L  S  L  P  D  T  S  H  R  I  K  I  D  I  L  K  T  Q …… 
 
 
spyM18_0541 ……TATTTCAATTACTATAAAGATAAGATACTCAACAGTTTTAATTAA 1364 
            …… Y  F  N  Y  Y  K  D  K  I  L  N  S  F  N  * 
JS95 silD   ……TATTTCAATTACTATAAAGATAAGATACTCAACAGTTTTAATTAA 1365 
            …… Y  F  N  Y  Y  K  D  K  I  L  N  S  F  N  * 
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Regulation of the sil locus is thought to occur through the expression of silC and silCR.  
Expression of silC causes suppression of two operons to very low levels: silE/D/CR and 
blpMH/NH/spy_0586 (7, 80).  However, once SilCR reaches its threshold level, it activates 
SilA via SilB, to initiate expression of the blpMH/NH/spy_0586 and silE/D/CR operons, 
causing suppression of silC.  Once SilCR levels decline back to normal levels, 
suppression by SilC will once again occur (7, 83).  Interestingly, silAB seems to show 
little to no response to SilCR, but has demonstrated activity when exposed to decreased 
temperature or H2O2 (7, 27, 76).  silC is also under the control of its own promoter, 
though how either silAB or silC is regulated is still unknown. 
It was then proposed that the promoter for blpMH, identified in vivo by the RIVET system, 
was under control of SilAB from the sil locus.  Examination of the DNA region between 
silE and blpMH showed the -35 and -10 regions of both promoters, predicted using online 
software (Figure 3.7).  Also present were the direct repeats for both blpMH (DR2) and 
silE (DR1), the DNA region to which the response regulator SilA binds in order to 
regulate expression, originally found by Belotserkovsky et al. in strain S. pyogenes JS95 
(27).  DR1 and DR2 contain a repeat consensus sequence of ACCTTT[T/C]A[T/A]G 
(Figure 3.7).  When comparing direct repeat sequences between strains, it was found that 
the spacer for DR2 in MGAS8232 was only 10 bp, while this spacer was 11 bp in JS95 
(Figure 3.8).  Comparing the repeat sequences of numerous S. pyogenes strains showed 
that both spacer sizes are present for DR2; with the 10 bp spacer present in strains 
MGAS8232, SF370, MGAS5005, and Manfredo, with the 11 bp spacer present in strains 
JS95, HSC5, and MGAS315 (Figure 3.8).  The spacer for DR1 appears to be 11 bp for all 
strains presented. 
3.3.3 in vitro activation of blpM  
Once the components of the sil locus and blp operon were identified, the ability of SilCR 
to induce the system was first tested.  Cas2 transformed with the IVI156 plasmid was 
grown in THY erm containing either the synthesized SilCR peptide, or a scrambled 
peptide control.  Cells were plated at various time points and activation of the blp operon 
promoter was monitored though the loss of tet resistance.  Despite testing at various 
  
146 
Figure 3.7: Promoter regions of blpMH and silE from S. pyogenes MGAS8232 
The underlined and italicized sequences show the predicted -35 and -10 regions of blpMH 
and silE.  A boxed letter indicates transcription start site with an arrow pointing in the 
direction of transcription.  Direct repeat pairs for the silE/D/CR (DR1) and blp (DR2) 
operons are bolded and labeled as left (L) and right (R) on either side of the 
corresponding spacer region according to the direction of transcription.  Consensus 
sequence of the repeat sequence is shown below with DR1 sequences shown in reverse 
complement to match DR2.  Final consensus sequence: ACCTTT[T/C]A[T/A]G. 
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                 ←silEE                   	↰ 
TTTTTCGATAGGATATCATTTGTAAAAGACCTTTCTATTAAATACTAAGCTATTATGACA 
                                                                 -10 
                                    DR1R        spacer       DR1L 
TATATATAGGGAGTTTTTATCAAAAATCTTAAAAGGTATTTATAAAAGCATGAATGGTAT 
                  -35 
 
CATTTAAACTTCTTAATTAATTAACTATTGTCACAGCGTAAGTGTAGAGAGGATAAAAA 
 
     DR2L       spacer       DR2R 
GACATTTCATGATGAAAAATAGCCTTTTAAGATTTTGAAACCAGGATACTGTTCTTTAT 
                                    -35                     -10 
         ↱ 
GATATTCTGTACTAGCTCGAGGTTGCAACGAGACAAATTTAAGAATTATGAAAAGAAGT 
 
          blpMH→ 
TATTCGATATGGAGATAAAGAAACTGGAAACATTTCACCAAATGACTATAGAAAAGCTT 
 
 
Consensus 
DR1L ACCATTCATG 
DR1R ACCTTTTAAG 
DR2L ACATTTCATG 
DR2R GCCTTTTAAG 
     5’-ACCTTTYAWG-3’
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Figure 3.8: Spacer comparison between S. pyogenes strains 
Direct repeat pairs for the silE/D/CR (DR1) and blp (DR2) operons are bolded and 
labeled as left (L) and right (R) on either side of the corresponding spacer region 
according to the direction of transcription. 
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concentrations,  SilCR failed to produce any detectable activation after 24 h (unpublished 
data).  Reasoning that proteases could potentially be destroying the peptides in vitro the 
experiment was subsequently attempted with the addition of the cysteine protease 
inhibitor E-64, yet after 24 h all colonies remained tet resistant.  Next, a serine protease 
inhibitor, AEBSF, was attempted after it was found that blocking the serine protease HtrA 
in S. pneumoniae caused an increase in blpMN (29, 86).  However, treatment of cells with 
AEBSF had no effect (unpublished data).  Numerous other methods rather than the 
synthetic peptides were attempted including HLA-DR4/DQ8 mouse cNT homogenate, 
growth with human peripheral blood mononuclear cells, human neutrophils, and human 
serum, in an attempt to create the required environment, yet all failed to activate blpMH in 
vitro (unpublished data).  Thus, despite all the different methods attempted, the blp 
operon could not be activated in vitro. 
3.3.4 MGAS8232 wild-type and Δblp competitive in vivo analysis 
In order to test the impact of BlpMNH in vivo, a knockout was created to delete the entire 
blp operon, designated MGAS8232 Δblp.  Used to inoculate HLA-DR4/DQ8 mice as 
before, Δblp was mixed 1:1 with MGAS8232 wild-type in a competition model.  The 
recovered bacteria were plated and 20 colonies were randomly picked and identified as 
Δblp or MGAS8232 via PCR.  As a control, the experiment was also repeated with 
mixtures grown in vitro for 24 h to mimic the cell densities that are reached in vivo.  
Growth in vitro appeared to show a slight shift to the wild-type, but still showing a wild-
type:Δblp ratio percent averaging 56.7:43.3 (Figure 3.9), demonstrating that the blp 
operon is likely not important for in vitro growth.  Surprisingly, when wild-type:Δblp was 
grown in vivo, the four of the seven mice returned only or predominantly wild-type, while 
the remaining returned ratios of wild-type:Δblp in roughly equal numbers (Figure 3.9)  
While not the expected result, it seemed to show that lack of the blp operon provided a 
disadvantage in vivo against wild-type and that activation of the operon may not always 
occur or else cells in vivo may exist in different locations.  
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Figure 3.9: Competition between wild-type S. pyogenes MGAS8232 and MGAS8232 
Δblp   
Wild-type and Δblp were mixed 1:1 and either grown overnight in vitro (N=7) or using 
the nasopharyngeal infection model in HLA-DR4/DQ8 mice (N=7).  Cells were plated on 
THY agar and gDNA was isolated from random colonies and subjected to PCR analysis 
to identify cells as either wild-type or Δblp. 
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3.4 Discussion 
S. pyogenes is an important human pathogen that utilizes the upper respiratory tract and 
the skin as the most common reservoirs of its host.  Research on this organism generally 
focuses on the virulence factors S. pyogenes possess in order to overcome the physical 
and immunological defenses of the human body.  However, another important part of the 
human body is the resident bacteria.  These bacteria create a competitive environment that 
potentially makes it difficult for invading bacteria to survive (31).  Therefore, a tool such 
as a bacteriocin could be advantageous for pathogens in order to colonize.  While the 
bacteriocins used by pathogens seems to receive little attention, E. coli, S. pneumoniae, 
Haemophilus influenzae, and Streptococcus mutans have all demonstrated an improved 
ability to colonize when compared to bacteriocin-negative controls (64, 87).  S. pyogenes 
has only been shown to express bacteriocins in a handful of strains and they have 
received little notice.  Using an upper respiratory tract model, this research is the first of 
our knowledge to demonstrate the in vivo activation of a Class IIb bacteriocin in S. 
pyogenes and the colonization advantage it may provide.   
Based on our results, it appeared that MGAS8232 possessed the bacteriocin BlpMNH, 
followed immediately downstream of blpNH by the two ORFs spyM18_0546 and 
spyM18_0547, one likely being the required immunity protein (Figure 3.1).  Based on 
sequence analysis, BlpMNH possessed the requirements of a Class IIb bacteriocin 
including GxxxG motifs and a double glycine for separation of the leader sequence from 
the mature peptide (Figure 3.2).  More recent work in the McCormick laboratory has 
been able to demonstrate a functional ex vivo BlpMNH bacteriocin, showing L. lactis with 
sensitivity to the combined recombinant BlpMH and BlpNH peptides.  Furthermore, L. 
lactis was resistant to the antimicrobial activity of BlpMNH when expressing a fragment 
that included both spyM18_0546 and spyM18_0547 (McCormick laboratory, unpublished 
data).  Which ORF encodes the immunity gene has yet to be determined.  Furthermore, 
this also provides data towards identifying the targets of BlpMNH.  Class IIb bacteriocins 
are typically effective against a narrow range of targets, many staying within the same 
species (45-47, 66).   Susceptibility of L. lactis may suggest a wider range of targets than 
expected.  Determination of further BlpMNH targets could be determined simply by 
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testing strains for susceptibility.  Likely candidates would be other streptococcal strains 
and in particular, those found within the oral cavity such as S. salivarius, S. mitis, S. 
oralis, S. gordonii, S. mutans, or S. pneumoniae (41).  
Upstream of blpMH are the genes that make up the sil locus (Figure 3.1).  While blpMNH 
seems to be widely found among virtually all S. pyogenes strains, sil only seems to be 
encoded in ~12-25% of the isolates tested (70, 88).  Additionally, the locus does not 
appear to be functional in all isolates.  Sequencing sil+ strains for deletions, frameshifts, 
and mutations in the silCR, silC, and silD, Plainvert et al. found that only 56% of strains 
appeared to have a functional sil locus based on sequence (69).  Furthermore, there 
seemed to be no link between the presence of sil and invasive status (27, 69).  Plainvert et 
al. also found functional sil on both invasive and non-invasive strains at 30% and 28%, 
respectively (27, 69).  Other groups, including Jing et al. and Billal et al. also found sil+ 
strains in both invasive and non-invasive strains (89, 90).  In fact, the presence of sil 
seemed to be more related to emm type, with common types being emm4, emm87, 
emm90, emm94, and emm118 (69, 88).  The emm type also gave a general indication as to 
whether or not sil was functional within the strain.  For example, emm87 appeared to be 
functional based on sequence nearly 100% of the time, while emm14 (JS95) nearly 
always had ATA as a silCR start codon, and emm4 and emm18 are known to have a 
truncated silD (69, 79, 88).  
Control of sil has demonstrated to be controlled through a regulatory circuit consisting of 
silC and silCR (7).  When off, SilC represses the blp operon as well as an operon 
consisting of the transporters (silDE) and silCR.  However, threshold level of SilCR 
allows these operons to be turned on, with the expression of silCR interfering with silC 
due to the large portion of overlapping sequence (7).  Indeed, the effect has been 
identified several times with invasive in vivo models.  Starting with JS95 and HSC5, 
neither expressing silCR naturally, loss of silC demonstrated the loss of virulence 
potential (9, 76) and the addition of exogenous SilCR showed a reduction in virulence 
and lesion size (78).  While in vitro, ΔsilC showed a reduction in biofilm formation (80) 
and the addition of SilCR demonstrated a reduced transcription of spyCEP (83).  In 
addition, using microarray, it was found that 46 genes were altered with the addition of 
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SilCR (27).  Nearly half (18 genes) were involved with metabolism, seven had a function 
involved with gene regulation, and interestingly, sagA (SLS) transcription was also 
increased.  Furthermore, sagA transcription was also increased by the addition of SilCR in 
a sil- strain, demonstrating that SilCR activates more than just the sil locus and blp operon 
(27, 86)  Exactly how SilC is able to repress its targets, and any other genes it may 
control, has yet to be elucidated. 
Upstream of silC is the AlgR/AgrA/LytR family transcription regulator silAB that is 
thought to activate the bacteriocin genes as well as the associated transporter genes.  The 
response regulator, SilA, binds via the LytR-type domain as a dimer to the DNA site 
made up of two nine bp direct repeats, [T/A][A/C][C/A]GTTN[A/G][T/G], separated by a 
spacer that seems to vary in length (7, 27, 91).  Based on the sequence found by 
Belotserkovsky et al. in strain JS95, which included an additional tenth nucleotide, the S. 
pyogenes MGAS8232 direct repeat followed the consensus almost exactly at 
ACCTTT[C/T]A[T/A]G (Figure 3.7) (27).  Belotserkovsky et al. had concluded that the 
S. pyogenes pattern was made up of ten nucleotides since modification of the tenth 
nucleotide (guanine) showed a detrimental effect to the promoter (27). 
Also shown to be important for proper activation is the AT-rich spacer length between 
repeats, typically ranging from 10-13 bp (92, 93).  The length of this spacer has shown to 
be important, as changes such as losing a single nucleotide has shown to have detrimental 
effects to expression (27, 55, 94-96).  Belotserkovsky et al. showed S. pyogenes JS95 to 
have a spacer of 11 bp and that expression was lost when modified to a length of 10 or 12 
bp (27).  As shown in Figure 3.8, the spacer region of DR2 is 10 or 11 bp depending on 
the strain, with MGAS8232 having a 10 bp spacer.  Based on the evidence from 
Belotserkovsky et al., this spacer would prevent SilA from binding to DR2, and therefore 
prevent transcription of the blp operon. 
Assembling the sil locus system within MGAS8232 leads to two major shortfalls.  The 
truncated silD implies that neither SilCR nor BlpMNH could be secreted.  However, the 
initial identification of PblpM, and subsequent repetition experiments in vivo, indicated that 
the promoter portion identified in pIVI156 was activated in vivo (Figure 2.10).  If 
BlpMNH activation did occur by SilA binding, SilCR secretion would have been required, 
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indicating that one or both of the silD truncations (Figure 3.1) could form with SilE to 
create a working transporter, or alternatively, a different transporter system was used.  
However, the failure of blpMNH activation in vitro through the addition of exogenous 
SilCR would suggest that activation did not occur through the sil locus.  In addition to 
SilCR, other potential environmental stimuli also failed to activate the blp operon 
including HLA-DR4/DQ8 mouse cNT homogenate, human peripheral blood mononuclear 
cells, human neutrophils, and human serum (unpublished data).   
While blpMNH could not be activated in vitro, we tested its impact using the in vivo 
model known to activate it.  A surprising almost ‘all or none’ type of response was 
recovered after inoculation by a 1:1 mix with roughly half going either way.  In one half, 
the ratio recovered between wild-type and Δblp was nearly even, suggesting that blpMNH 
was not activated, and therefore, not important for colonization (Figure 3.9).  The other 
half seemed to demonstrate an activation of the blp operon since there was little to no 
Δblp strain recovered (Figure 3.9).  It is thought that the MGAS8232 wild-type present 
was exposed to the correct environmental stimuli to cause expression of the blp operon, 
eliminating Δblp due to the lack of an immunity protein.  Why stimulation occurred only 
in half of the mice is unknown and continued work will attempt to identify the 
environmental condition activating the blp operon.  However, this in vivo work does 
suggest that while blpMNH is unlikely to be regulated by the sil locus due to SNPs, the 
lack of Δblp in some instances would suggest that blpMNH is able to regulate and 
transport through another system. 
Colonizing the pharynx, S. pyogenes must make a ‘space’ for itself in order to obtain 
nutrients and grow against a plethora of other bacteria.  Specifically, on the human body 
as a host, free nutrients can be limited, causing many different bacteria to attempt to 
colonize the same niche.  Therefore, bacteriocins provide a powerful tool that could be 
used by S. pyogenes, as well as other pathogens, to aid in the colonization process.  This 
research represents the first attempt to determine the use of the Class IIb bacteriocin 
BlpMNH by S. pyogenes when colonizing a nasopharyngeal model.  While it seemed that 
blpMNH was not under control of sil, it could explain why blpMNH remains within nearly 
all strains while functional sil seems to be in such a small percentage.  Although the 
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mechanism that causes the activation of blpMNH in MGAS8232 still needs to be 
established, it appears to be functional, providing a potential mechanism to help 
outcompete bacteria also striving for the pharynx of the human host. 
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S. pyogenes is a well known pathogen that is responsible for over 500 000 deaths world-
wide each year.  While much is known about S. pyogenes pathogenesis, how this 
organism is able to successfully attach, colonize, and compete within the human pharynx 
remains incomplete (1, 2).  This is due to the fact that a large number of factors exhibit 
overlapping functions, creating a complex system that is difficult to dissect.  In order to 
further solve this problem, information needs to be gathered at a genomic level to 
evaluate how S. pyogenes alters gene regulation within specific environments.  Numerous 
methods exist, each having their own advantages and setbacks. In this research, RIVET 
was successfully used for the first time with S. pyogenes, to identify genetic elements that 
were specifically induced during the entire colonization process of the nasopharyngeal 
humanized mouse model.   
4.1 Chapter 2 Conclusions 
RIVET was chosen due to its ability to detect gene induction activity throughout the 
entire infection period, as opposed to alternative methods that capture results at specific 
time points.  In addition, since each recovered RIVET clone is sequenced, even those 
from microenvironments within the model can still be identified.  Part of the second-
generation RIVET system was the use of counter-selection, and while this was attempted 
with the use of HSV-tk and ganciclovir, it unfortunately proved too unreliable to pursue.  
Despite this set back, patching to identify tet sensitive clones was still successfully 
performed to identify 9 potential ‘typical’ promoters, demonstrating a functional system 
(Table 2.4).   
In the past decade there has been a surge in the increase of sRNA found in bacterial 
chromosomes with increasing questions about their role in biological systems and precise 
mechanisms of action (3).  Several methods have been used in order to identify sRNA in 
bacteria including bioinformatics, microarrays, RNA-seq, and RIVET.  sRNA may be 
better identified in RIVET since they are not locked to a specific algorithm as with 
bioinformatics and may experience fewer overall artifacts due to the absence of a cDNA 
synthesis step as in microarrays and RNA-seq (3-5).  Potentially, sRNA for three 
interesting virulence factors, mga, speA, and mf3, was found utilizing the RIVET system.  
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These virulence factors have shown states of repression during the late growth phases of 
animal models, presumed to be transitioning to the persistent state (6, 7).  It is possible 
that S. pyogenes makes use of sRNA as a mechanism of tight repression of these genes, as 
well as others, in response to precise in vivo conditions.  Many other potential sRNA 
candidates were also identified by the RIVET system and have yet to be explored more 
thoroughly to identify possible roles in colonization.  
When considering ‘typical’ promoters that appeared to control the expression of genes, 
three of these, pyruvate formate-lyase, tagatose-6-phosphate aldose/ketose isomerase, and 
a polar amino acid ABC transporter are all suggestive of genes being active in an 
environment where nutrients are scarce, such as the nasopharynx (8-13).  The functions of 
the remaining genes identified by RIVET are less obvious due to the limited amount of 
available information and their potential role in the colonization process.  However, 
further verification with clone IVI156 revealed a promoter for the bacteriocin-like gene 
spyM18_0544 (blpMH) with consistently induced in vivo activity (Figure 2.10).  This lead 
to further work to identify how blpMH was used by S. pyogenes in the colonization 
process. 
4.2.1 Future Work 
The promoters identified through RIVET represent potential genetic elements 
contributing to the overall adaptation of S. pyogenes when colonizing the nasopharynx in 
order to survive.  Confirming true in vivo activation through further testing via the RIVET 
method or qRT-PCR is the first step in deciphering their role in the colonization process.  
In addition to this, further investigational analysis of remaining recovered clones could be 
performed in order to identify more in vivo induced promoters. 
Continued development of RIVET within S. pyogenes could also successfully make use 
of other methods to facilitate a post-in vivo selection screening method in the same vein 
as counter-selection.  One potential method is the inclusion of a fluorescent marker under 
the control of a constitutive promoter within the cassette.  This would allow the use of 
FACS to identify those cells without the cassette after the in vivo selection.  Other groups, 
for example, have taken a cassette containing a single antibiotic resistance marker and 
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inserted it after the first codon of a second resistant marker causing it to be split, losing 
expression of the gene.  Resolution of the cassette allowed for the reassembly of the split 
gene and the activation of a new antibiotic resistance (14, 15).  Lastly, the recessive 
nature and streptomycin resistance of rpsL could be exploited.  This would require the 
addition of the wild-type MGAS8232 rpsL into the cassette, while the chromosomal rpsL 
would be mutated, as found in S. pyogenes JRS4, to create a base streptomycin resistance.  
When both rpsL versions are present in the same cell the resistant version is recessive 
and, therefore, only loss of the cassette allows for streptomycin resistance (16, 17).  The 
successful addition of one of these systems would allow for a far more efficient screening 
process and a greatly improved RIVET system in S. pyogenes. 
4.2 Chapter 3 Conclusions 
Found to be a Class IIb bacteriocin, blpMH would require blpNH for bacteriocidal activity 
and the associated immunity protein for self-survival (Figure 3.1).  To our knowledge, 
this is the first time blpMNH has been shown to be activated in vivo under biological 
conditions.  Within MGAS8232, we also believe blpMNH can be under the control of a 
regulatory system other than sil.  This stems from the inability of wild-type MGAS8232 
to respond to the SilCR pheromone in vitro or growth in many ex vivo conditions, yet can 
eliminate MGAS8232 Δblp from the correct in vivo environment (Figure 3.9).   
S. pyogenes must be able to outcompete endogenous bacteria already present whithin the 
human body (13, 26-28).  In spite of this, few species of S. pyogenes are known to 
express bacteriocins, and none have been shown to express Class IIb, or make use of a 
bacteriocin to promote in vivo survival (18-25).  Bacteriocins and their use against 
pathogens is an increasing area of research due to its potential as an antibiotic alternative 
(29).  Yet, their use by the pathogens themselves as another virulence factor for gaining 
access to its ideal niche does not appear to be an area of active research.  Deciphering 
how S. pyogenes may make use of bacteriocins for niche adaptation is a fascinating area 
of potential research and could have impacts on our knowledge of other human 
pathogens.  Since we are still at the beginning stages, many questions still remain 
concerning regulation, immunity, and secretion of blpMNH during the colonization 
process of S. pyogenes.  Continued research will ultimately increase our overall 
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knowledge of how S. pyogenes, and possibly other pathogens, interact with the 
microbiota of the human body when attempting to colonize and cause infection. 
4.2.1 Future Work  
A necessary part of the bacteriocin system is an immunity protein.  Recent work from our 
group using functional experiments has identified an immunity phenotype within a 
fragment containing both spyM18_0546 and spyM18_0547.  Similar experiments can be 
repeated with smaller portions of this fragment to identify the coding region responsible 
for immunity function.  The immunity protein, along with blpMNH, likely makes up the 
entire operon regulated by the promoter identified by IVI156 with the RIVET system. 
Further work is also critical in determining the method of secretion for BlpMNH.  It is 
first necessary to determine if the present silE, silD, and spyM18_0541 are responsible for 
the secretion of BlpMNH.  It may be possible to express both bacteriocin and transporter 
from a plasmid under the control of an inducible promoter (such as pMSP3535) within a 
heterologous host such as L. lactis.  One possibility is that the truncated silD is not 
required, as the secondary transport protein has been shown to be unnecessary for at least 
one Class IIb bacteriocin, and possibly others (30).  Should silE not be the transporter, 
further searching through the use of bioinformatics may be used to identify a potential 
source for further testing. 
Finally, the lack of induction via SilCR would suggest regulation through a different 
system.  However, attempting to decipher how blpMNH and its immunity protein are 
regulated may be difficult.  Should regulation occur by the binding of a protein to the 
DNA region upstream of blpMNH, whether as part of a two-component system or another 
regulatory system, pull down assays with in vivo grown MGAS8232 cell lysates, for 
example, could be performed using the known DNA sequence attached to beads as bait.  
Mass spectrometry could then be used to identify any separated proteins.  Identification of 
this regulator would be necessary to determine the activation process of blpMNH within 
the nasopharynx. 
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4.3 Overall Conclusions 
Utilizing the RIVET method in order to identity promoters involved with the colonization 
process by S. pyogenes has laid the foundation for numerous areas of research to pursue.  
Adjustments to the RIVET system used with S. pyogenes could improve its efficiency and 
applicability for analysis in other environments such as human blood or saliva, or in 
models of necrotizing fasciitis or other invasive diseases.  A fascinating potential 
colonization-promoting mechanism used by S. pyogenes identified via RIVET is through 
the use of bacteriocins.  Interest in bacteriocins has increased significantly in the past ten 
years, especially in LAB, due to the potential use of bacteriocins as an antibiotic 
alternative in both clinical and food industry settings (31).  However, the bacteriocins of 
pathogens, used as virulence factors, have not yet received much attention.  The few 
studies represented have demonstrated the importance of bacteriocins with S. pneumoniae 
(32) and S. mutans (33) in order to colonize their preferred niche, validating their 
importance.  Identifying the activation of bacteriocins, through this work, by S. pyogenes 
during colonization also contributes to this idea.  Ascertaining when these bacteriocins 
are expressed, along with the bacteria they target, may provide important information as 
to how pathogens such as S. pyogenes cause disease and may aid in identifying improved 
ways to inhibit or prevent their colonization and reduce the global burden. 
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Appendix 2: Clones recovered using RIVET 
Clone Size 
(bp) 
Designation Region in 
Genome 
Gene 
designation 
Features 
IVI1 96 antisense 1741745 to 
1741840 
spyM18_2077 positive regulatory protein Mga 
IVI3 129 cryptic 1713341 to 
1713213 
spyM18_2050 putative PTS system, enzyme II, 
A component 
IVI4 244 cryptic 570003 to 
570246 
spyM18_0710 putative ATP-dependent DNA 
helicase 
IVI7a 214 cryptic 912892 to 
912679 
spyM18_1098 putative thiamine biosynthesis 
lipoprotein precursor 
IVI7b 178 antisense 1152397 to 
1152574 
spyM18_1380 putative uridine kinase 
IVI11 71 antisense 214459 to 
214389 
spyM18_0239 hypothetical protein 
IVI14a 853 antisense 640829 to 
639977 
spyM18_0802 SagC, hypothetical protein 
IVI14b 108 cryptic 873659 to 
873766 
spyM18_1051 putative D,D-carboxypeptidase, 
penicillin-binding protein 
IVI14c 57 cryptic 147131 to 
147075 
spyM18_0155 hypothetical protein 
IVI15 64 cryptic 1725608 to 
1725671 
spyM18_2064 mitogenic exotoxin Z precursor 
IVI16 113 intergenic 751419 to 
751307 
spyM18_0916 
 
spyM18_0921 
546 bp at 5' side: putative 
peptidoglycan hydrolase 
655 bp at 3' side: N-terminal 
fragment of Sib38 homolgue 
IVI17a 312 antisense 1546687 to 
1546998 
spyM18_1868 hypothetical protein 
IVI17b 162 antisense 678000 to 
677839 
spyM18_0836 putative ATP-dependent 
exonuclease, subunit A 
IVI19 232 antisense 1491691 to 
1491460 
spyM18_1806 hypothetical phage protein 
IVI22 320 cryptic  1271790 
to 1271471 
spyM18_1541 putative undecaprenyl-PP-
MurNAc-pentapeptide-
UDPGlcNAc GlcNAc 
IVI23a 151 cryptic 1601103 to 
1601253 
spyM18_1926 conserved hypothetical protein 
IVI23b 44 cryptic 1010750 to 
1010707 
spyM18_1202 conserved hypothetical protein 
IVI24 514 cryptic 136555 to 
137068 
spyM18_0144 V-type Na+ -ATPase subunit I 
IVI26a 296 cryptic 1073889 to 
1073594 
spyM18_1498 hypothetical phage protein 
IVI26b 298 cryptic 1482683 to 
1482388 
spyM18_1793 hypothetical phage protein 
IVI27 417 antisense 721697 to 
721281 
spyM18_0890 putative pyrimidine regulatory 
protein 
IVI28a 107 antisense 677377 to 
677271 
spyM18_0836 putative ATP-dependent 
exonuclease, subunit A 
IVI28b 78 cryptic 986273 to 
986197 
spyM18_1177 putative sugar ABC transporter 
(permease protein) 
IVI29a 107 antisense 591092 to 
590986 
spyM18_0742 hypothetical phage protein 
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IVI29b 105 antisense 1231877 to 
1231981 
spyM18_1488 hypothetical phage protein 
IVI29c 38 cryptic 539410 to 
539447 
spyM18_0676 putative cell division protein 
IVI30 161 intergenic 1640515 to 
1640355 
spyM18_1973 
 
spyM18_1974 
73 bp at 5' side: conserved 
hypothetical protein 
117 bp at 3' side: putative type I 
site-specific deoxyribonuclease 
IVI34a 161 intergenic 1640515 to 
1640355 
spyM18_1973 73 bp at 5' side: conserved 
hypothetical protein 
    spyM18_1974 117 bp at 3' side: putative type I 
site-specific deoxyribonuclease 
IVI34b 51 cryptic 1714518 to 
1714568 
spyM18_2050 putative PTS system, enzyme II, 
A component 
IVI35 78 cryptic 1464307 to 
1464230 
spyM18_1763 hypothetical phage protein 
IVI37 107 antisense 1781199 to 
1781093 
spyM18_2133 putative transposase 
IVI38 89 intergenic 626749 to 
626661 
spyM18_0789 conserved hypothetical protein 
IVI41 203 cryptic 396484 to 
396686 
spyM18_0486 putative UDP-N-
acetylglucosamine 
pyrophosphorylase 
IVI43 49 antisense 1871198 to 
1871246 
spyM18_2232 hypothetical protein 
IVI46 210 antisense 1835539 to 
1835748 
spyM18_2185 conserved hypothetical protein 
IVI48 310 antisense 913289 to 
913598 
spyM18_1098 putative thiamine biosynthesis 
lipoprotein precursor 
IVI49 1029 promoter 1893418 to 
1894446 
spyM18_2257 putative chromosome segregation 
protein 
IVI52 249 cryptic 1448278 to 
1448030 
spyM18_1741 putative transcription regulator 
IVI53 481 promoter 1027534 to 
1027054 
spyM18_1223 putative amino acid ABC 
transporter, periplasmic amino 
acid-binding protein 
IVI55 54 antisense 971714 to 
971767 
spyM18_1163 hypothetical protein 
IVI57a 185 antisense 146737 to 
146921 
spyM18_0155 hypothetical protein 
IVI57b 83 antisense 841031 to 
841113 
spyM18_1014 extracellular hyaluronate lyase 
IVI59 296 cryptic 1482683 to 
1482388 
spyM18_1793 hypothetical phage protein 
IVI60 959 promoter 182746 to 
183704 
spyM18_0197 hypothetical protein 
IVI62 163 cryptic 1146888 to 
1146726 
spyM18_1373 putative internalin A precursor 
IVI65a 257 antisense 21654 to 
21398 
spyM18_r02 rRNA-23S ribosomal RNA 
IVI65a 257 antisense 27655 to 
27399 
spyM18_r04 rRNA-23S ribosomal RNA 
IVI65a 257 antisense 84557 to 
84301 
spyM18_r06 rRNA-23S ribosomal RNA 
IVI65a 257 antisense 262614 to 
262358 
spyM18_r08 rRNA-23S ribosomal RNA 
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IVI65a 257 antisense 1344577 to 
1344833 
spyM18_r09 rRNA-23S ribosomal RNA 
IVI65a 257 cryptic 1634201 to 
1634457 
spyM18_r11 rRNA-23S ribosomal RNA 
IVI65b 54 cryptic 1603230 to 
1603177 
spyM18_1929 conserved hypothetical protein 
IVI69a 193 antisense 186190 to 
185998 
spyM18_0204 glucose-6-phosphate isomerase 
IVI69b 51 cryptic 1611161 to 
1611111 
spyM18_1939 glycoprotein endopeptidase 
IVI70 203 cryptic 566923 to 
567125 
spyM18_0707 cell-division protein 
IVI72 600 promoter 622769 to 
623367 
spyM18_0784 transcriptional regulator 
IVI78 92 antisense 641030 to 
640939 
spyM18_0802 hypothetical protein 
IVI81 145 cryptic 1248054 to 
1247910 
spyM18_1515 hemolysin 
IVI82a 682 antisense 466442 to 
467123 
spyM18_0583 DhaKLM operon coactivator 
DhaQ 
IVI82b 348 cryptic 850043 to 
850390 
spyM18_1022 coproporphyrinogen III oxidase 
IVI84 842 promoter 1669042 to 
1668201 
spyM18_2004 hypothetical protein 
IVI87 1001 promoter 1587104 to 
1588104 
spyM18_1912 pyruvate formate-lyase 
IVI91 210 cryptic 988364 to 
988155 
spyM18_1179 sugar ABC transporter ATP-
binding protein 
IVI92 151 antisense 1500024 to 
1500174 
spyM18_1815 acetyl-CoA carboxylase subunit 
alpha 
IVI93a 325 cryptic 752667 to 
752343 
spyM18_0921 hypothetical protein 
IVI93b 131 antisense 863452 to 
863322 
spyM18_1041 succinic semialdehyde 
dehydrogenase 
IVI94 237 antisense 396966 to 
396730 
spyM18_0486 bifunctional N-
acetylglucosamine-1-phosphate 
uridyltransferase/glucosamine-1-
phosphate acetyltransferase 
IVI95a 132 antisense 1139356 to 
1139487 
spyM18_1367 hypothetical protein 
IVI95b 78 intergenic 1391342 to 
1391419 
spyM18_1669 
 
spyM18_1670 
7 bp at 5' side: amino acid ABC 
transporter permease 
20 bp at 3' side: ATP-dependent 
RNA helicase 
IVI97a 191 cryptic 571500 to 
571689 
spyM18_0710 bifunctional ATP-dependent 
DNA helicase/DNA polymerase 
III subunit epsilon 
IVI97b 115 antisense 252617 to 
252503 
spyM18_0282 oligopeptide permease 
IVI100 97 promoter 612261 to 
612357 
spyM18_0771 hypothetical protein 
IVI101 111 antisense 1377561 to 
1377671 
spyM18_1656 hypothetical protein 
IVI106 248 antisense 401018 to 
400771 
spyM18_0494 metal binding protein of ABC 
transporter (lipoprotein) 
IVI112 107 antisense 591092 to spyM18_0742 hypothetical protein 
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590986 
IVI115 431 cryptic 1690774 to 
1690344 
spyM18_2030 prolyl-tRNA synthetase 
IVI116 155 cryptic 1601101 to 
1601255 
spyM18_1926 hypothetical protein 
IVI118a 724 antisense 6604 to 
5881 
spyM18_0007 transcription-repair coupling 
factor 
IVI118b 252 antisense 1407068 to 
1407319 
spyM18_1692 trans-acting positive regulator 
IVI119a 198 antisense 1391644 to 
1391841 
spyM18_1670 ATP-dependent RNA helicase 
IVI119b 183 cryptic 1725606 to 
1725788 
spyM18_2064 mitogenic exotoxin Z 
IVI125 103 antisense 1017508 to 
1017610 
spyM18_1213 hypothetical protein 
IVI129 170 cryptic 1220056 to 
1219887 
spyM18_1463 hypothetical protein 
IVI132 251 antisense 416432 to 
416182 
spyM18_0513 phosphate starvation-induced 
protein 
IVI135 288 cryptic 1073881 to 
1073594 
spyM18_1286 hypothetical protein 
IVI138a 468 cryptic 1067947 to 
1067480 
spyM18_1276 phage protein 
IVI138b 295 antisense 1027614 to 
1027908 
spyM18_1224 amino acid ABC transporter 
ATP-binding protein 
IVI138c 103 antisense 441923 to 
441821 
spyM18_0556 dephospho-CoA kinase 
IVI138d 84 cryptic 1721939 to 
1722022 
spyM18_2057 anthranilate synthase component 
II 
IVI140 327 antisense 968624 to 
968950 
spyM18_1160 pyridoxamine kinase 
IVI142 184 intergenic 562668 to 
562851 
spyM18_0703 
 
spyM18_0704 
2 bp at 5' side: conserved 
hypothetical protein 
510 bp at 3' side: conserved 
hypothetical protein 
IVI143 168 cryptic 233754 to 
233921 
spyM18_0261 glyceraldehyde-3-phosphate 
dehydrogenase, plasmin receptor 
IVI146 77 antisense 1500543 to 
1500619 
spyM18_1815 putative acetyl-CoA carboxylase 
alpha subunit 
IVI148 1016 antisense 1760729 to 
1761744 
spyM18_2110 putative pyruvate formate-lyase 2 
IVI152 1029 antisense 446733 to 
445706 
spyM18_0562 putative exoribonuclease R 
IVI154 185 cryptic 1196279 to 
1196095 
spyM18_1429 putative D-Ala-D-Ala adding 
enzyme 
IVI156 985 promoter 433733 to 
434717 
spyM18_0544 putative BlpM homologue 
IVI157a 148 antisense 107943 to 
107796 
spyM18_0111 acetate kinase 
IVI157b 105 cryptic 1571714 to 
1571818 
spyM18_1893 putative divalent cation transport 
IVI157c 65 antisense 1893419 to 
1893355 
spyM18_2256 putative serine protease 
IVI157d 35 cryptic 14043 to 
14077 
spyM18_0014 putative cell division protein 
  
179 
IVI159 63 antisense 1184631 to 
1184693 
spyM18_1416 putative competence protein 
IVI163 88 antisense 332105 to 
332192 
spyM18_0393 exotoxin type A precursor 
IVI164 245 cryptic 367319 to 
367563 
spyM18_0446 putative ATP-dependent protease 
proteolytic subunit 
IVI165 84 cryptic 13964 to 
14047 
spyM18_0014 putative cell division protein 
IVI167a 327 cryptic 1220838 to 
1220512 
spyM18_1464 conserved hypothetical phage 
protein 
IVI167b 133 antisense 1455118 to 
1455250 
spyM18_1750 hypothetical phage protein 
IVI167c 126 antisense 616307 to 
616182 
spyM18_0777 hypothetical phage protein 
IVI173 91 cryptic 484019 to 
484109 
spyM18_0600 putative shikimate 5-
dehydrogenase 
IVI176 42 promoter 344746 to 
344787 
spyM18_0414 hypothetical protein 
IVI177 113 cryptic 1530798 to 
1530686 
spyM18_1856 ABC transporter ATP-binding 
protein 
IVI178 50 antisense 1207032 to 
1206983 
spyM18_1446 MF3 
IVI181a 773 antisense 983703 to 
982931 
spyM18_1174 phosphopantothenoylcysteine 
decarboxylase 
IVI181b 186 antisense 677648 to 
677463 
spyM18_0836 ATP-dependent exonuclease 
subunit A 
IVI185 309 antisense 1546690 to 
1546998 
spyM18_1868 hypothetical protein 
  
  
180 
CURRICULUM VITAE 
Brent Armstrong, B.Sc. (Hons) 
EDUCATION 
2009- present The University of Western Ontario, London, On, Canada 
Ph.D. candidate in Microbiology and Immunology  
2007-2009 The University of Western Ontario, London, On, Canada 
 M.Sc. candidate in Microbiology and Immunology (Transferred to Ph.D. 
program) 
2003-2007 University of Guelph, Guelph, On, Canada 
B.Sc. (Hons.) in Molecular Biology and Genetics 
1998-2003 Resurrection Catholic Secondary School, Waterloo, On, Canada 
HONOURS AND AWARDS 
2008-2013 Western Graduate Research Scholarship ($2235 per term) 
2007-2008 Western Graduate Research Scholarship ($1367 per term) 
2006-2009 Dean’s Honour List  
2003-2004 University of Guelph Entrance Scholarship ($1000) 
1998-2003 Honour Roll 
 
RESEARCH EXPERIENCE 
2007-present Doctorate Thesis Project, The University of Western Ontario. 
Thesis title: “The Identification of in vivo Induced Genes in Streptococcus 
pyogenes”. 
Research Advisor: Dr. John K. McCormick. 
  
181 
2006-2007 Honours Thesis Project, University of Guelph. 
Thesis title: “Molecular Analysis of the apxIBD Genes of Actinobacillus 
suis”. 
Research Advisor: Dr. Janet I. MacInnes 
TEACHING EXPERIENCE 
2009 Training and direct supervision of an Honour’s Project student 
2009 Training and direct supervision of an NSERC summer student 
2008-2013 Training and direct supervision of all work study students. 
2008-2011 Teaching Assistant for Biology of Prokaryotes (2100a) at the University of 
Western Ontario.   
PRESENTATIONS 
Armstrong, B.D., Heinrichs, D.H. and McCormick, J.K. “Identification of in vivo 
induced genes in Streptococcus pyogenes”.  Infection and Immunity Research Forum.  
London, Ontario, Canada (2012). 
Armstrong, B.D. and McCormick, J.K. “Counter-selection in Streptococcus pyogenes”.  
Banff Conference on Infectious Diseases.  Banff, Alberta, Canada (2010). 
Armstrong, B.D. and McCormick, J.K. “Counter-selection in Streptococcus pyogenes”.  
Canadian Society of Microbiologist’s annual meeting poster presentation. Calgary, 
Alberta, Canada (2008). 
Armstrong, B.D. and MacInnes, J.I. “Molecular Analysis of the apxIBD Genes of 
Actinobacillus suis”.  Honours student poster presentation. University of Guelph, Guelph, 
Ontario, Canada (2007). 
